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Abstract 
Exhaled breath VOCs analysis is safe and non-invasive method of monitoring for human 
metabolic profiles and has the potential to become diagnostic tool in clinical practise. This 
thesis first describe in detail the different aspects of exhaled breath VOCs and its use as 
diagnostic tool in respiratory diseases.  
The current exhaled breath analysis work-flow including breath sampling, analysis and data 
processing is also described. A single exhaled breath sample can contain in excess of 500 
different chemical species. There is a wide range of factors that can cause the variability to 
individual breath profiles. In order to detect small changes in breath profiles, a standardised 
and reproducible approach to exhaled breath analysis methodology is required. The long 
term storage of exhaled breath samples using multi-sorbent tubes is investigated, the 
optimum storage protocol and condition is discussed.  
A portable breath sampling system was also developed for remote sampling. The 
introduction of this new feature enables breath sampling to be carried out outside the 
designated laboratory with no location restriction. This feature combined with the easy to use 
and non-invasive original sampling unit designed for subjects with impaired lung function 
minimise participant stress level and discomfort. It also utilises the custom developed air 
supply filtration assembly to create a standardised purified breathable air that can minimise 
the method variability and improve standardisation to breath samples collected. 
This methodology is tested in an excise induced bronchoconstriction (EIB) study where two 
groups of participants: healthy and excise induced bronchoconstriction (EIB) positive 
undergo high intensity cardiopulmonary exercise testing (CPET). The data from two groups 
of participants is analysed and three markers which shown correlation with EIB positive 
participants are determined.  
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Glossary of terms 
AUC                       Area under the curve 
BCA                       Breath collecting apparatus 
BHT                       Butylated hydroxytoluene 
BMI                        Body mass index 
CI                           Chemical ionisation 
COPD                    Chronic obstructive pulmonary disease 
CPET                     Cardiopulmonary exercise testing 
CPX                       Cardiopulmonary exercise 
DC                         Direct current 
EBC                       Exhaled breath condensate 
EI                           Electron ionisation 
EIB                         Exercise-induced bronchoconstriction 
EVH                        Eucapnic voluntary hyperpnoea 
FEV1                      Forced expiratory volume in 1 second 
FVC                        Forced vital capacity 
GC-FID                   Gas chromatography - flame ionization detector 
GC-MS                   Gas chromatography – mass spectrometry 
IMS                         Ion mobility spectrometry 
LAS                         laser absorption spectroscopy 
LCL                         Lower control limit 
MHR                       Maximum heart rate 
MVA                       Multivariate analysis 
MVV                       Maximal voluntary ventilation 
NIST                       National Institute of Standards and Technology 
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NO                            Nitric oxide    
OPLS-DA                 Orthogonal partial least square discriminant analysis 
PC                            Principal component 
PCA                          Principal component analysis 
PEF                          Peak expiratory flow rate 
PTFE                        Polytetrafluoroethylene 
PTR-MS                   Proton transfer reaction mass spectrometry 
RF                            Radio frequency 
RI                             Retention index 
ROS                         Reactive oxygen species 
RSD                         Relative standard deviation 
SIFT-MS                  Selected ion flow tube mass spectrometry     
SPME                      Solid-phase microextraction 
TD                            Thermal desorption 
UCL                         Upper control limit 
VC                            Vital capacity 
VCO2                         Carbon dioxide output 
VE                             Minute ventilation 
VO2                           Oxygen uptake 
VOC                         Volatile organic compounds                    
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CHAPTER 1. AN INTRODUCTION TO BREATH VOCS AND 
CURRENT EXHALED BREATH ANALYSIS 
METHODOLOGY  
1.1. The composition of exhaled breath VOCs 
Exhaled human breath is produced when inhaled ambient air is exhaled through nasal or 
oral cavities. The composition of exhaled breath changes from the inhaled ambient air 
mainly due to the intake of oxygen into the body and removal of carbon dioxide from the 
body. It is a complex matrix of volatile organic compounds, non-volatile organic compounds 
and inorganic compounds. The main components of exhaled breath are nitrogen (75% v/v), 
oxygen (16% v/v) water vapour (5% v/v), carbon dioxide (4% v/v) and argon (1% v/v). 
Exhaled breath has relative humidity of 100% due to water diffusing from the alveoli and 
other parts of the airway.  
Exhaled breath also contains several hundreds of known volatile organic compounds 
(VOCs) in trace amounts which can variate from parts per million (ppmv) down to parts per 
trillion (pptv). These volatiles metabolites are present in the bloodstream and diffuse into 
exhaled breath via alveolar capillary, thus compounds are usually metabolites from protein 
breakdown and are good indicators of human biochemical mechanisms. Common occurring 
volatiles metabolites such as ammonia have been studied extensively over an extended time 
using SIFT-MS (1) (2); Ammonia was shown to a major volatile metabolite in the body at 833 
ppb, other common volatiles measured were acetone at 477 ppb, methanol at 461 ppb, 
ethanol at 112 ppb, isoprene at 106 ppb, propanol at 18 ppb and acetaldehyde at 22 ppb. 
Other less common VOCs are present in ppb or ppt concentrations. Most of these common 
human volatiles compounds have been linked to metabolic pathways in the body. Majority of 
ammonia is produced in the oral cavity and is also produced in the body as protein 
breakdown product (3) (4). After consumption of foods and drinks, the level of methanol 
usually increases by an order of magnitude. Methanol and ethanol are possibly generated as 
anaerobic fermentation products of sugar contained in food and drinks by gut bacteria (5). 
Acetone is a product of decarboxylation of acetoacetate and the dehydrogenation of 
isopropanol (6). Isoprene is generated through cholesterol synthesis. Propanol is a product 
of the enzyme-mediated reduction of acetone (3). Acetaldehyde is generated endogenous 
ethanol metabolism and might be linked to carcinogenic effect of alcohol, but also can be 
produced from sugar cellular activity.  
The exhaled breath is saturated with water vapour, apart from the gaseous VOCs, it also 
contains aerosol particles transported from lower respiratory tract and it reflects the 
13 
 
composition of alveolar extracellular lining fluids. These non-volatile compounds include a 
wide range of compounds ranging fromorganic molecules such as urea, organic acids, 
amino acids, peptides, proteins to inorganic ions. It also contains important metabolites such 
as leukotrienes and isoprostanes which are inflammatory mediators which can bevaluable 
means of monitoring lung diseases.  
1.2. The physiology of exhaled breath VOCs 
The VOCs in breath are products of metabolic pathways in human body, VOCs produced in 
remote parts of the human body enters the blood stream at parts of body where it originated. 
The VOCs are then transported in the blood stream to alveolus to be exhaled into the breath. 
The alveolus is located at the end of the lung where blood carrying CO2 and VOCs enters 
the pulmonary arterial capillaries around the alveolus. The interface between the capillary 
endothelium and type-1 alveolar cells is only 0.1µm thin thus facilitates the rate of gas 
transfer.  
 
Figure 1.2. Schematic of respiratory alveolar and capillary membranes (a) Alveolar 
epithelium (b) Respiratory membrane, oxygen diffuse into alveolus into red blood cell 
via capillary, while carbon dioxide diffuses into alveolus from the red blood cells into 
the exhaled breath (7).  
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The concentration of a specific VOC in the alveoli is proportional to its concentration in 
blood. A mathematical model relating concentration between alveoli and blood is shown 
below: 
𝐶஺ =
𝐶௩
𝜆௕:௔௜௥ + ?̇?஺/?̇?஼
 Equation 1.2.1. 
𝐶஺ is alveolar concentration of specific compounds, 𝐶௩ is the venous blood concentration, 
𝜆௕:௔௜௥is blood: alveoli partition coefficient, ?̇?஺/?̇?஼ is the alveolar ventilation: cardiac output 
ratio. This model describes steady state inert gas elimination from lung as a single alveolar 
compartment with alveolar ventilation: cardiac output ratio close to one (8). 
However this model seems to fail for compounds such as acetone and isoprene, so revised 
models has been published recently (9): 
𝐶஺ = 𝜆௕:௔௜௥𝐶௔ Equation 1.2.2. 
 𝐶௔is concentration of compounds in arterial blood.  
The exact location of where metabolic VOCs enter the alveolar compartments are still under 
research. The relevant compartments and their gas volume are: alveolar walls 250-300 mL, 
epithelium 60-80 mL, endothelium 50-70 mL, interstitium 100-185 mL, macrophages 50 mL, 
supportive tissues 250 mL and capillary system 400 mL. Although some VOCs such as 
ammonia are generated in oral cavity by bacterial action on oral urea. 
The VOCs detected in human exhaled breath are reflective of the entire body’s metabolism, 
many cells produce VOCs as products of their metabolic pathway. 
Although the mechanism of transportation of systematic VOCs produced in remote parts of 
the body to lung is well understood (8) (9), however, the biochemical process that leads to 
VOCs biomarker production in human body can be difficult to determine. The determination 
of biogenic origin of VOCs biomarker is important providing understanding to the metabolic 
pathways which links to certain diseases. The presence and amount of VOCs biomarker 
provides information to biological statues of the body.     
Research into production of VOCs from single cell lines helps establishing the origin of many 
VOCs biomarkers. By studying a single cell line, the researcher is able to control 
environment, genotype and growth of cells, as well as to eliminate other factors that comes 
from other cells to establish.   
1.3. The origin of exhaled breath VOCs 
Exhaled breath VOCs can be separated into two categories based on their origin: 
endogenous and exogenous. Breath VOCs diffuse readily from and into the red blood cells 
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and rest of the body via alveolar-capillary epithelium. Endogenous breath VOCs are usually 
end products of metabolic pathways that are excreted via breath, these are compounds such 
as isoprene and acetone. Exhaled breath VOCs are reflective of the entire human body’s 
metabolism, as many cells emit VOCs. However, many sources of endogenous breath 
VOCs and their links to metabolic pathways are not yet understood.  
The sources of exogenous breath VOCs can be through inhalation through ambient air, 
ingestion of food and drinks or skin absorption. These compounds are possibly metabolised 
in the body and excreted in breath. Philips et al investigated the endogenous and exogenous 
nature of commonly occurring breath VOCs by comparing room air and alveolar breath (10). 
Out of the 3481 VOCs observed, 1753 VOCs had positive alveolar gradients and 1728 had 
negative alveolar gradient where the concentration of the VOCs is higher in the room air 
than in exhaled breath. For exogenous compounds not significantly metabolised or 
catabolised such as room air contaminants, their alveolar gradient is near zero. The 
equilibrium between VOCs in the blood and in the alveolar air is assumed be rapid and near 
complete. Due to large proportion of exhaled breath VOCs being compounds of an 
exogenous origin, it is important to be able to distinguish these compounds from the truly 
endogenous compounds.  
1.4. The variability of exhaled breath VOCs 
An average breath sample could contain several hundreds of VOCs, however, apart from the 
commonly occurring compounds such as acetone or isoprene, the compounds found in 
human breath can differ significantly between individuals. Philips et al studied the breath 
profile of 50 healthy humans and found that out of the 3481 different VOCs identified, only 
27 can be observed in all 50 participants (10), thus indicating the inter-individual variation. 
Due to the high sensitivity of the increasing breath analysis method, there is wide range of 
factors that can cause the variability to individual breath profiles; the main factors are age, 
gender, human body state, food/drink and exposure to air contaminants.  
Several studies have found direct link of age and gender of subject to breath VOCs. 
Isoprene concentration is found to be in significantly lower level in children compared to 
adults, and it is also found to increase during puberty (11) (12). It is also found to be in 
higher level in male subjects compared to female. Breath ammonia level was reported to 
increase directly with age (13). 
The other major factor to variability in breath VOCs is food or drink intake. Smith et al has 
investigated the effect of glucose ingestion and alcohol consumption on common breath 
metabolites such as ammonia and acetone using SIFT-MS. The study has found decrease in 
ammonia and acetone level following food/drink intake (14) (15).  
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Food and drinks are known to emit trace level VOCs in the human body over time. Recent 
study has used monitored the catabolism of isotope-labelled ethanol oral ingestion using 
real-time breath gas analysis with PTR-MS (16). It has found ethanol was transformed into 
deuterated acetone and isoprene. The absence of deuterated acetaldehyde indicated more 
rapid metabolism preventing it from entering blood stream. Other study monitored breath 
VOCs following the ingestion of raw garlic, it has found that rapid increase in sulphide 
compounds and slow increase of acetone even after 30 hours of ingestion (17). These 
studies have demonstrated the duration of release of trace volatiles from food can vary 
significantly depending on the metabolism process it is involved in, thus also demonstrating 
the complexity of breath VOCs.  
Exposure to air borne contamination can also significantly influence the composition of 
exhaled breath. Studies have found compounds present in cigarette smoke such as 2,5-
dimethylfuran, acetonitrile, benzene, toluene and styrene are present in exhaled breath of 
both smokers and passive smokers (18). Additionally, acetonitrile, hydrogen cyanide, 
ethane, pentane and benzene are known to be present in exhaled breath of smokers when 
compared to non-smokers (19).  
Air borne contaminants can also enter the body through inhalation and skin absorption, and 
can be released at different rates through breath or other excretion. Common air 
contaminants such as toluene, benzene or limonene emitted from pollution or household 
products are commonly found in exhaled breath, these compounds can be absorbed by 
blood during inhalation and released over a long period of time. Toluene and benzene are 
known to be carcinogenic and therefore can trigger adverse biochemical reactions in body.    
1.5. Exhaled breath VOCs as diagnostic tool and applications 
1.5.1. History 
Breath analysis has been used to detect diseases since the times of Hippocrates in ancient 
Greek, physicians used the smell of breath to identify status of health. Even in modern times, 
the smell of breath is still a valid indicator of diseases. It is known for many years a fruity 
smell of acetone in breath indicate diabetes, fishy smell of breath indicate liver disease, 
whereas urine smell of breath may indicate kidney diseases. 
However, in order for breath analysis to become an objective diagnostic tool, it has to 
progress beyond the realm of subjective sniffing of breath. This process was started around 
200 years ago by Antoine-Laurent de Lavoisier the “father of modern chemistry”, he 
analyzed the breath of guinea pigs and discovered animals produced carbon dioxide from 
consuming oxygen. He also created breath trap where carbon dioxide produced by human is 
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reacted with a potassium hydroxide solution through the mercury to  form precipitate. Since 
carbon dioxide is very abundant in human breath, it is relative easy to detect, but many other 
VOCs that are present in trace amounts in breath are much more difficult to trap in 
detectable quantities. 
The modern age of breath analysis began in 1971, when Noble prize winner Linus Pauling 
discovered these trace amount VOCs in human breath and proved the complexity of breath, 
he was able to reveal the presence of 250 VOCs in an average breath (20).  
In 1999, Michael Philips and his co-workers were able to demonstrate the variation in human 
breath of 50 participants. He revealed presence of thousands of VOCs among the 50 
participants and 27 common VOCs that is found in all subjects. The VOCs that are common 
in all subjects indicates the essential VOCs from human metabolic pathways (10). 
1.5.2. Exhaled breath VOCs in Asthma 
Asthma is a common chronic inflammatory lung disease. It is also becoming increasingly 
common in developed country and has become the most common chronic condition in the 
west. Anybody at any age can develop asthma, although it seems to be more common in 
children. In the UK, more than 5.2 million people suffer from asthma which is 9% of 
population. Internationally, 300 million people are affected by asthma, and 250,000 people 
die from asthma attacks every year. But 90% of asthma death is preventable with proper 
treatment. With the advances in medical treatments, the asthma death rate is decreasing, 
but even mild asthma will still pose risks of death. The symptoms of asthma include 
coughing, wheezing, shortness of breath and chest tightness. 
Asthma is a complex disease with many factors that control the level of asthma symptoms. 
There are two general types of asthma: atopic and non-atopic. Atopic asthma is extrinsic and 
developed toward hypersensitivity allergic reactions to certain environmental factors; it is 
also known as allergic asthma. The environmental factors which can cause atopic asthma 
are variable to individuals and there are many potential causes. Some common causes 
include air pollution, pollen and house dust mites. The second general type of asthma is 
non-atopic asthma, although both type of asthma have the same symptoms, but non-atopic 
asthma is intrinsic and might be caused by factors such as excise, stress, anxiety, cold air, 
smoke, viruses or other non-allergic factors; this type of asthma is also known as non-
allergic asthma. Research suggest asthma is developed early in life during the development 
of human immune system through a combination of genetic factors and environmental 
exposure to allergens, pollution or stress etc.  
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Asthma is clinically classified by four severity categories:  intermittent, mild persistent, 
moderate persistent and severe persistent. The severity of asthma is determined mostly by 
frequency of symptoms, forced expiratory volume in 1 second (FEV1) and peak expiratory 
flow rate (PEF). Other factors to be considered when determining asthma severity include 
frequency of nocturnal symptoms, frequency of exacerbations and FEV1/FVC ratio. Severe 
asthma sufferers will show daily or continual symptoms, frequent exacerbations, FEV1 lower 
than 60% predicted, frequent nocturnal symptoms and limited physical activities, whereas 
mild asthma sufferers will only have occasional symptoms less than once a week, 
occasional nocturnal symptoms less than once every two months and FEV1 higher than 
80%. Severe asthma will need to be treated high dose of corticosteroid plus long-acting 
inhaled β2-agonist and another controller, but mild asthma wouldn’t need any controller at 
all.  A table showing classification of asthma severity is shown below: 
Table 1.5.2. The classification of asthma based on the severity of the symptoms (21). 
Severity Symptoms Night time symptoms  Lung function 
Severe persistent Continual symptoms Frequent FEV1<60% predicted 
 
Frequent exacerbations 
 
FEV1/FVC reduced <5% 
 
Limited physical activity 
  
  SABA used several times a day     
Moderate persistent Daily symptoms >1/week FEV1>60% predicted 
 
Daily use of SABA 
 
<80% predicted 
 
Exacerbations>2/week 
 
FEV1/FVC reduced 5% 
  Exacerbation affects activity     
Mild persistent Symptoms >2/week but not daily 3-4/week FEV1>80% predicted 
  Exacerbations may affect activity   FEV1/FVC normal 
Mild intermittent Exacerbations brief <2/week FEV1>80% predicted 
 
Symptoms < 2/week 
 
FEV1/FVC normal 
  No controller needed     
 
As the lung becomes inflamed during an asthma exacerbation, the epithelial cell lining of 
bronchioles is disrupted and the epithelial cells start to desquamate. The eosinophilic cells 
increase in the bronchial wall. The cellular changes cause the bronchial wall to swell. The 
muscle around the airway contracts creating resistance to airways. The goblet cells start to 
19 
 
secrete mucus into the airway; the mucus will also cause additional obstruction in the 
airways. All the constriction in the airway causes it to narrow which result in coughing, 
wheezing and shortness of breath. However, this obstruction in the airway unlike irreversible 
chronic obstructive pulmonary diseases is reversible with early and proper treatment. If it is 
left untreated, asthma can cause irreversible and long term loss of lung function or even 
death.  
Asthma is normally diagnosed and classified using a spirometer. The spirometer measures 
the volume of inhaled and exhaled air. It is used to produce measure vital capacity (VC), 
forced vital capacity (FVC) and forced expiratory volume (FEV). Another way of accessing 
asthma condition is by is by bronchoscopy. However, it is invasive and may cause 
discomfort.  
In 1991, the field of breath analysis for asthma was started by Gustafsson who suggested 
who demonstrated the presence of nitric oxide (NO) in animals and human (22). He also 
indicated NO was endogenously produced in the lung by an NO synthase and suggested its 
important role in lung function. In 1994, Kharitonov tested the breath of asthma patients, and 
determined an increased NO level in asthma patients compared to control group (23). NO is 
currently used as biomarker of asthma, and different types of NO sensor is available 
commercially.  
Hydrocarbons have known to be products of lipid peroxidation in the lung. During asthma 
symptoms, immune and inflammatory cells release reactive oxygen species (ROS) which will 
induce lipid peroxidation of membrane fatty acids. This is likely to damage membrane 
function, hence causing constriction to the airways. In recent years, saturated and 
unsaturated hydrocarbon compounds have been suggested as markers of asthma. 
1.5.3. Exhaled breath VOCs for Lung cancer 
Lung cancer is a form of cancer that is caused by uncontrollable cell growth in lung tissue. 
98% of lung cancer is a result of transformation of healthy epithelial cells into primary 
carcinomas. The cause of this transformation is damage to genome of cells due to exposure 
to carcinogens. This uncontrollable cell growth if not treated will quickly spread to rest of the 
lung by the process of metastasis, and into other parts of body. The cancer tissue is likely to 
block the normal function of the lung and the resultant symptoms are difficulty breathing, 
chest pain and weight loss.  
Internationally lung cancer is the one of most common and serious types of cancer, people 
diagnosed with lung cancer has 86% death rate within 5 years. However, if detected and 
treated early, the survival rate is likely significantly increases from 10~23% (stage 3 lung 
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cancer) to 40~50% (stage 2 lung cancer) or 60~80% (stage 1 lung cancer). The purpose of 
breath analysis of lung cancer is to provide early detection at stage 1 or stage 2 of lung 
cancer before it develops into stage 3. 
The breath analysis research into finding marker compounds of lung cancer started in 1985 
by Gordon and his colleagues (24). They used computerised GCMS to indicate 22 possible 
lung cancer markers out of 150 compounds among 12 lung cancer patients and 17 controls. 
Out of the 22 candidate compounds, 16 were oxygen containing compounds and 4 was 
sulphur containing compounds. Although they couldn’t determine the exact identity of 22 
compounds, it had shown the enormous potential of breath analysis for lung cancer 
detection.   
In 1988, O’Neil and Gordon classified 386 human breath compounds into 16 chemical 
classes using GCMS method with 8 lung cancer participants (25). Out of the 16 chemical 
classes, they were able to identify 1-oxygen and 2-oxygen containing classes to be potential 
lung cancer markers. They also suggested 9 potential lung cancer markers: propenal, 
acetone, 2-butanone, phenol, benzaldehyde, acetophenone, nonanal, ethylpropanoate and 
methylisobutenoate.  However, no sulphur containing compounds were found to be potential 
markers.    
In 1999, Michael Philips and co-workers began large scale lung cancer breath analysis 
project. They were able to recruit in total 108 participants with abnormal chest radiograph 
who were scheduled for bronchoscopy and 50 healthy participants as control. Lung cancer 
was later confirmed to 60 out of 108 participants. The breath samples were analyzed by 
GCMS method. They were able to identify 22 breath VOCs that are discriminated between 
lung cancer and healthy participants. Out of the 22 VOCs, 15 were alkane or alkane 
derivatives, the other 6 were isoprene, benzene or benzene derivatives. It seems to have 
supported some of O’Neil’s potential marker compounds (26). 
In 2003, Michael Philips and co-workers was able to determine the presence of 9 lung 
cancer markers based on 178 bronchoscopy patients and 41 healthy participants (27). Out 
of 178 bronchoscopy patients, 87 were diagnosed with lung cancer. The type of cancer 
diagnosed in the 87 participants was also separated into primary lung cancer and metastatic 
lung cancer.  Participants with primary lung cancer were found to have elevated level of 
alkanes and monomethylated alkanes, but this is less likely in metastatic lung cancer 
participants. The 9 marker lung cancer compounds are butane, 3-methyl tridecane, 7-methyl 
tridecane, 4-methyl octane, 3-methyl hexane, heptanes, 2-methyl hexane, pentane and 5-
methyl decane. Out of the 9, butane was found to be the best discriminator. 
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1.5.4. Summary of recent lung disease studies using exhaled breath VOCs 
Below is a summary of lung disease biomarkers studies using exhaled breath VOCs in the 
last five years from 2012 to 2016.  
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Table 1.5.4. List of biomarkers studies for asthma, COPD and lung cancer using exhaled breath VOCs from 2012 to 2016 
Year Authors 
Type of 
lung 
disease Participant number 
Collection 
method Analysis Method 
Data analysis 
method Identified markers  
2012 
Caldeira 
(28) 
Allergic 
asthma in 
children 
27 control, 32 with 
allergic asthma, 10 
with allergic rhinitis Tedlar bag GC × GC-TOF-MS PLS-DA 
nonane, 2,2,4,6,6-pentamethylheptane, decane, 3,6-
dimethyldecane, dodecane, and tetradecane 
2012 
Buszewski 
(18) 
Lung 
cancer 
44 control, 29 with 
lung cancer Tedlar bag GC-TOF-MS ANOVA 
Butanal, 2-butanone, ethyl acetate, ethylbenzene, 2-pentatone, 1-
propanol, 2-propanol 
2012 Basanta (41) COPD 
32 control, 39 with 
COPD 
Thermal 
desorption 
tubes GC-TOF-MS 
PCA, MLR and 
ROC 
Undecanal, Hexanal, Dodecanal, Decanal, Nonanal, Pentadecanal, 
Oxirane-dodecyl, Cyclohexanol, Buanoic acud, pentanoic acid, 2-
pentylfuran 
2012 Phillips (42) COPD 
63 control, 119 with 
COPD Bio-VOC GC-MS ROC 
Isoprene, Acetic acid, Benzaldehyde, Benzene, Butanea, Carbon 
dioxidea, Hexanal, Nonadecane, Phenol, Phthalic anhydride, 
Sulphur dioxide Toluene 
2013 
Gahleitner 
(32) 
Asthma in 
children 
12 control and 11 
with asthma 
Thermal 
desorption 
tubes GC-MS PCA 
(1-(methylsulfanyl)propane, ethylbenzene, 1,4-dichlorobenzene, 4-
isopropenyl-1-methylcyclohexene, 2-octenal, octadecyne, 1-
isopropyl-3-methylbenzene and 1,7-dimethylnaphtalene) 
2013 
Robroeks 
(33) 
Asthma in 
children 
40 children with 
asthma Tedlar bag GC-TOF-MS SVM 
2-ethyl-1,3-butadiene, Cyclohexane, 2-octen-1-ol, 1.2-methyl-4H-
1,3-benzoxathiine, Benzene 
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2014 
Martinez-
Lozano 
Sinues (34) COPD 
25 with COPD and 
25 controls Direct TOF-MS PCA Acetone and Indole  
2014 
Smolinska 
(43) 
Asthma in 
children 252 children Tedlar bag GC-TOF-MS PCA 
Acetone, 2,4-dimethylpentane, 2,4-dimethylheptane, 2,2,4-
trimethylheptane, 1-methyl-4-(1-methylethenyl) Cyclohexen, 2,3,6-
trimethyloctane, 2-undecenal,  Biphenyl,  2-ethenylnaphtalene, 
2,6,10-trimethyldodecane, Octane, 2-methylpentane, 2,4-
dimethylheptane, 2-methylhexane 
2014 Fu (36) 
Lung 
cancer 
88 controls, 97 with 
lung cancer Tedlar bag FT-ICR Wilcoxon test 
2-Butanone, 2-hydroxyacetaldehyde, 3-hydroxy-2-butanone, 4-
hydroxyhexanal 
2014 Handa (37) 
Lung 
cancer 
39 controls, 50 with 
lung cancer Direct IMS 
Decision tree 
algorithm 
n-Dodecane, 3-methyl1-1 = butanol, 2-methylbutylacetat or 2-
hexanol, n-nonal or cyclohexanon, isopropylamin, ethylbenene, 
hexanal, cyclohexanon, heptanal 
2015 Cazzola (38) COPD 
7 control, 27 with 
COPD Tedlar bag GC-MS PLS-DA 
Benzene, 1,3,5-tri-tertbutyl-, Decane, Butylated hydroxytoluene, 
Decane, 6-ethyl-2-methyl-, Hexane, 3, ethyl-4-methyl- Hexyl 
ethylphosphonofluoridate, Limonene, 1-Pentene, 2,4,4-trimethyl-, 
2-Propanol 
2015 Ligor (39) 
Lung 
cancer 
361 controls, 123 
with lung cancer Tedlar bag SPME-GC/MS n/a 
1-Propanol, 2-butanone, 3-butyn-2-ol, benzaldehyde, 2-methyl 
pentane, 3-methyl pentane, n-pentane, n-hexane 
2016 Gaida (44) COPD 
52 healthy non-
smokers, 31 
smokers with COPD 
and 30 ex-smokers 
with COPD 
Tenax DA 
filter GC-MS ANOVA and LDA 
m/p-Xylene, 1,6-Dimethyl-1, 3,5-heptatriene, o-xylene, 1-Ethyl-3-
methyl benzene, Phenole, m/p-Cresol, linalyl acetate, Tridecane, 
Indole 
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1.6. Exhaled breath VOCs collection and analysis methods 
1.6.1. Current exhaled breath VOCs collection methods 
Exhaled breath VOCs are usually pre-concentrated by analysis due to most trace VOCs are 
in the ppbv to pptv range. Also it is not always possible to have sample analysis system 
where the test subjects are, so breath samples are usually collected on-site and transported 
to the laboratory later. The most common breath collections methods used are Tedlar bags, 
adsorbent tubes and canisters. The method and materials used to for breath collection must 
be not absorb, adsorb or react with any VOCs to maximise recovery.   
Tedlar bags are made from poly(vinyl fluoride) films developed by DuPont Corporation in 
1960s. Each bag had Teflon hose/valve where gas can enter. Tedlar bags come in a variety 
of sizes ranging from 0.6L to 25L, with 1L size the most commonly used for breath collection. 
Due to its low cost and easiness to use, they have been used widely for breath collection. 
However, Tedlar bags are permeable to low molecular VOCs such as methanol and 1,3-
butadiene which can cause poor recovery at 50% to 80% (45). A storage study monitored a 
mixture of common VOCs and found rapid decline in VOCs concentration level over 70 
hours period (46). Breath samples collected using Tedlar bags are recommended to be 
analysed within 10 hours. The losses of VOCs were due to a combination of adsorption and 
diffusion through bag wall. Additionally, Tedlar bags are prone to carry over between 
samples if the bags are re-used, residual VOCs have shown to be difficult to remove even 
after flushing and heating cleaning procedures (47). Tedlar bags are more suitable for non-
polar and medium polarity compounds.   
Canisters are stainless steel containers with inert inner surface to avoid adsorption and 
permeability. A wide range of VOCs collected in canisters have shown to be stable for 30 
days or longer. It can vary in sizes from 1L to 6L. Canisters can be treated after sample and 
re-used with no sample carry over. Canisters are much more expensive compared to other 
two collection methods, so it is less widely used in comparison. 
Adsorbent tubes are typically made of stainless steel and can contain a variety of solid 
adsorbent materials. This includes activated carbon, silica gel, organic porous polymer such 
as Tenax or Amberlite resins. Different types or combination of sorbents materials can be 
selected for trapping a wide range of compounds with high recovery (>90%). The trapping 
efficiency is dependent upon the chemical properties of the compounds of interest and 
adsorbent material. Trapped compounds can be removed efficiency when heated to a high 
temperature during thermal desorption, this ensures no carry over between samples. 
However, the range of VOCs that can be collected is limited by the adsorbent materials 
used. Generally, it is more suitable to less volatile and polar VOCs with carbon number 
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ranging from 3 to 30. It is relative low cost compared to canister method. Typically, 10 mL to 
3 L of breath samples are collected onto adsorbent tubes for analysis.  
Solid-phase microextraction (SPME) is another pre-concentration method that can be used 
for breath collection. It uses a fiber coated with extracting phase which can be liquid or solid 
sorbents. Due to the physical properties of the fibers, only a relatively small volumes 10 to 
20 mL of sample can be collected with limited range of VOCs. However, SPME is not 
affected by water vapor in breath as much as adsorbent tubes due to its high selectivity for 
target compounds. 
1.6.2. Current exhaled breath VOCs sampling devices 
In principle, there are two approaches to exhaled breath VOCs collections: 
 Mixed expiratory sampling – Total breath collection including dead space air and 
alveolar air 
 Alveolar air sampling – Only pure alveolar gas is collected 
Mixed expiratory collection method is easy to perform with no additional sampling equipment 
required, it has been most frequently used in practical applications. However, pure alveolar 
collection is recommended due to the significantly increased level of endogenous VOCs 
collected compared to mixed expiratory collection method. This is because for VOCs 
exchanges between blood and alveolar air, dead space air is considered a contaminant and 
dilutes the concentration of VOCs when breath is collected.  
The first modern exhaled breath VOCs sampling device was developed by Pauling et al (20). 
Exhaled breath volatiles was collected using a cold trapping method by blowing through a 
stainless steel tube chilled in isopropyl alcohol dry ice bath. The stainless tube was then 
heated and analysed by GC-FID. They were able to observe around 250 different VOCs. 
This sampling collection method collected mixed expiratory air and required considerable 
respiratory effort from the subject for breath collection. Since then, advances in technology 
have made breath VOCs sampling more user friendly and is able to selectively collect 
alveolar air. Schuert et al developed a breath sampling device using end-tidal CO2 to 
separate dead space gas from alveolar gas from patients under assisted mechanical 
ventilation (48). 1 L exhaled breath was collected onto activated charcoal trap and analysed 
by GC-FID. The study has reported doubling in expired acetone and pentane concentration 
using the CO2 controlled alveolar air sampling method compared to mixed expiratory 
sampling. Philips et al developed a breath collecting apparatus (BCA) to collect alveolar air 
(49). The device utilises microprocessor controller to collect alveolar breath onto adsorbent 
tube. The participant wears a nose clip and breath in and out through a wide bore tube which 
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presents very little resistance to expiration. Breath samples were collected for 5 minutes at 2 
L min-1. A typical chromatogram identified 150 to 200 different VOCs.  
 
Figure 1.6.2. Sampling devices which collected alveolar air. (Top) CO2 controlled 
sampling of alveolar gas in mechanically ventilated patients by Schuert et al (48) 
(Bottom) Breath collecting apparatus (BCA) developed by Philips et al (49). 
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1.6.3. Current exhaled breath VOCs analysis methods 
There are two general types of analytical technique for breath analysis: real-time 
measurements, and off-line analysis. Real-time analytical techniques have the advantages 
of breath VOCs readily analysed without pre-concentration steps or separation technique, 
however, this can also lead to loss of sensitivity compared to off-line techniques. Real-time 
breath analysis techniques include: Proton transfer reaction mass spectrometry (PTR-MS), 
selected ion flow tube mass spectrometry (SIFT-MS), laser absorption spectroscopy (LAS) 
and ion mobility spectrometry (IMS). In these techniques, breath VOCs samples are 
analysed as the participant breath into the apparatus which allows breath to breath 
resolution, thus has enables real-time continuous analysis during an intervention. Karl et al 
measured breath isoprene using PTR-MS technique, the study has found breath isoprene 
concentration increases within a few seconds after exercise is started as result of increase in 
heart rate (50).  
In off-line analysis, samples are usually collected on-site and then transported to laboratory 
for analysis. These techniques usually involve pre-concentration and separation technique 
which is more time consuming, but also generates very high sensitivity. Gas chromatography 
– mass spectrometry (GC-MS) is the most commonly used off-line analytical technique. The 
MS data sets are easy to handle and suitable for multivariate analysis, also the existence of 
extensive compounds library such as NIST makes compound identification much easier. 
However, off-line technique such as GC-MS also have extensive requirements such as 
expertly trained staff for operation and data analysis, extra time for storage and 
transportation, also the need for detailed procedures to follow.  
Another breath VOCs analysis technique that has seen rapid progress in recent years is the 
development of chemical sensor technology, also called ‘electronic nose’. This device 
consists of head space sampling, sensor array and pattern recognition modules in order to 
mimic human olfaction. The disadvantage of electronic nose include lack of sensitivity and 
selectivity compared to other methods, but in recent years, studies have reported the 
potential of electronic nose for breath analysis in the detection of lung diseases. Natale et al 
investigated the potential of using electronic nose to diagnose lung cancer using breath 
VOCs profiles (51). Geffen et al reported electronic nose was able to distinguish between 
COPD and healthy subjects (52). 
1.6.4. TD-GC-MS setup for breath analysis 
This section will describe the TD-GC-MS setup employed for the current breath analysis 
used in this thesis. 
28 
 
1.6.4.1. Gas chromatography 
1.6.4.1.1. The GC elution process 
Gas chromatography (GC) is a physical separation method which compounds are separated 
between two phases: one is a liquid or solid stationary phase with large surface area; the 
second one is a gas unidirectional mobile phase which carries the compounds through the 
column. The compounds going through the column are then separated based on the 
distribution of each individual compounds between the mobile phase and stationary phase. 
Since compounds that are distributed in stationary phase become static, they only move 
while they are in the mobile phase, so compounds that have higher distribution in the mobile 
phase will pass through and leave the column faster than compounds with lower distribution.  
 
Figure 1.6.4.1.1.1. The GC separation process 
Compounds with lower distribution coefficient will be eluted from column first. The 
distribution coefficient K of a compound can be calculated using the following equation: 
𝐾 =
𝐶ௌ
𝐶ெ
                                       Equation 1.6.4.1.1. 
Cs is the concentration of solute in the mobile phase; Cm is concentration of solute in 
the stationary phase. 
The process which compounds are transported and separated through chromatographic 
system is known as chromatographic development. There are different types of 
chromatographic development, but elution development is the only development that occurs 
in GC. Elution development is consisting of a series of absorption-extraction processes that 
occurs as the sample move through the chromatographic system. As the sample travels 
along the column, equilibrium is established between gas mobile and stationary phase so 
that the probability of sample compounds colliding with large surface area of stationary 
phase and entering it is the same as the probability of a compounds obtaining enough kinetic 
energy to leave the stationary phase and entering the gas mobile phase. The distribution of 
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a compound between the two phases is always thermodynamically driven towards 
equilibrium. However the gas mobile phase is constantly moving displacing concentration of 
solute in the gas mobile phase forward, so concentration of solute at the front of peak in the 
mobile phase will increase and exceeds the equilibrium concentration. As a result, the solute 
in the front of the peak will be continuously entering the stationary phase to reach the 
equilibrium concentration. At rear of the peak, the concentration of solute in gas mobile 
phase will be lower than the equilibrium concentration since the solute is being displaced 
forward, the solute now enter the gas mobile phase from stationary phase to attain 
equilibrium. However, only the solute molecules with kinetic energy greater than the potential 
energy of their association with molecules of stationary phase will leave and enter the mobile 
phase. When the number of molecules with enough kinetic energy to enter the mobile phase 
equals the number of molecules with not enough kinetic energy and retained in the 
stationary phase, the equilibrium is attained (55) (56). 
 
 
Figure 1.6.4.1.1.2. The elution process 
1.6.4.1.2. The plate theory 
In order to understand how separation can be achieved, an equation needs to be derived for 
retention volume of a compound, hence equation for elution curve of the compound. The 
plate theory was originally created by Martin to derive an expression for elution curve of the 
compound. The plate theory is based on the assumption that a compound is always in 
equilibrium between the two phases. However, due the constant movement of the gas 
mobile phase, equilibrium is never truly achieved. So the column is considered to be divided 
into number of plates, each plate has a certain length, solute will spend a finite time in each 
plate. The size of each plate will provide enough dwell time for the solute so equilibrium is 
achieved between the two phases, therefore the smaller the plate is, the more efficient the 
solute exchange between the two phases are, the more plates are present in the column. 
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The number of theoretical plate N in a column is also known as column efficiency and 
reflects the separation power of a column. A equation can be derived to determine plate 
number by measuring retention time 𝑡ோand peak width 𝑊௛: 
𝑵 = 𝟓. 𝟓𝟒 ቀ 𝒕𝑹
𝑾𝒉
ቁ
𝟐
                                                                                         Equation 
1.6.4.1.2.1. 
A large plate number and small peak width indicates an efficient column. 
Another way of expressing the efficiency of column is plate height H. It is height of column 
occupied by one plate. H has units of length and is better than N for comparing efficiencies 
of columns of different length, it is also known as Height Equivalent to One Theoretical Plate 
(HETP). Plate height 𝐻 can be calculated by following equation: 
𝑯 =  𝑳
𝑵
                                                                                                       Equation 
1.6.4.1.2.2. 
𝐿 is the column length. A small H will indicate an efficient column. 
1.6.4.1.3. The rate theory 
When sample is first injected into a GC column, it is a narrow band, but as the sample 
travels through the column the solute will start to randomly disperse and spread. The 
distribution of sample molecules will form a Gaussian shape. The dispersion of sample is 
very important to consider, since if the dispersion is great, then different compounds will mix 
together and peaks that emerge will be have low resolution. The dispersion of solute is due 
to physical processes which take place which can be explained partly by the plate theory, 
but it didn’t address non-equilibrium conditions, so another approach known as the rate 
theory was published by Van Deemter in 1956 to describe the kinetic factors in peak 
dispersion. The rate theory defines three important factors that contribute to peak dispersion 
in packed column: multi-path dispersion, longitudinal diffusion, resistance to mass transfer in 
the two phases. The Van Deemter equation that describes variance per unit length of a 
packed column to linear velocity of mobile phase in terms of plate height (𝐻) is shown below. 
As you can see, it is separated into three parts, A, B and C each represent a dispersion 
factor, and 𝜇 is the linear velocity. 
 
𝑯 = 𝑨 + 𝑩
𝒖
+ 𝑪𝒖                                                                                        Equation 1.6.4.1.3.1. 
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Most of columns that are used currently are capillary column, so the Van Deemter equation 
cannot be applied to them. Since in cappilary columns there are no packing particles, so all 
the solute molecules will take the same path, hence multi-path dispersion (Factor A) will not 
occur. 
Longitudinal diffusion (factor B) occurs due to the natural random diffusion process of solute 
contained in gas or liquid, which produces Gaussian form distribution. The solute diffuse 
from region of high concentration to an area of low concentration. Van Deemter derived the 
following equation for longitudinal diffusion: 
𝑩 =  𝟐𝑫𝒎
𝒖
                                                                                                   Equation 1.6.4.1.3.2. 
𝐷௠is diffusivity of the solute in the mobile phase. 
Small value of diffusion coefficient will generate small factor B and small H. Since B is 
divided by u, by using a high linear velocity carrier gas or flow rate it will minimise factor B by 
decreasing the time solute spends in column and solute diffusion. 
Factor C is resistance to mass transfer in both mobile phase and stationary phase. This 
resistance to mass transfer occurs when the molecules close to boundary of the two phases 
will travel to the other phase before the molecules that are further away and will have longer 
distance to travel. As a result, the moving mobile phase will push the molecules that are 
closer further away from molecules that are further away, thus will result in dispersion. 
Factor C can be separated into two equation for the two phases. 𝑑௙ is effective thickness of 
stationary phase, 𝑑௣ is effective thickness of mobile phase. 𝑓ଵ and 𝑓ଶare both constants, 𝐷௠ 
is diffusivity of solute in mobile phase, 𝐷௦ is diffusivity of solute in stationary phase and 𝑘 is 
capacity ratio of solute. 
𝑪 = 𝒇𝟏𝒌𝒅𝒑
𝟐
𝑫𝒎
𝒖 +
𝒇𝟏𝒌𝒅𝒇
𝟐
𝑫𝒔
𝒖                                                                                 Equation 1.6.4.1.3.3. 
To minimise Factor C, stationary or mobile phase should be thin and diffusion coefficient 
needs to be large. Rapid diffusion through mobile or stationary phase will keep the solute 
molecules together. Thin stationary phase will speed up mass transfer into and out of 
stationary phase. Creating thin stationary phase can be achieved by applying thinner coating 
on column, but lowering diffusion coefficient can only achieved by using low viscosity 
stationary phase. 
The modified equation for open tubular column or capillary column is invented by Golay, so it 
is known as the Golay equation: 
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𝑯 = 𝟐𝑫𝒎
𝒖
+ 𝒇𝟏𝒌𝒓
𝟐𝒖
𝑲𝟐𝑫𝒔
+ 𝒇𝟐𝒌𝒓
𝟐𝒖
𝑫𝒎
                                                                          Equation 
1.6.4.1.3.4. 
𝑟 is the column radius and 𝐾 is the distribution coefficient of the solute between the two 
phase. 
1.6.4.2. Thermal desorption 
In recent years, thermal desorption (TD) has become the method of choice for most ambient 
monitoring applications due to the 1000 fold sensitivity enhancement when compared with 
solvent extraction. A wide range of weak, medium and strong commercial sorbents are 
available for a wide of applications. Therefore sorbent selection compatible for TD and 
analyte of interest is essential to consider prior to experimental use. Sorbent packed tubes 
can typically contain between 1 and 4 sorbents arranged in order of increasing sorbent 
strength from sampling end. Multi-sorbent tubes are especially useful when monitoring a 
wide range of compounds at different volatility. A range of factors need to be considered to 
sorbent selection for multi-sorbent tubes including the volatility range of target compounds, 
sorbent temperature compatibility, storage stability and water retention (53). There is no 
such thing as a truly ‘universal’ adsorbent tube that can cover all applications, however, the 
most broadly applicable multi-sorbents combination for a single tube is Tenax TA backed up 
by a medium strength graphitized carbon black (eg. Carbopack B or Carbograph 1 TD) 
backed up by a strong carbonized molecular sieve sorbent (eg. Unicarb or carbonxen 1003). 
This multi-sorbents combination can be used for quantitatively a wide volatility range of 
compounds from C3 to C26. However, there is one limitation to this sorbents combination 
which is the strong carbonized molecular sieve sorbent is prone to water retention, due to 
the high level of humidity in human breath, carbonized molecular sieve sorbent isn’t an ideal 
sorbent material. Standard sized tubes packed with equal bed length and weight of Tenax 
TA and Carbograph 1TD is selected for measuring breath VOCs for this study. When using 
multi-sorbent tubes, it is essential to use backflush desorption where the flow of gas through 
the tube during desorption is the opposite direction of flow during sampling, thus protecting 
the stronger sorbents from higher boiling point analytes.  
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Figure 1.6.4.2. Schematic diagram of multi-sorbent tube with weaker Tenax TA 
sorbent and medium strength Carbograph 1TD sorbent. 
The analytes retained by the adsorbent tube can be injected into the GC in either a 1-stage 
or 2-stages thermal desorption process. In a 1-stage process, the analytes are thermally 
desorbed directly into the GC. For 2-stage thermal desorption, a focusing device is used to 
trap and rapidly inject the analytes into the GC. The 2-stage process is the preferred 
process, the introduction of a focusing device such as capillary cryofocusing or cold trapping 
significantly improve chromatography. Capillarycryofocusing collection involvespassing 
carrier gas through capillary tubing at very low temperature (as low as -160°C depending on 
the application), this method produces very good chromatography by reducing peak 
distortion and improving peak resolution, but the method can be costly due to the use of 
cryogen, and the water vapor contained in the sample can be deposited as ice causing 
blockage to the capillary and dilute the sample., Therefore cold trapping is the preferred 
focusing device used in thermal desorbers. In the first stage of thermal desorption, the 
adsorbent tube is heated to high temperature under Helium carrier gas in the reverse flow of 
sampling. The analytes are transferred and retained onto the electrically cooled cold trap. At 
the second stage, the cold trap is rapidly heated to high temperature (Up to 100°C s-1) 
causing the analytes to transferred into the GC. This rapid second stage thermal desorption 
process allows analytes to be transferred in as little as 100 to 300 µl of carrier gas, thus 
significantly improve analyte sensitivity and chromatography (54).      
1.6.4.3. Quadrupole Ion trap mass spectrometry 
The Varian quadrupole ion trap MS instrument used have two different ionisation methods: 
electron ionisation (EI) and chemical ionisation (CI). In EI, the ion source exposes the 
sample to 70 eV of electrons from filaments, as analyte molecule interact with the thermal 
electrons from the beam, the sample molecule will have one electron knocked off and 
become positively charged ion. Since the positively charged analyte ion has gained energy 
through energy transfer, it is likely to fragment to loss energy. It is also likely the initial 
energy transfer to the molecule will cause fragmentation as well. EI is also known as hard 
ionisation due to the high level of fragmentation it causes, but the fragmentation pattern it 
generates is unique to specific compound and can be used for qualitative analysis. The 
ionisation process of molecule is shown below: 
𝑴 + 𝒆ି → 𝑴ା∙ + 𝟐𝒆ି                                                                                      Equation 1.6.4.3. 
The quadrupole ion trap mass spectrometry is three dimensional analogue of the more widely 
used linear quadrupole mass filter. The ion trap consists of three electrodes with hyperbolic 
surfaces: the central ring electrode and two adjacent endcap electrodes (See Figure 
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1.6.4.3.1.). The electrodes are separated by ceramic spacers. A radio frequency (RF) 
generator generates a voltage that is applied to the central ring electrode which alternatively 
reinforces and dominates the direct current (DC) voltage that is applied to the endcap 
electrodes, thus generates a three dimensional hyperbolic electrical field within the ion trap. 
Ions generated from ionisation source which enter the electrical field are subjected to 
stabilising and destabilizing forces, and oscillate in both R- and Z-directions. The R- direction 
is a combination of X and Y axis. Therefore the ions are trapped in a three dimensional stable 
trajectory in between the ring electrodes and end cap electrodes which allows no degrees of 
freedom (57).  
 
Figure 1.6.4.3.1. Schematic diagram of quadrupole ion trap consisting of the central 
ring electrodes and two adjacent endcap electrodes. The ion trap is radially 
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symmetrical with hyperbolic cross section, R0 and Z0 represent its size. R-direction is 
a combination of X and Y planes. 
Similar to linear quadrupole mass filter, the trapped ions are then ejected by increasing RF 
voltage, this pushes the ions into unstable orbit and exit through the end electrode. The 
Mathieu stability diagram describes RF and DC voltages that determines the range of ion 
mass that can are in stable trajectory inside the ion trap. Radial stability is expressed in terms 
of ar and qr must be simultaneously maintained. As RF voltage increase, ion move along the 
qz axis until they become unstable at the boundary where qz = 0.908. When ions reach the 
unstable region, their kinetic energy increase causing ions to be ejected out of their stable 
trajectory in the Z-direction, finally they exit the ion trap through endcap electrode. The ejected 
ions then enter the conversion dynode and electron multiplier where it will send a signal 
response to form mass spectrum.    
 
Figure 1.6.4.3.2. The Mathieu stability diagram for quadruple ion trap (58). Ion are 
simultaneous stable in both the R- and Z- planes if their az and qz are within the 
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shaded stable region. As RF voltage is increased, qz value increases to the value of 
0.908 while az = 0, then ions become unstable and are ejected out of ion trap. 
CHAPTER 2. EXHALED BREATH ANALYSIS WORK-FLOW 
2.1. Introduction 
The current exhaled breath analysis work-flow employed can be separated into 3 main 
stages: Exhaled breath sampling, breath sample analysis and data processing. This section 
will describe each stage of the work-flow in the detail.    
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Figure 2.1. The current exhaled breath VOCs analysis work-flow chart with 3 main 
stages: Exhaled breath sampling, breath sample analysis and data processing.  
2.2. Exhaled breath VOCs sampling 
2.2.1. Ethics 
All studies were conducted in accordance with the ethical principles of Good Clinical Practice 
and the Declaration of Helsinki. Detailed exhaled breath VOCs sampling protocol based 
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coded G09-05 on the current breath analysis work-flow was submitted and approved by 
ethics advisory committee at Loughborough University. Research proposals for any 
subsequent breath VOCs sampling studies involving human subjects were approved 
separately by ethics advisory committee at Loughborough University.  
2.2.2. Preparation for sample collection 
2.2.2.1. Breath masks preparation 
All breathing apparatus that are in direct contact with subjects are thoroughly cleaned and 
disinfected prior to experimental use. This include Mirage S2 full face masks (ResMed, UK), 
PTFE interface connections and sampling valves. The cleaning procedure employed follows 
recommended ResMed face mask cleaning procedure in accordance with the standard ISO 
17664: Sterilisation of Medical Devices.  
The breathing apparatus were first full disassembled and disinfected with ortho-
phthalaldehyde CIDEX OPA 0.55% solution (Johnson and Johnson, UK). The disinfected 
breathing apparatus were then rinsed with 5 L of warm water to clean off any residue 
disinfectant solution. Finally, the breathing apparatus were air dried and then vacuum dried 
at 50°C for 2 hours before being reassembled. The breath masks were then carefully packed 
in individual container before transported to breath sampling station. 
2.2.2.2. Adsorbent tubes preparation 
The adsorbent tubes used for exhaled breath collection were conditioned and analysed prior 
to experimental use. The adsorbent tubes used in our breath collection studies were multi-
sorbent tubes consist of Tenax TA 35/60 mesh and Carbograph 1TD 20/40 mesh (Markes 
International, UK) with a stainless steel tube casing on the outside (L89 mm × 6.4 mm O.D.). 
The two sorbent trap materials have very different physical properties; The Tenax TA has a 
recommended conditioning temperature of 325°C and Carbograph 1TD has a higher 
temperature limit at 350°C to 400°C (59). The adsorbent tubes were conditioned using a 
modified Hewlett Packard 5890 GC oven (Agilent Technologies, UK) at 310°C for 2 hours 
under high purity nitrogen gas from a Nitrogen generator (Peak Scientific, UK). The 
adsorbent tubes were conditioned in the opposite flow direction to sampling at a flow of 100 
ml/min. The tubes were cooled downed to 30°C for 1 hour before capped with 1/4” brass 
caps fitted with PTFE ferrules using spanner. 
The conditioned adsorbent tubes were then analysed on TD-GC-MS at isothermal 
temperature program at 300°C for 10 minutes to check for any VOCs residuals. The tubes 
were initially cooled to -10°C and desorbed at 300°C for 5 minutes. The inspected 
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conditioned adsorbent tubes were capped and stored at 4°C before transported to sampling 
station. 
2.2.3. Participant preparation 
All participants were given information sheet explaining the aim of study and brief breath 
sampling description. Prior to study, participant have been asked to avoid the use of make-
up and fragrance which can cause contamination to the sample collection. Depending on the 
study, participants might also be asked to fill in health questionnaire, consent form and 
exhaled breath collection questionnaire, or additional questionnaires. Exhaled breath 
collection questionnaire examines the participant’s food and drink intake prior to the start, 
any make-up or other products with strong odour that can cause contamination to the breath 
sampling. 
Participants have also been informed to terminate the breath sampling at any time if 
discomfort is felt by either pulling the safety strap on the full face mask or ask the breath 
sampling staff to take off the mask. Participant is also encouraged to try breathing in the 
medical air for a few breaths before the mask is strapped on to check comfort level. There is 
also a 5 minutes climatization period before breath sample collection.   
2.2.4. The adaptive breath sampler setup and exhaled breath collection 
The adaptive breath sampling apparatus was described in detail previously by Basanta et al 
(41). It consists of 3 main units: medical air supply, breath sampling unit and control interface 
on laptop PC. 
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Figure 2.2.4. Schematic diagram of adaptive breath sampling system. (A) full face 
breathing mask; (B) PTFE connector with sampling capillary; (C) adsorbent tube; (D) 
micro-control valves; (E) pressure transducer; (F) electronics interface; (G) sampling 
pump; (H) Laptop computer running DAC card and Labview software; (I) PTFE T-piece 
connector; (J) one-way valve; (K) 3-stage filtration assembly; (L) pressure regulator; 
(M) air supply generator. 
The medical air for breath sampling is supplied direct to the face mask generated by nitrogen 
generator (Peak Scientific, UK). The air supply from the generators pass through 3-stage 
filtration assembly: 100-12-DX filter element, 100-12-BX filter element and CI100-12-000 
2002-series adsorbent filter element (2000 Balston series, Parker Corporation, USA). 100-
12-DX and 100-12-BX filter elements are 2-stage coalescing particle filters that can remove 
99.99% of 0.01 Micron particles. The third stage filter is an activated carbon adsorbent that 
can remove any trace oil vapours from the compressor. Each filter element contains an 
automatic float drain. When used in combination with air compressor and aftercooler, the 
purified air supply after 3-stage filtration is able to meet the requirement of ISO8573-1:2010 
Class 1.X.1 which specifies maximum particle concentration of 0.08 ppm, maximum 
pressure dewpoint of -70°C and maximum oil vapour concentration of 0.008 ppm (60).  
The purified medical air (> 20 L min-1) was then supplied to the face mask through a custom 
made PTFE T-piece (Tefloturn Ltd, UK) using silicone tubing connection (4.8 mm bore, RS 
components, UK). A one-way valve (Clement Clarke International Ltd, UK) was attached to 
the bottom of PTFE T-piece to avoid room air contamination.  
The breath sampling unit utilises a custom made sampling control unit with pressure sensor 
to control alveolar air collection. The sampling control unit consists of two electrofluidic 
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micro-switch valves (Lee, LFA1201718H, UK) with driver electronics and an integrated 
circuit pressure sensor which incorporated a Luer fitting connection that allowed it to be 
connected to face mask via silicone tubing. The sampling control unit is connected to a 
Laptop PC via a 25-way D-type electrical connector fitted with 6024E PCMCIA data 
acquisition card (National Instruments, UK). A custom built Labview virtual instrument 
program (National Instruments, UK) was used to operate the sampling control unit. The 
pressure sensor output voltage tracks the subject’s inhalation and exhalation inside the full 
face mask, and is plotted in real-time as continuous waveform generating a breath profile on 
the Labview software interface. In order to sample alveolar air, the user can specify the 
proportions of the breath profile to be collected. The Labview software is then able to assess 
the real-time breath profile and enable targeted breath sampling based on user setting. The 
breath profile can be saved in .csv format at end of breath sampling.  
The adsorbent tube is attached to the face mask via custom made PTFE connector 
(Tefloturn Ltd, UK). An approximately 5 cm MXT guard column sampling capillary (Thames 
Restek, UK) was fitted inside a Luer fitting into the face mask positioned close to participant 
nose. The other end of the capillary is positioned inside the adsorbent tube inlet end close to 
the mesh screen. As subject inhales and exhales, the two micro-switch valves controlled by 
Labview interface switches between sampling and vent modes to enable targeted alveolar 
breath sampling. During sampling mode, the sampling pump (Escort ELF pump, MSA, UK) 
draws subject’s exhalation into the adsorbent tube at a flow rate of 0.8 L min-1. During vent 
mode, no breath is collected onto the adsorbent tube. The exhaled breath is collected until 
the target volume has been reached. Breath collection usually takes around 5 to 10 minutes 
to achieve 2 L to 2.5 L target volume. If time allows, 2 breath samples are usually collected 
for each participant. The participant is asked to maintain relaxed normal breath pattern 
through nose during breath collection (Figure 2.2.4.). Before breath collection, participant is 
asked to acclimatise to the purified air for 3 to 5 minutes.  
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Figure 2.2.4. the participant is strapped to full face mask (A) using headgear clips (I). 
An adsorbent tube (C) is attached to the face mask via a custom made PTFE 
connector fitted with sampling capillary (B). Sampling pump is used to suck exhaled 
breath into the adsorbent tube via silicone tubing (H). A 3.4 mm bore silicone tubing 
(G) is connected to other port on the face mask which is connected to the sampling 
control unit that monitors the pressure output voltage inside face mask and is plotted 
as continuous waveform. Purified medical air is supplied via silicone tubing (F) 
through a custom made PTFE connector (D) fitted with one way valve (E) into face 
mask. The full face mask also contain an emergency release cord (J) that can be 
pulled by participant to remove mask.   
2.2.5. Background air collection  
Additional to the breath samples collected, 1 room air sample and medical air supply sample 
are collected on the same day. A 2.5 L (equivalent volume to breath sample collected) room 
air sample was collected onto a conditioned adsorbent tube for 2.5 minutes at a flow rate of 
1 L min-1 using Escort ELF sampling pump. The medical air supply sample can be collected 
by adjusting the pressure regulator to 1 L min-1 and sampling for 2.5 minutes onto a 
conditioned adsorbent tube.  
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2.3. TD-GC-MS instrumentation and sample analysis 
The exhaled breath VOCs samples collected were analysed using thermal desorption – gas 
chromatography – mass spectrometry (TD-GC-MS) system (Figure 2.3.). The exhaled 
breath VOCs trapped onto the adsorbent tubes were injected into the analysis system using 
a 2-stage thermal desorption process. The thermal desorption unit consists of Unity Series 1 
thermal desorption unit coupled to an Ultra thermal desorption auto sampler unit with 100 
adsorbent tubes capacity (Markes International Ltd, UK). During primary desorption stage, 
the compounds trapped onto the adsorbent tube were thermal desorbed onto U-T2GPH 
general purpose hydrophobic cold trap (Markes International Ltd, UK) by heating the tube to 
300°C with a desorption flow of 50 ml min-1 for 5 minutes. The desorbed compounds were 
retain onto the cold trap at - 10°C. During the secondary desorption stage, the retained 
compounds were rapidly desorbed off the cold trap and injected into the GC-MS analysis 
system by heating the cold trap to 300°C at maximum heating rate with a flow rate of 50 ml 
min-1 for 5 minutes. 
 
Figure 2.3. Schematic diagram of TD-GC-MS setup used in breath analysis. High 
purity helium is pumped into Unity Series 1 thermal desorption unit coupled to an 
Ultra thermal desorption auto sampler unit (A) where breath sample collected on 
adsorbent tubes is injected into Varian 3800 gas chromatograph (B) and separated 
using a DB-5 capillary column (C), the separated breath sample is then analysed 
using a Varian Saturn 4000 ion trap mass spectrometer (D)   
The breath analytes are injected into the Varian 3800 gas chromatograph at a flow rate of 2 
ml min-1 via a fused silica column transfer line (0.25 mm I.D, Suepelco, UK) heated to 280°C. 
The analytes then pass through a DB-5 capillary column ( (5%-Phenyl)-methylpolysiloxane, 
L30m × 0.25 mm I.D. × 0.25 µm film thickness, Agilent Technologies, UK) at a constant flow 
rate of 2 ml min-1. The GC oven uses temperature ramp program to separate the analytes 
with an initial temperature 40°C heated to a final temperature 300°C (Hold time 8 minutes) at 
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a rate of 5°C/minute. The separated analytes are then transferred into the ionisation source 
of Varian Saturn 4000 ion trap mass spectrometer and ionised through electron ionisation. 
The resultant ions responses are measured by the detector as mass to charge ratios 
information.    
𝐾 =
𝐶ௌ
𝐶ெ
  
𝑴 + 𝒆ି → 𝑴ା∙ + 𝟐𝒆ି 
2.4. Exhaled breath VOCs data analysis 
2.4.1. Data processing work-flow 
The data processing methodology work-flow employed is illustrated in Figure 2.4.1. The 
workflow consists of mainly 3 stages: initial data deconvolution, creation of breath matrix and 
multivariate analysis of the created breath matrix.  
 
Figure 2.4.1. The work-flow diagram of exhaled breath data processing method 
consisting of data deconvolution, creation of breath matrix and multivariate analysis.  
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2.4.2. GCMS data deconvolution 
The first stage in the data processing work-flow is deconvolution of raw data generated by 
GCMS. The data is first checked through for any major contamination, high level of volatile 
contaminants from participant can cause high intensity peaks at the start of chromatogram, 
the over loading peaks can cause ion suppression to low intensity peaks and makes 
chromatogram unusable.  
The usable raw data was then deconvolved using AnalyzerPro software version 2.5.1.7. 
(Specktralworks, UK). The data deconvolution parameters were optimised using test data 
with known co-eluting compounds. The data deconvolution parameters used is summarised 
in Table 2.4.2. Retention index ladder was also added to each chromatogram prior to 
deconvolution in AnalyzerPro software. The creation of retention index ladder will be 
discussed in the next section. The deconvolved data was exported into .csv format which 
can be latter assessed in Excel spreadsheet (Microsoft, USA). Each exhaled breath sample 
typically generates around 400 to 600 compounds. Each identified component was defined 
by retention time, retention index, scan number, intergrated peak area, peak height, peak 
width, signal to noise ratio, peak purity, base peak and number of ions. The output data is 
then manually checked against raw GCMS data to check for false positives or any 
components missed by the software. 
Table 2.4.2. Data deconvolution parameters used in AnalyzerPro software.  
Deconvolution parameters  Settings 
Area threshold 500 counts 
Width threshold 0.05 Min 
Signal to noise ratio 3 
Resolution very low 
Scan window 1 
Gaussian smooth 3 
Minimum ions in a component 1 
 
2.4.3. Retention index  
Retention index (RI) ladder is incorporated into breath sample analysis to allow for data 
alignment. The use of retention index is also essential for inter-laboratory data comparison 
since retention index is independent of instrument type, column length, flow rate or condition. 
The Kovats retention index is well established method that was first outlined in 1950s when 
performing research into the composition of essential oils: 
𝑹𝑰 = 𝟏𝟎𝟎 × ൤𝒏 +
𝒕𝒓(𝒖𝒏𝒌𝒏𝒐𝒘𝒏)ି𝒕𝒓(𝒏)
𝒕𝒓(𝑵)ି𝒕𝒓(𝒏)
൨                                                                        Equation 2.4.3. 
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𝑅𝐼 is the retention index value, 𝑛 is the number of carbon atoms of straight chain alkane that 
elutes before the unknown analyte with a retention time of 𝑡௥(௡). 𝑡௥(ே)is the retention time of 
the straight chain alkane that elutes after the unknown analyte, and finally 𝑡௥(௨௡௞௡௢௪௡)is the 
retention time of the unknown analyte of interest.  
The retention index standard used for breath analysis consists of a 18 compounds mixture 
made from straight chain alkane, chlorinated alkanes and alcohol functional classes (See 
Table 2.4.3.1.). Pure chemical standard for each compounds was purchased from Sigma 
Aldrich (USA) or Fisher Scientific (USA) and diluted using dichloromethane to a final 
concentration of 50 ppm. The RI solution was then injected into a blank thermal desorption 
tube using a 1 µl syringe at a injection volume of 0.1 µl, the spiked thermal desorption tube 
was then analysed using TD-GC-MS.         
Using the known retention times of a series of straight chain alkane mix from carbon number 
C8 to C20, retention index values are assigned to each alkane based on its carbon number 
(See Figure 2.4.3.). The assigned retention index values are then plotted against alkanes’ 
retention time to form the primary retention index ladder.  
Table 2.4.3.1. List of compounds that consist the retention index standard used for 
breath analysis 
Functional group class Compound name Carbon number Assigned RI number 
Alkane 
Octane 8 800 
Nonane 9 900 
Decane 10 1000 
Undecane 11 1100 
Dodecane 12 1200 
Tetradecane 14 1400 
Heptadecane 17 1700 
Eicosane 20 2000 
Chlorinated alkane 
1- Chlorohexane  6   
1- Chloroheptane  7  
1- Chlorooctane 8  
1-Chlorononane 9  
1- Chlorodecane 10   
Alcohol 
1-Hexanol 6  
2- Heptanol 7  
2- Octanol 8  
5- Nonanol 9  
1- Decanol 10   
 
Due to the high humidity in breath samples, the stationary phase of the capillary column is 
continuously degraded. The water content of the breath samples cause hydrolysis to the 
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siloxanes of the stationary phase, multiple reactions can occur and results in formation of 
cyclosiloxanes which are observed in the chromatogram (See Figure 2.4.3.). These 
cyclosiloxanes are found in every breath sample chromatogram and are used as secondary 
retention index ladder. The 5 commonly found siloxanes which cover a wide duration of 
chromatogram were assigned a retention index value based on the primary alkane retention 
index ladder (See Table 2.4.3.). The assigned retention index values of these cyclosiloxanes 
are then plotted against their retention times for each breath sample, thus this is then used 
to align all breath sample data.  
Table 2.4.3.2. The 5 commonly found cyclosiloxanes used in the secondary retention 
index ladder for aligning breath sample components.  
 
Common breath siloxanes 
RI 
value Expected retention time 
Extracted ion 
chromatogram  
S1 Cyclotetrasiloxane, octamethyl 998 10.768 281 
S2 Cyclopentasiloxane, decamethyl 1142 15.357 355, 267, 73 
S3 Cyclohexasiloxane, 
dodecamethyl 1303 20.128 73, 341, 429 
S4 Cycloheptasiloxane, 
tetradecamethyl 1516 24.448 73, 281, 327, 415 
S5 Cyclooctasiloxane, 
hexadecamethyl 1664 28.091 
355, 73, 221, 147, 401, 
281 
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Figure 2.4.3. TIC chromatograms of primary retention index ladder using alkane 
compounds from C8 to C20 (bottom) and secondary retention ladder using breath 
cyclosilane compounds from S1 to S5 (see Table 2.4.3.2.) (top)   
2.4.4. Creation of breath matrix 
The breath matrix is a spreadsheet of integrated peak areas for each identified breath 
component plotted against sample name. Each identified breath component is assigned 
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breath library reference consisting of the calculated RI value and its de-convolved mass 
spectrum, the breath library reference is written in the format of BRI-XXX-YY-YY-YY-YY-YY. 
XXX stands the RI value and YY are the 5 most abundant ions in its extracted ion 
chromatogram. The list of identified breath components was input into Varian MS 
workstation software to generate a spectrum library where it is then processed against raw 
data files for peak area integration. The peak area integrated by Varian software is manually 
checked against raw data files. The final peak areas were used to create breath matrix.    
2.4.5. Multivariate analysis 
Due to complexity of the breath matrix generated, it is not usually not possible to summarise 
and virtualise the data without using statistical tools. Multivariate analysis (MVA) is based on 
the statistical principle of multivariate statistics, where multiple variables are analysed at the 
same time with observations. The aim of MVA is to reduce the amount of data if there is 
correlation present between variables and observations, thus determining the variable that 
correlates with the factors of interest (eg. Disease state).  
The breath matrix created was imported into MVA software SIMCA-P Version 12 (Umetrics, 
Sweden). The dataset was first pre-treated by applying the same block weight and Pareto-
scaling for each variable. In scaling methods, the data are treated by dividing each variable 
by the scaling factor which adjust the fold difference between metabolites by converting the 
data into difference in concentration relative to scaling factor. Pareto scaling divide each 
variable by the square root of the standard deviation, this ensures large fold changes are 
decreased more than small fold changes, hence small changes in dataset becomes more 
dominant, i.e. compounds at trace ppbv or pptv level becomes more apparent in the model. 
Pareto scaling also stays closer to the original measurements than other scaling methods by 
retaining the original unit (61).  
The pre-treated breath matrix then undergo unsupervised principal component analysis 
(PCA) and supervised orthogonal partial least square discriminant analysis (OPLS-DA) or 
partial least square (PLS) data modelling. The unsupervised PCA modelling is usually 
applied first to the initial pre-treated breath matrix as overview of the dataset for determining 
trends and outliners. After determining a group of variables with correlation to the 
observation, the supervised OPLS-DA is then applied to discriminating between groups (eg 
asthmatic and healthy) and identifying biomarker candidates.    
PCA uses orthogonal transformation to combine the original variables (ie. 𝑋ଵ, 𝑋ଶ…) into a set 
of linear uncorrelated variables called principal components (ie.𝑍ଵ,𝑍ଶ…). The new principal 
components are chosen so that the first principal component accounts for the most of 
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variation of the dataset, and the second principal component accounts the next largest 
variation in the dataset and so on (62).   
𝒁𝟏 = 𝒂𝟏𝟏𝑿𝟏 + 𝒂𝟏𝟐𝑿𝟐 + 𝒂𝟏𝟑𝑿𝟑 + ⋯ 𝒂𝟏𝒏𝑿𝒏                                                      Equation 2.4.5.1. 
𝒁𝟐 = 𝒂𝟐𝟏𝑿𝟏 + 𝒂𝟐𝟐𝑿𝟐 + 𝒂𝟐𝟑𝑿𝟑 + ⋯ 𝒂𝟐𝒏𝑿𝒏                                                      Equation 2.4.5.2. 
𝑎௡ are coefficients values are chosen so the new principal components are uncorrelated.  
 
 
Figure 2.4.5. The projection of principal components PC1 and PC2 along axis, PC1 
and PC2 are orthogonal to each other.  
The loading plot is used to determine the relationship between principal components to the 
original variables by summarising the variables and explaining the position of observations in 
the scores plot. Each original variable is assigned 𝑝 value which is weigh or importance of 
the variable to the model. If axis of the original variable lines up with the principal 
component, then 𝑝 is close to 1 therefore it has a strong influence on the principal 
component. If the component is orthogonal to the variable, then 𝑝 value is close to 0 and 
hence no influence on the principal component. If the component is opposite to the variable 
axis, the 𝑝 value is close to -1 and this shows a strong negative influence on the principal 
component. The loading plot is useful reducing the breath matrix to the smaller dataset that 
can be used for supervised modelling. 
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After identifying initial trends and reducing down the variables, a new dataset which have 
shown correlation to the observations is created and a supervised OPLS-DA or PLS model 
is applied. The aim of supervised pattern recognition methods is determine the relationship 
between the X and Y matrices. It uses a learning or training dataset to allocating unknown 
variables to the correct group. The starting point of PLS is linear discriminant analysis which 
is a linear combination of the original variables 𝑋ଵ, 𝑋ଶ etc (62): 
𝒀 = 𝒂𝟏𝑿𝟏 + 𝒂𝟐𝑿𝟐 + ⋯ 𝒂𝒏𝑿𝒏                                                                           Equation 2.4.5.3. 
The original 𝑛 measurements for each object have been combined into a single value of 𝑌, 
so the data have been reduced from 𝑛 dimensions to one dimension. The coefficients 𝑎 are 
chosen so 𝑌 value reflects the maximum difference between groups. OPLS model is 
extension to the PLS regression method which use information in the 𝑌 matrix to decompose 
the 𝑋 matrix into blocks of structured variation correlated to and orthogonal to 𝑌. The main 
advantage of OPLS-DA is its ability to separate predictive from the non-predictive orthogonal 
variation making the loading vector 𝑝 easy to interpret (63). OPLS model is built on class 
membership 0 or 1, therefore it is used mainly for datasets with 2 classes (eg asthmatic or 
healthy).  
The SIMCA-P software uses a cross validation approach which divides the 70% of the data 
into a training set used to calculate the 𝑌 values, and 30% of the data into a test set that is 
used to identify the correct group. The process is repeated until the model finds an optimum 
result.  
S-plot is score plot of 𝑝 values which describes the magnitude of each variable against 
𝑝(𝑐𝑜𝑟𝑟) describes the reliability of each variable. It combines the covariance and correlation 
from the supervised OPLS-DA model to determine the variables that discriminate between 
groups. Peaks with low importance are grouped in the middle, variables with high covariance 
and reliability are located at the far corners, thus enables good visualisation of the data and 
useful to determining potential biomarkers (64). 
2.5. Research objectives 
This chapter has explored the aspects of exhaled breath VOCs, and its applications as a 
diagnostic tool for respiratory diseases. It has also described in detail the methodology and 
its theoretical principles used for exhaled breath analysis including breath sampling, analysis 
and data processing.  
There are many confounding factors to the current methodology that need to be considered. 
As discussed in the first chapter, inter- breath sample variability can be due to a huge variety 
of factors. The condition of participant such as exposure to airborne contaminations, diet 
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intake, menstrual cycle and diurnal variation all adds to the complexity of breathomics, the 
introduction of external artefacts can significantly increase the difficulty in detecting small 
changes in participant breath VOCs profile. Therefore it is essential to achieve optimum 
standardised and reproducible approach to all aspects of breath sample collection.  
Many of the participant factors are difficult to manage, since everyone has a distinctive diet, 
metabolism, lifestyles and body conditions. However, a standardised and reproducible 
approach to the exhaled breath sampling methodology can still significantly reduce variability 
to the breathomics data. This thesis aims to explore a number of approaches to standardise 
the breath sampling method: 
 The storage stability of exhaled breath VOCs retained on the multi-sorbent 
tubes – Clinical studies can take months or even years to finish due to participant 
shortage. The analysis of these breath samples collected from participants can be 
spread out over several month if not years. This can introduce inter-instrumental 
variability to the data that can cause significant difficulties during data processing. A 
long term storage experiment of exhaled breath VOCs was carried out to establish a 
validated storage protocol for exhaled breath sampling. 
 The development of standardised portable breath sampling system – it is not 
always feasible for collect breath sample from participants in designated clinical 
locations, remote breath sampling can enable a much wider range of breath studies 
to be carried out. However, the level of VOCs at different locations can vary 
significantly. Therefore it is important for participants to be provided with 
standardised inspired air. The design and development of the portable breath 
sampling system utilising standardised air supply is described in Chapter 3.  
 The application of the standardised approach to clinical study of exercised 
induced bronchoconstriction (EIB) – Exercise-induced bronchoconstriction (EIB) is 
a common pulmonary disorder characterized by airflow obstruction occurring after 
several minutes of physical activity. This study sought to determine if there is 
detectable changes in participant exhaled breath VOCs profile after high intensity 
cardiopulmonary exercise testing (CPET). The portable breath sampling system 
developed will be used to collect breath samples from participants before and after 
their CPET inside sports facility. Sports facility can introduce extra air borne 
contaminants from human sweats and odour. This study will test the application of 
the developed protocol and device in a clinical study. 
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CHAPTER 3: THE DEVELOPMENT OF A BREATH ANALYSIS 
METHODOLOGY: TOWARDS A REPRODUCIBLE APPROACH 
AND SAMPLE STORAGE 
3.1. Introduction  
3.1.1. Evaluation of the current workflow 
Exhaled breath VOC analysis has experienced growing attention recent years as a method 
for observing biochemical processes, and discovering biomarkers. The non-invasive and 
safe nature of breath VOC analysis has excited significant interest in its potential as a clinical 
diagnostic test. In particular has been the focus of research on diseases such as lung 
cancer, COPD, tuberculosis, asthma and other types of cancer (65) (66) (42) (67) (68). 
The current work-flow for exhaled breath analysis employed was reviewed by Guallar-Hoyas 
et al, which can be separated into 3 stages: sampling, analysis and data processing. 2.5 L 
breath samples were collected using an adaptive breath sampler at optimised flow rate of 1 
L min-1. The breath sampler was connected to a full face mask. The samples were collected 
in Tenax/Carbotrap adsorbent tubes and stored at 4°C until they were analysed within 72 
hours of sampling.  
Exhaled breath samples were analysed using two-stage thermal desorption (Unity series 1, 
Markes International, USA) interfaced to gas chromatography (Varian CP-3800, Agilent, 
USA) and ion trap mass spectrometer (Varian 4000, Agilent, USA). A mixture of straight 
chain hydrocarbons, chlorinated hydrocarbons and alcohol standards were used for 
retention indexing. This retention index ladder created was then mapped onto the retention 
times of ubiquitous siloxanes to produce a secondary retention index ladder. Resultant data 
from exhaled breath samples were processed to create a breath matrix based on retention 
index and mass spectra. The breath matrix consists of the peak area of isolated VOCs 
compounds coded by RI number and ion fragments against participant codes. This breath 
matrix can be input straight into multi-variate analysis (MVA) to identify candidate 
biomarkers.  
Exhaled breath samples are saturated with water vapour, a 2.5 L sample contains 
approximately 125mg of water. Such levels of water degrade gradually the stationary phase 
in the GC column affecting the retention time of chromatographic peaks and causing 
variation in the data. The profiling of VOCs compounds using retention index and mass 
spectra has proven to be effective for reducing data variation, especially against the effect of 
water vapour. This provides data suitable for inter-laboratory and inter-study comparison. 
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This method uses retention index to manage variation, but the manual syringe injection 
involved in retention index standards, introduces other aspects of analytical variability that 
prove difficult to manage. This approach could be enhanced by the incorporation of stable 
isotope-labelled internal standards into breath samples.  
This current method requires a breathable air supply and as such is restricted to locations 
where this is available. Certain studies require samples to be collected in the field or clinic or 
community and transporting participants to a location with an air supply is rarely practical, or 
welcomed by participants. Additionally, the level of exogenous compounds within breathable 
air supplies originating from background room contamination or the manufacture of 
components may often be present at higher concentrations than exhaled VOC biomarkers. 
This present challenges for the development of clinical breath sampling protocol and so the 
development of a portable breath sampler presented an opportunity to reduce such 
background contaminants. 
3.1.2. Increasing storage times 
The storage stability of breath sample adsorbent tubes for thermal desorption is an important 
aspect of breath analysis methodology. Currently, the samples are stored at 4°C and should 
be analysed within 72 hours due to the risk of low-volatility compounds migrating onto 
stronger adsorbents inside the sampling tube. The stronger carbon black adsorbent is not 
completely inert, and may cause degradation of labile low-volatility compounds leading to 
irreversible adsorption and incomplete recovery during desorption (53). Often the collected 
breath VOC adsorbent tubes are analysed immediately after sampling to minimise any 
variability, however it might not be possible to always achieve this. In such cases, the 
adsorbent tubes should be be put into adequate storage conditions until sample analysis. 
The storage conditions adopted varies depending on the type of adsorbent tubes used. 
Single Tenax TA sorbent tube have been observed to be stable under room temperature 
conditions for up to 1 year for benzene, xylene and toluene, and up to 2 years for stable 
chlorinated hydrocarbons (69) (70). Although trapped VOC are more stable in single 
adsorbent tubes, multi-bed adsorbent tubes are used more often in breath research because 
a wider volatility range of compounds may be captured. Multi-bed adsorbent tubes need to 
be stored under refrigerated conditions for no longer than the maximum recommended 
period of 30 days for targeted compounds (53) (71) to supress the migration of VOCs from 
weaker to stronger adsorbents within multi-bed adsorbent tubes. Migration can lead to 
irreversible adsorption and hence incomplete recovery during the analysis. This type of 
migration can be minimised by increasing the length of weaker adsorbent or adding a 
medium strength adsorbent. Additionally storing the samples at a lower temperature, 
reduces the amount of kinetic energy the VOCs have to migrate between adsorbents and 
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hence minimises the rate of migration. The effects of storage have been revealed to be 
compound dependent (71). A recent short-term (2 weeks) storage and transportation study 
of multi-adsorbent breath VOCs samples reported no significant difference on 15 breath 
compounds related to asthma (72). However no study to date has investigated the long-term 
effect of storage on multi-adsorbent exhaled breath samples on a metabolomics scale. 
Additionally, past studies have often investigated exogenous breath compounds that are not 
related to biochemical pathways in the human body and may behave differently to 
endogenous breath components during storage. As the area of breath VOCs research grows 
it is essential to understand the impact of storage on the whole breath metabolomics profile 
for method validation.  
3.1.3. Experimental objectives 
The experimental objectives were identified for the method development activity in this 
project: 
 enhanced quality assurance through the incorporation of internal standards 
 fully mobile breath sampling 
 higher purity air supplies 
 longer storage times 
3.2. Varian TD/GC/MS system long term breath sample reproducibility and 
quality control 
3.2.1. Introduction 
The elements of the method development activity were embodied in a study to determine the 
effect of long-term (12 month) storage at - 80°C on the whole breath profile. The hypothesis 
was that storage at - 80°C would minimise the VOC migration between adsorbents enabling 
multi-bed adsorbent samplse to be stored for a long time prior to analysis. 25 breath 
samples, obtained rapidly from a single participant were analysed in 5 batches by TD-GC-
MS at 5 time points throughout 12 months storage. The storage stability of the trapped and 
recovered compounds were evaluated  
Instrumentation and/or storage conditions can introduce variations to breath sample analysis 
which may introduce difficulties to processing and modelling the data. By applying internal 
standards to breath samples it should be possible to account for such variations and this 
study investigated the feasibility of using deuterated standards to manage variability in 
breath analysis. The main aims are to determine: 
 Intraday breath samples variability 
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 Long term breath samples variability 
 Use the deuterated standards to establish instrument quality control and minimise its 
variability 
 Application of this method into studies 
3.2.2. Internal standards breath sample doping system setup 
The deuterated compounds were chosen to span the retention times of the chromatogram 
with an RI range from 755 to 1605 (5 minutes to 30 minutes); the range where most VOCs in 
breath samples occur.  
Table 3.2.2.1. Internal standards used for breath analysis 
Compound 
name Formula 
Molecular 
weight 
Calculated 
RI 
Toluene-d8 C7D8 100.1877 755 
Decane-d22 C10D22 164.4172 969 
Hexadecane-d34 C16D34 260.448 1605 
 
The internal standards were made into permeation sources that were placed in a test 
atmosphere generator that diluted the compounds released by diffusion with high purity 
nitrogen at low pressure. Low pressure was essential to minimise error since high pressure 
nitrogen flow will reduce the permeation rate. Gas flows were monitored and adjusted to 
constant values and the permeation source temperatures were maintained at 40°C 
throughout experiment (See Figure 3.2.2.). 
The permeation source doping system conditions used are shown in Table 3.2.2.2. 
 
Table 3.2.2.2. Permeation source doping system conditions 
Parameter Flow-rate Pressure Doping time Temperature Split 
Setting 50 ml.min-1 10 psi 30 s 40C 0 
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Figure 3.2.2. Schematic diagram of internal standards permeation system 
3.2.3. Breath sample analysis reproducibility quality control study 
3.2.3.1. Method 
Breath sample variability was investigated by taking 6 breath samples doped with 
same amount of internal standards were analysed on Varian GCMS within the same 
day since January 2012 on a weekly basis until September 2012. The peak area 
(MCounts) for internal standards were calculated and recorded. The RSD% of the 
internal standards’ peak areas from these 6 samples was used to estimate the 
intraday variation. The long term variability can be calculated as RSD% of peak area 
over time.  
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Figure 3.2.3.1. TIC chromatogram of 2.5 L breath sample doped with internal 
standards toluene-d8, decane-d22 and hexadecane-d34. The EIC chromatogram of the 
three internal standards are shown on the right hand.   
The peak area data from the internal standards were also used for introduce 
instrumental quality control. The responses to the internal standards were 
established by calculating the mean EIC peak areas from 20 doped breath samples. 
The upper control limit (UCL) and lower control limit (LCL) for each standard were 
also established as ± 2 standard deviations from the mean EIC peak areas of the 
standards recovered from the 20 doped breath samples.  
The peak areas of the internal standards responses were evaluated continuously 
and if they did not fall within between the LCL and UCL the instrument parameters 
were re-tuned to re-establish the optimised responses.  
Breath samples introduce contamination into the ion trap mass analyser which 
reduces the response. Observation of the internal standards’ responses alongside 
the instrument parameters enabled the contamination level of the ion trap to be 
determined. If retuning the instrument failed to bring the instrument into compliance 
within the control limits the ion trap and ionisation sources were disassembled and 
serviced.  
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The Varian 4000 mass spectrometer default parameters for achieve optimised 
responses are shown in Table 3.2.3.1. 
Table 3.2.3.1. Summary of Varian 4000 mass spectrometer parameters 
Parameters Settings 
Mass range 40 to 450 m/z 
Scan type  full 
Run time 60 minutes 
Maximum ion time 25000 µs 
Ionization type  Internal EI 
Emission currents 10 µAmps 
Electron multiplier range 0 to 3000 Volts 
Scan time 0.38 seconds/scans 
Scan frequency  2.63 Hz 
Transfer line temperature 300℃ 
Manifold temperature 50℃ 
Ion trap temperature 150℃ 
 
3.2.3.2. Results 
Average intraday variation was calculated to be 10.3% ± 4.6% from a total of 156 doped 
breath sample data throughout 9 months (See Figure 3.2.3.2.1.). The sources of this 
variation may be attributed to variations in: auto sampler injection, manual doping; and 
degradation of the ion trap from breath contaminants; causing reduction in response. In 
some breath samples, degradation in the responses to the internal standards response can 
be observed as the number of samples analysed increase. This was thought to be due to the 
water vapour in breath samples. interacting with active phases in the thermal desorption 
cryogenic trap, transfer components and GC column to form cyclic siloxanes. This 
phenomenon also caused reductions in retention time and peak. The effect of siloxane 
emphasise the importance of RI and internal standards for breath analysis. The effect of 
siloxane can be eliminated by either system bake out or increase electron multiplier voltage. 
The relationship between ion time and internal standards response will be discussed in the 
next section. 
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Figure 3.2.3.2.1. Variation of Toluene-d8 response for duration of 9 months on Varian 
GC/MS 
Long term sample variability was calculated as the total variation of the internal standards’ 
responses (RSD %) of 156 samples as 17.4%. 8.8% of samples were outside 3 standard 
deviation range, 28.2% of samples were outside 2 standard deviation range (See Figure 
3.2.3.2.1.). The samples response outside 3 standard deviation indicates system retuning or 
service was required. 
The ion time (µs) is the ionization time of the last scan in a Varian 4000 mass spectrometer. 
It indicates the amount of time ions were accumulated in the ion trap. The maximum ion time 
is set at 25000 µs for full scan. This is an essential instrument parameter for monitoring the 
state of the instrument. A reduction in ion time from its maximum on instrument parameter 
usually indicate possible contamination of the ion trap (perhaps from siloxanes) which 
reduces the ion accumulation time of analyte ions in the ion trap, and hence reduces the 
responses to analytes. 
22 doped breath samples were analysed throughout 1 month where the instrument 
parameters were kept constant except for ion time. The build-up in contamination with 
increasing breath samples was evident with the ion time decreasing accompanied by a 
reduction in the Toluene-d8 response, see Figure 3.2.3.2.2. The reduction in ion time was 
rectified by either a “bake out” or a system service. 
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Figure 3.2.3.2.2. Peak areas of toluene-d8 internal standard measured from 22 breath 
samples (black squares) and ion time measured before sample analysis (white circles) 
plotted against analysis date for one month duration. 
3.2.3.3. Summary 
Long term and intraday variability in breath samples were evaluated and the effect of various 
instrumental parameters on responses to internal standards was observed. The combination 
of internal standards and instrumental parameters tuning was successfully used to improve 
instrument stability, reduce variability and enhance the established method. Overall, the 
variability of the method was established to be 17% under this method. The rigorous use of 
formal quality control approaches and reports was intended to improve the reliability of data 
processing, and the application of these approaches to the sample storage will be shown in 
later section. 
3.3. The stability of volatile organic compounds trapped onto a dual-bed 
Tenax TA: Carbograph 1TD adsorbent trap from exhaled breath  
3.3.1. Breath sample collection 
The study was conducted in accordance with the ethical principles of the Declaration of 
Helsinki. The research method followed non-invasive exhaled breath sampling protocol 
coded G09-P5 that was approved by Ethics Advisory Committee at Loughborough 
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University. The participant gave written consent and was screened by a health 
questionnaire.  
One healthy male participant was recruited for this study to provide 25 exhaled breath 
samples. To minimise variation between samples, all breath samples were collected within a 
3 hours’ time frame. The participant was encourage to remain hydrated and drink water 
every 30 min. In addition to the breath samples, 5 room air samples and 5 medical air supply 
samples were collected after breath sample collection.     
Exhaled breath samples were collected from the participant fitted with a non-vented medical 
full face mask (ResMed, Mirage Full Mask Series 2) supplied with purified medical air at 
approximately 35 L min-1. The participant was first acclimatised to the purified air supply for 
10 min while breathing in a relaxed manner; through their nose. A pressure sensor fitted 
through one of the mask inlets measured and recorded pressure output voltage change 
inside the sealed mask tracking participant’s breath profile. Labview virtual instrument 
software controlled micro-valves in the sampling control unit that switched between sampling 
and vent modes based on participant’s breath profile. These software controlled valves 
enabled reproducible and targeted sampling of small airway exhaled breath. An inert 
capillary was connected to a second inlet on the facial mask to collect breath sample when 
the micro-valve switched to sampling mode; causing breath to be drawn through the mixed 
adsorbent trap (Tenax® TA/ Carbograph 1 TD, Markes International, UK). Each 2.5 L breath 
sample takes around 10 to 15 minutes to collect. A detailed adaptive breath sampler setup 
and workflow used here has previously been described (41). 
3.3.2. Heart rate and blood pressure measurements 
The participant’s blood pressure and pulse rate were measured every 15 minutes throughout 
the experiment using an automatic blood pressure monitor HPL-300. Metabolic rate is 
reflected in blood pressure and pulse rate and changes in these physiological parameters 
affects the level of many endogenous VOCs in breath, hence efforts were taken to keep the 
participant in a constant physiological state. Room temperature was also monitored every 15 
minutes.  
Participant’s systolic blood pressure was measured with average of 148 mmHg with ± 4% of 
variation, diastolic blood pressure was measured with average of 103 mmHg with ± 6% of 
variation, pulse rate was measured with average of 69 with ± 8% of variation, temperature 
was measured with average of 17.4°C with ± 1% of variation.  
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3.3.3. Long term breath sample storage at - 80°C  
All exhaled breath samples collected were randomised and then sealed with air tight storage 
packaging (73). After sample adsorbent tubes have reached - 80°C, their caps were 
retightened to avoid cap loosening. The samples were packed into air tight box and stored in 
- 80°C freezer. In order to assess the long term storage stability of breath samples, the 
collected samples were stored for up to 1 year.  
3.3.4. Sample analysis on TD-GC-MS 
During the storage experiment, batches of 5 randomised and replicate breath samples, 
along with 1 room air sample and 1 air supply sample were analysed at 5 time points 
respectively. The time intervals for sample storage and then analysis were based on a 
central composite design and set at 0 month no storage, 1.5 month, 6 month, 10.5 month 
and 12 month. The last time point 12 month was delayed to 12.5 month due to instrument 
service. 
The breath VOCs collected were analysed using a Varian 3800 GC interfaced to a Varian 
Saturn 4000 ion-trap mass spectrometer. The sampled VOCs were recovered and injected 
onto the GC-MS by a 2 stage Markes Unity Series 1 thermal desorption unit using a general 
purpose hydrophobic cold trap. The instrumentation parameters are summarised in Table 
3.3.4. The stored samples at - 80°C were allowed to warmup to room temperature for 3 
hours before analysis with all frozen condensate thawed and evaporated. Instrument 
parameter checks and quality control evaluation were performed prior to analysis to ensure 
that the system was operating within control limits. One internal standard was run before 
sample analysis as part of quality control. Two blanks were run between each sample to 
avoid carry over contaminations. 
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Table 3.3.4. Instrumental parameters 
Thermal desorption Gas chromatography Ion trap mass spectrometer 
Parameters Setting Parameters Setting Parameters Setting 
Pre-desorption purge 1 min Initial temperature 40°C Mass range  40 m/z to 445 m/z 
Tube desorption  5 min at 300°C Final temperature 300°C Scan mode EI auto 
Pre-trap purge  1 min Hold temperature/time 300°C for 8 min Emission current 10 µAmps 
Trap desorption 5 min at 300°C   Rate 5°C/min Target TIC 20000 counts 
Heating rate Maximum °C/min Initial pressure 27.3 psi Maximum ion time 25000 µseconds 
Flow path temperature 180°C Final pressure 56 psi Scan time 0.38 seconds/scan 
Trap low temperature -10 °C Hold pressure/time 56 psi for 7.83 min Data rate 2.63 Hz 
HV temperature  180°C Rate 0.55 psi/min Trap temperature  150°C 
Cold trap flow rate 50 cm3/min GC column DB-5 60m length × 0.25mm i.d. × 0.25 µm film thickness Manifold 50°C 
Cold trap packing General purpose hydrophobic Total analysis time  60 min Transferline temperature 300°C 
Split ratio Splitless Carrier gas Helium   
    Carrier gas flow rate 2 cm3/min     
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3.3.5. Quality control 
The relationship between retention index and retention time was determined by the analysis 
of retention index standard mixture consisting of 16 hydrocarbon compounds at a 
concentration of 75 ppm (w/v) dissolved in dichloromethane was injected manually before 
sample analysis to act as quality control.  
The retention index analysis enabled instrument performance checks before the sample 
analysis and provided the retention index scale for the subsequent breath components. 
However it could not be used to account for within-day and between-days reproducibility, 
hence internal standard dopants were infused onto breath samples. The internal standard 
dopants were the deuterated compounds toluene-d8, decane-d22 and hexadecane-d34. The 
permeation sources are stored under a constant temperature of 40°C, high purity nitrogen at 
flow rate of 50 cm3 min-1 was used to dope headspace VOCs from the permeation sources 
onto breath sample tubes at outlet for set duration of 30 seconds. Permeation rates of 
internal standards were measured by changes in weigh and their on-column masses were 
calculated to be 19.5 ng, 2.7 ng and 1.3 ng for 2.5 L sample volume. The peak area, 
retention time and peak parameters of internal standards were plotted into control chart to 
assess the sample stability across the year.  
3.3.6. Data deconvolution 
GC-MS data were deconvoluted using AnalyzerPro (Spectral Works, UK), one breath 
sample typically yielded approximately 500 components. All isolated components were 
assigned a retention index value based on a primary retention ladder generated from the 
retention index standards and a secondary retention ladder based on five ubiquitous 
siloxane components present in all breath samples. The retention indexed breath 
components were integrated using Varian MS Workstation software (Varian, UK) generating 
an extracted ion chromatogram for each component. 
Because of retention time shifts across the 12 month storage period the peak integration 
was performed separately for the 5 sample batches with updated retention index/retention 
time windows. Each breath component was given a unique breath library reference code that 
started with prefix BRI followed by retention index value and five most abundant ions in de-
convolved mass spectrum (BRI-XXX-XX-XX-XX-XX-XX). A breath matrix was created from 
the extracted ion chromatography peak areas for all the breath components against the 
sample name. The data processing workflow adopted here has been discussed in detail in a 
previous publication13 
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3.4. Results and discussion 
3.4.1. Determination of system variability using internal standards quality 
control chart 
Peak areas of internal standards from every breath sample and background samples were 
deconvoluted and recorded throughout the 12 month storage period. The variation in peak 
areas of internal standards serves as a method to assess system stability across longitudinal 
study and enables comparison of breath sample data at different time points. Additionally the 
determination of system variation in sample set and batch was used to separate system 
variation from longer term breath sample storage stability variation. The %RSD system 
variability across the sample set for 12 month duration was 22.1% for Toluene-d8, 26.9% for 
Decane-d22 and 24.2% Hexadecane-d34. The mean variation between the three internal 
standards was calculated to be 24.4% and indicates system variability within the year. The 
sample set includes 25 breath samples, 5 background room air samples, 5 medical air 
supply samples and 5 internal standards blanks. Example chromatograms of the sample 
sets are shown in Figure 3.4.1.1. The sample set was analysed in batches at 5 time points 
across 12 month period. The %RSD system variation at each sample batch was 11.4% ± 3% 
for Toluene-d8, 17.8% ± 7% for Decane-d22 and 15% ± 3% Hexadecane-d34. The mean 
variation between the three internal standards was 14.9% and indicates the amount of 
variability of breath samples that exists even if it is taken from the same participant within 
short amount of time.  
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Figure 3.4.1.1. TIC chromatogram of storage sample set including participant breath 
sample (top), medical air supply sample (middle) and background room air sample 
(bottom). 
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One contributing factor to the variation in sample set and sample batches was error in 
manual operation of infusion of internal standards onto breath samples. This error can be 
observed in the decrease of variation in sample batches analysed at later time points due to 
better handling of the operation. Figure 3.4.1.2. is a box-whisker plot of the combined marker 
scores (CMS) of the three internal standards peak intensities across the 12 month storage 
period. CMS was calculated from collective scores from the three internal standards peak 
intensities based on their Euclidean distance shown in Equation 3.4.1. Additionally, 
unsupervised principal component analysis (PCA) of three deuterated standards peak 
intensities across 12 month was shown in top right corner of Figure 3.4.1.2. In the PCA plot, 
no distinction between peak intensities obtained different sample storage durations was 
observed indicating low systematic effect across the sample set.  
𝑪𝑴𝑺 = ට∑ 𝑰𝑹𝟐𝟑∝ୀ𝟏                                                                                                Equation 3.4.1.  
 
Figure 3.4.1.2. Box-whisker chart illustrates combined marker scores (CMS) classified 
by breath sample storage durations. (On the top right corner) Unsupervised principal 
component analysis (PCA) of all 3 deuterated standards peak areas throughout the 
year. 5 observations respectively from each time points 0 (black dots), 1.5 month 
(triangle), 6 month (square), 10.5 month (triangle) and 12.5 month (open circle) are 
shown. 
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3.4.2. Relationship between breath components and storage duration 
The breath matrix contained 592 breath components separated into 161 endogenous and 
423 exogenous breath components. Multivariate analysis was performed on all three data 
sets using SIMCA-P+ software (Version 12.0.1.0, Umetrics, UK) to determine the effect of 
long term storage on exhaled breath VOCs of various origins. All three data sets contained a 
data matrix of library referenced breath components as variables and time points referenced 
sample names as observations. All variables were assigned to single block weight of 
1(1/SQRT) and Pareto base scaling (Par). Pareto base scaling was selected due to its ability 
to magnify low to medium range signals in analysis without inflating the background noise, 
and hence stay closer to original data set than UV scaling. This scaling subtracts each 
variable from the mean of the data set and divides the difference by the square root of the 
standard deviation. Unsupervised principal components analysis (PCA) was then performed 
for all three data to determine the correlation between storage time and breath components.  
The levels of cyclic siloxane compounds generated from breath samples reflects degradation 
of the active phases within the instrument and may complicate data modelling. For this 
study, the same GC column was used for the entire duration. The quality control dataset 
indicated that the retention time had shifted roughly 1 minute after 12 month and the levels 
of cyclic siloxanes seem to increase after longer storage periods, and this may due to 
column degradation as opposed to storage effects. In order to eliminate the effect of GC 
column degradation from data modelling, all cyclic siloxane compounds were removed from 
the data set. Compounds that were present in less than 30% of the breath samples were 
also excluded from data modelling.   
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Figure 3.4.2.1. (A) Unsupervised principal component analysis (PCA) of 592 storage 
sample components both endogenous and exogenous originals. The model used 25 
observations, 5 observations from each time points respectively: 0 (black dots), 1.5 
month (triangle), 6 month (square), 10.5 month (open triangle) and 12.5 month (open 
circle) are shown. 
Figure 3.4.2.1. shows the unsupervised principal component analysis (PCA) score plot of 
592 variables with each time point represented by a distinctive symbol. The score plot 
contains two principal components with total variance explained by the model with the value 
of 55.0% for PC1 and 29.3% for PC2. This value is the fraction of sum of squares explained 
in that component. A distinct separation can be observed between breath samples stored for 
duration within 6 month and beyond the 6 month period. The data response from storage 
time points within 6 months (0, 1.5 and 6 month) seems to cluster and this clustering 
decreases significantly after 6 month, indicating increased variation within breath samples 
components as storage duration becomes longer. A trend in opposition to the decrease in 
variability observed with the internal standards. The score plot also has calculated sensitivity 
and specificity of 100% and 94% based on hierarchical clustering. The difference between 
endogenous and exogenous breath components can be observed from individual score plots 
in Figure 3.4.2.2. Although as shown in both score plots, a distinction can be made between 
breath components analysed before and after 6 month storage period, endogenous breath 
components show additional distinction within the 3 time points under the 6 month storage 
period. As observed from Figure 3.4.2.2.A, a distinction between endogenous breath 
71 
 
components stored for under and above 1.5 month can be seen, however this separation is 
a lot less apparent in the score plot generated from exogenous compounds in Figure 
3.4.2.2.B. This seems to indicate endogenous compounds are stable for shorter amount of 
time than exogenous compounds when stored under - 80°C. Score plot generated from 
endogenous breath components had total variance value of 43.6% for PC1 and 25.8% for 
PC2 with a sensitivity of 91% and specificity of 100%. As for exogenous components score 
plot, total variance value was calculated to be 29.0% for PC1 and 13.4% for PC2, it also has 
sensitivity and specificity of 100% and 83%.  
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Figure 3.4.2.2. (A) Unsupervised principal component analysis (PCA) generated from 
151 endogenous breath components. (B) PCA of 423 exogenous components 
identified from storage samples. Both models used 25 observations, 5 observations 
from each time points respectively: 0 (black dots), 1.5 month (triangle), 6 month 
(square), 10.5 month (open triangle) and 12.5 month (open circle) are shown. 
The difference was further investigated using hierarchical cluster analysis (Figure 3.4.2.3.). 
The distance between two clusters is measured by difference in variance. Two sub-clusters 
can be observed in endogenous components dendrogram between response generated 
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from time point at 6 month and up to 1.5 month, these sub-clusters cannot be observed from 
exogenous dataset. 
 
Figure 3.4.2.3. Dendrogram of endogenous (left) and exogenous (right) breath 
components dataset generated from hierarchical cluster PCA analysis. This illustrates 
the difference in clustering between endogenous and exogenous components, 
although both datasets show distinct separation at 6 month, a sub-clustering of 6 
month of endogenous compounds can be observed which is not present in 
exogenous dataset. 
The trend in the data was explored further with partial least squared regression (PLS) to 
determine the relationship between peak intensities (predicted variable X) and storage 
duration (response variable Y) in the endogenous data. The model generated three principal 
components with a goodness of fit value of 90.8% and a predictive value of 91.2% for 
principal component 1 (PC1) indicating a strong relationship between X and Y variables. The 
relationship between X and Y variables can be visualised by plotting PC1 scores against 
storage duration. PC1 contain 57% of total variance. (See Figure 3.4.2.3. and Equation 
3.4.2.)  
What is apparent is that endogenous VOC appear stable at 1.5 and by 6 month instability 
can be detected with variability increasing non-linearly at 10.5 month and 12.5 month. 
Comparison between the endogenous and exogenous model indicates endogenous breath 
compounds are more prone to variability during storage. The stability of endogenous breath 
compounds are explored further in the next section. 
 𝒚 = 𝟎. 𝟖𝟖𝟐𝟏𝒙𝟐 + 𝟏𝟐. 𝟓𝟔𝟒𝒙 − 𝟏𝟑𝟎. 𝟒𝟏                                                               Equation 3.4.2. 
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3.4.3. Stability of breath components under long term storage 
A paired two-tail t-test was carried out on all endogenous compounds peak intensities to 
assess the difference between each time point against the reference time point (0 month). 
Systematic variation calculated from internal standards was deducted from the calculation. 
The p-values calculated from differences in peak intensities between the reference time 
point (0 month) and 1.5 month indicated significant difference for 9 compounds at P = 0.05 
(Figure 3.4.3.1.). In terms of the whole endogenous breath components, this suggests that 
94% of compounds were stable at this point in time. At 6 month time point, p-values from 44 
compounds were observed to be significantly different. Out of the 44 compounds, 24 were 
observed to have shown an increase in intensity at the 6 month time point and the remaining 
20 compounds showed a decrease. The stability of whole breath sample had reduced to 
73% from 94%. At 10.5 month time point, another 53 compounds were observed to show 
significant difference compared to their peak intensities at 0 month. The stability had 
reduced to 41%; the majority of breath components were now unstable. At 12.5 month, 
another 10 compounds has shown significant variation in their p-value, the reduction in 
number of compounds that have shown significant variation from 95 to 78 indicates the 
breath matrix may be stabilising. 
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Figure 3.4.3.1. The number of compounds changing significantly (black dot with solid 
line) at various time points over the 12.5 month storage period.  
The other two lines illustrates number of compounds shown significant increase 
(square symbol with dotted line) and number of compounds shown significant 
reduction (triangle symbol with dashed line) at various time points.  
Paired two-tailed t-test was used to determine the significance level for each 
endogenous breath components at P = 0.05. Additionally, the percentage of 
compounds stabile at each time points is shown (dash symbol with dotted line). 
PCA and PLS analysis enabled determination of a first order quadratic relationship between 
changes in breath components and storage time. First order curve line relationship reveal 
the underlying multi step reactions occurring in breath components during storage. 
Evaluation of the percentage change in the endogenous breath components revealed how 
breath components behaved differently compared to each other.  
Within a total of 159 endogenous compounds 60% of the compounds were observed to 
increase in response, and 19% showed a reduced response over 12.5 months storage.  
76 
 
9% of the compounds observed to increase in response were new, appearing after 6 month. 
The majority, 86%, of compounds exhibiting reduced responses were completely missing 
after 6 month of storage. This indicates possible decomposition, loss or formation from 
decomposition occurring during storage.  
7% of compounds observed were within the systematic variation of the systems and 
therefore were identified to be stable throughout storage.  
4% of compounds shown increased response after 6 month then reduced response at 12 
month time point, and adversely 9% of compounds shown reduced response after 6 month 
but response increased at 12 month.  
These observations suggest complex and as yet undescribed reactions and interactions that 
combined to form the time dependent relationship shown in Figure 3.4.3.2., thus suggests 
that there are markers of sample aging within the breath matrix. 
 
 
Figure 3.4.3.2. Scatter plots of the mean of PC1 scores generated from partial least 
squares regression (PLS) of endogenous breath components (black dot with dotted 
line) and exogenous breath components (square with dashed line) against storage 
duration.  
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3.4.4. Identification of storage variable breath components 
The most sensitive endogenous compounds to long term storage are compounds which 
show either complete loss, or are created during storage. There were 33 compounds in this 
category.  
Out of 25 compounds which show complete loss after 6 month, the majority 56% had mass 
spectra indicative of hydrocarbon, ester, aldehyde, alcohol or fatty acid functional groups. 
36% exhibited m/z 57, 43, 71, 85, 41 fragmentation pattern evident of possible 
hydrocarbons, ester or aldehyde compounds. It is also possible they can be methylated 
alcohol or fatty acid compounds. 20% exhibited m/z 69, 67, 81, 83 fragmentation pattern 
representing possible fatty acids or alcohol compounds. 1 compound belonging to newly 
formed compounds after 6 month was also elucidated to be a hydrocarbon. 3 out of 33 
compounds in both groups observed m/z 69, 111, 110 fragmentation pattern belong to 
cycloalkane group. Another 2 compounds from both groups contains m/z 91, 92 
fragmentation pattern were likely to be Benzeneamide or benzenealdehyde derivatives.  
These compounds were present at low peak intensities, for example the mean intensity of 
the 33 compounds that showed complete loss after 6 month storage was 8734 counts. This 
may be estimated to be equivalent to an on-column mass of 55 pg of internal standard. With 
a breath sample volume collected at 2.5 L, the mean exhaled concentration may be 
estimated to be no lower than 22 ng m-3. Such low concentrations might be a potential factor 
contributing to their increased sensitivity to long term storage.  
12 VOCs with the highest correlation to storage duration were matched against the NIST MS 
library within the Varian MS software, see Table 3.4.4.1. and Figure 3.4.4. The assignments 
were based on forward and reverse matching of de-convoluted mass spectrum of target 
compounds to library reference spectrums, a satisfactory match score above 650 must be 
achieved for identification. If multiple matches with similar forward and reverse scores were 
found, a comparison of observed retention index value (IU) and reference retention index 
value from NIST library were performed to achieve the most satisfactory match possible. In 
cases when no satisfactory matches can be obtained or reference retention index 
comparison is not successful, an estimation of the functional group of the compounds based 
on their fragmentation pattern was given. Due to the low intensity of the compounds’ peaks, 
forward and reverse matching of specific compounds could not always be achieved, and so 
an estimate of compounds identity was generated through a list of library matches with the 
same fragmentation pattern and within ± 50 IU of retention index value. Some of the low 
intensity compounds are close to limit of detection, it is possible the compounds haven’t 
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decomposed completely as the peak intensity suggested, but there abundance was below 
the capability of the instrument. 
The functional groups of the compounds that show increased or reduced response are more 
varied and complex to elucidate, from observing their fragmentation pattern, 18% are 
possible hydrocarbon, ester or aldehyde functional group compounds, 7% are fatty acids 
and alcohol functional groups compounds. The discriminators generated from multivariate 
analysis that exhibited most correlation to long term storage are all from within this category. 
The 8 VOC variable that generated the highest correlation score of PCA S-plot were 
elucidated and listed in Table 3.4.4.2. 
 
 
Figure 3.4.4. Extracted ion chromatograms of 12 endogenous compounds that shown 
the most significant changes normalised using log10 transformation. Lower x-axis 
shows retention index units (RIU) and upper x-axis shows their equivalent retention 
time (tR).
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Table 3.4.4.1. List of 12 endogenous breath components that were shown most significant difference comparing to starting time 
point. 
  Median /month         
Name 0 1.5 6 10.5 12.5 Libray entry MS F/R RI O/E CAS No. 
BRI-1525-69-83-41-55-97 13892 16508 14215 0 0 Unsaturated fatty acid    
BRI-1471-71-83-84-70-45 7074 10024 0 0 0 Unknown alkane    
BRI-1124-57-41-70-56-43 25599 37400 51619 0 0 1-Octanol, 3,7-dimethyl- 804/642 1124/1130 106-21-8  
BRI-1154-85-41-57-43-71 2511 4173 0 0 0 4-Methylpentyl pentanoate    1154/1218 35852-47-2 
BRI-1387-41-56-70-55-68 5919 3405 0 0 0 1-Nonanethiol  1387/1219  1455-21-6  
BRI-1077-57-41-56-43-59 4689 11354 0 0 0 Decane, 3-methyl-  1077/1051 13151-34-3  
BRI-913-151-161-133-152-153 0 0 7186 10049 5314     
BRI-1504-91-92-0-0-0 0 0 0 31877 17374 Benzeneamide or benzenealdehyde derivative   
BRI-1728-57-43-71-41-85 0 0 3171 3559 5986  1-Decanol, 2-hexyl 566/823 1728/1790 2425-77-6  
BRI-1401-69-111-110-0-0 0 0 0 4477 8780 Methylated cycloalkane or alcohol    
BRI-1007-131-133-0-0-0 0 0 0 2256 2048     
BRI-954-120-45-64-0-0 0 0 548 856 1328 Benzoic acid or benzamide derivative       
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Table 3.4.4.2. List of 8 endogenous breath components that were the highest discriminators in MVA. 
  Median /month         
Name 0 1.5 6 10.5 12.5 Libray entry MS F/R RI O/E CAS No. 
BRI-783-59-60-43-42-44 1.5x107 1.6×107 2.4×107 3.6×107 9.2×107 Acetone  783/455 67-64-1  
BRI-789-81-95-94-82-93 7975082 8522656 2.7×107 3.4×107 5×107 3-Methyl-1-penten-4-yn-3-ol 756/672 789/697 3230-69-1  
BRI-1066-91-108-89-92-90 3.6×107 4.3×107 5.1×107 9.4×107 1×108 Unknown fatty acid    
BRI-1332-91-92-90-0-0 14750 21325 34215 49438 60238 
Benzeneamide or benzenealdehyde 
derivative   
BRI-835-88-73-89-47-90 255502 296132 455604 746667 802253 Allyl methyl sulfide 723/723 835/660 10152-76-8 
BRI-825-61-90-45-41-49 50009 50789 113125 180638 172868 Propane, 1-(methylthio)- 887/863 825/670 3877-15-4  
BRI-820-88-73-89-61-91 530068 626937 961182 1622886 1663602 Allyl methyl sulfide 699/677 820/660 10152-76-8 
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3.5. Summary 
A 12.5 month storage study assessed the stability of exhaled breath compounds at - 80°C. 
Previous studies have focused on the stability of a mixture of synthetic breath compounds or 
a set of target compounds in human breath. The reported results have varied depending on 
the compounds and/or adsorbents studied. Chlorinated compounds on a single adsorbent 
bed have been reported to be stable for 2 years while 2 to 4 weeks stability has been 
reported for common breath compounds on multi-bed adsorbent tubes (70) (71) (72) (74).  
This study is the first that has explored and sought to characterise the changes in the whole 
breath sample (592 compounds) when stored for 1 year on dual-bed adsorbent tubes. The 
initial hypothesis was that no change in the VOC profile occurs at - 80°C.  
The hypothesis held for samples stored for 1.5 month. Results from paired two-tailed t-tests 
indicates that 94% of endogenous compounds were stable at the 1.5 month time point and 
this reduced to 73% compounds stable at 6 month. Longer than this and the percentage of 
stable compounds drops to 41% at 10.5 month. Although at 12.5 month time point, the 
stability appears to increase back to 52%.  
It seems reasonable to suggest a storage period of 1.5 month for breath VOC compounds as 
indicated by multivariate analysis and t-test. Even at 1.5 month interval, 6% of endogenous 
compounds have shown significant difference compared to starting time point. This is likely 
to be due to complex nature of breath metabolome where stability of compounds vary 
significantly due to its chemical properties. Therefore the storage method of choice for 
breath VOC study is highly dependent on the target compounds species. Determination of 
type of compounds that are more prone to deterioration during storage can be difficult due to 
breath matrix’s complexity.  
However some observable patterns have emerged; over half 56% of endogenous 
compounds that shown complete loss after 6 month have the m/z 57, 43, 71, 85, 41 or m/z 
69, 67, 81, 83 fragmentation pattern and it is likely compounds with these fragmentation 
pattern belong to hydrocarbon, ester, aldehyde, alcohol or fatty acid functional groups (Table 
3.4.4.1.). If these functional groups are sensitive to storage conditions, and with many breath 
VOC biomarkers discovered over the years related to various diseases belonging to these 
functional groups, a more vigorous storage and transportation methodology needs to be 
adopted to avoid de-stabilising these sensitive compounds in large scale biomarker 
elucidation studies. It also need to be made clear that although the storage sensitive 
compounds may belong to hydrocarbon functional group, it is only a small portion of the 
overall hydrocarbons that exist in breath; majority hydrocarbon groups are observed to be 
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stable in breath. With many storage sensitive compounds having low peak intensities, it is 
possible that sensitivity comes from both chemical properties and concentration.      
One of the causes of instability of VOCs during storage may be attributed to the dual-bed 
adsorbent tubes (Tenax® TA/ Carbograph 1 TD) used. Migration of VOCs trapped between 
the two materials would result in irreversible binding of some species indicating a reduced 
stability of the breath sample. Although low temperature would reduce this effect, it is seems 
that migration of VOCs between the adsorbents still occurs, even at - 80°C. The rate of 
migration is slower than previously reported at higher temperature taking months to become 
apparent.  
It is also possible that high water levels inside the adsorbent beds had significant effect on 
the stability of breath components, with increases in carbonyl compounds such as acetone 
after 6 month that may be created through process of hydrolysis. Also the increase in 
cyclosiloxanes and higher abundance compounds (e.g. acetone) may be obscuring the 
statistical detection of other much smaller signal responses. This highlights the utility of 
studying the stability of the whole breath VOC profile as the changes in breath compounds 
may impact each other. 
An important element to this study was the successfully implementation of gas phase 
internal standards to characterise systemic variation (24.4%) across 12.5 month year and 
importantly the variation within breath sample replicates (14.9%) taken from the same 
individual over 3 hours sampling period. The variability of replicate breath VOC profiles is 
likely to be higher than 14.9% due to changes in a participant’s physiology such as changes 
in pulse rate, water intake and restroom breaks. Psychological stress has also been reported 
as a factor for specific chemicals in breath (75). This variability is expected to be significantly 
different from compound to compound and this would have contribute to the hugely varying 
stability of breath components. Therefore it is possible that a portion of the breath 
compounds that have shown significantly difference at later time points to be due to 
variability of the participant rather than storage.  
Limitations in this study was that quantification of breath VOCs was not feasible. Although a 
rough estimation based on the Toluene-d8 internal standard concentration, its true quantity 
can only be realised with calibration. For example, the concentration of 3, 7-dimethyl 1-
octanol (Table 3.4.4.1.) is estimated to be 64.4 ng m-3 at starting time point.  
This study only investigated the stability of breath samples at - 80°C. The result may not be 
applied to other storage temperatures. Further study should be focused on long term stability 
of breath samples at multiple temperatures such as freezer temperature - 20°C, refrigerator 
83 
 
temperature 4°C and room temperature 22°C. This is particularly important for transportation 
of breath samples between labs, since often refrigerator temperature 4°C is used.  
This study collected large amount of replicate breath samples within 3 hr from the same 
participant. This was to avoid introducing variations from multiple participants. However a set 
of breath samples collected from a different participant may show deviation to the stability 
model calculated. A follow-up study on multiple participants would be advised to screen for 
more storage sensitive compounds and reduce the chance of false discoveries.  
Lastly, another limitation is amount of time points chosen for this study; 5 time points were 
used to ensure sufficient replicates samples for each time point. On the other hand, renewed 
experiments with more time points would establish accuracy of the current prediction model.     
This study indicates a maximum storage period for breath samples at - 80C should be no 
longer than 6 month for specific targeted studies, and care will be needed to demonstrate 
the absence of storage artefacts. The maximum “safe storage time” at - 80C storage for 
non-targeted studies is indicated to be 1.5 month. This study also provides method validation 
for large scale biomarker elucidation studies that require extended storage and 
transportation up to this time. It also supports with the previous breath VOCs stable period of 
2 to 4 weeks for multi-adsorbents tube stored samples.  
The complex changes of in the recovered breath VOC profile during storage has revealed 
the presence of complicated chemical and physical reactions and interactions that cause a 
loss of sample stability between various chemical species. This further highlights that the 
sensitivities of target compounds in biomarker studies to other contributing factors other than 
the diseases also needs to be considered and tested. 
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CHAPTER 4. DEVELOPMENT OF PORTABLE ADAPTIVE 
BREATH SAMPLER FOR REMOTE EXHALED BREATH VOCS 
COLLECTION 
 
4.1. Introduction 
The concept of a portable adaptive breath sampler originated from the adaptive breath 
sampler created in 2006 (41). The original adaptive breath sampler was developed and 
employed in breath biomarker elucidation studies. These led to the creation of a breath 
sampling and analysis work-flow that fully utilised the sampler’s specifications. A breath 
sampling control unit enables selected alveolar portions of an exhaled breath profile to be 
passed through an adsorbent tube while a human participant breathe normally. The adaptive 
breath sampler was designed for studies with participants with an impaired respiratory 
function such as people with COPD. The sampler was configured to adapt to variability in 
participants’ breathing during breath collection. The sampler was controlled from a virtual 
instrument (Labview) that enabled different parts of a breath profile to be selected and 
sample volumes to be adjusted at will. The use of continuous measurement of the pressure 
in the upper airways enabled the sampling controls to adapt to different breathing patterns.  
The portable adaptive breath sampler developed in this study incorporated the specifications 
of the original breath sampler, and enhanced it by adding elements of portability and 
improved background contamination control.  
The primary enhancement made in the portable breath sampling was the in-field sampling 
capability. A significant limitation of the original design was the requirement for a purified air 
supply. This meant that it had a fixed location which limited participant recruitment. The 
introduction of this new specification enabled breath sampling to be carried out in the field 
with no restriction on location. It was designed to be setup quickly in clinical settings, sports 
venues and even in domestic and community care settings. This feature combined with the 
easy to use and non-invasive original sampling unit maintained the capability of working with 
participants with an impaired lung function minimise participant stress level and discomfort.  
The original adaptive breath sampler used inert material and air purification filters to 
minimise the levels of exogenous VOCs level present in breath samples. This restricted the 
location of the sampler to locations where a medical air supply was available. Further it was 
not possible to control the purification process that was run with commercial filters. A 
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custom-built portable purified air supply was developed for the adaptive breath sampler. The 
air supply had to meet the following criteria: 
 efficient drying of the air supply 
 purification 
 removal of dust and particulates 
 based on re-usable materials such as molecular sieve and activated carbon 
This enabled better user control of the nature of the samples collected and created 
standardised background with a low exogenous VOCs level regardless of where a breath 
sample was taken. 
4.2. Portable breath sampler design 
4.2.1. Health and safety 
All desiccants and purification media were obtained from by Acros Organics or Fisher 
Scientific, and were assessed for possible hazards with information taken from Fisher 
Scientific Material Safety Data Sheets, see Table 4.2.1. All the materials were classified with 
a health rating of at least 1; direct contact with humans poses a health risk. In particular 
Ascarite and calcium oxide cause burns and pose a higher health risk (NFPA rating 3), and 
therefore were excluded. Importantly, desiccants generate dust which causes irritation to eye 
or skin and upon inhalation result in irritation to the respiratory tract. Chronic inhalation will 
lead to lung damage. An additional dust filter was specified to eliminate this possibility and 
prevent damage to a participant’s respiratory system.
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Table 4.2.1. Health and safety information on desiccants. 
Name Component 
NFPA rating 
Toxicity Target organ Stability 
MSDS 
revision date F H I 
Molecular sieve Zeolites (100%) 0 1 0 
Contains trace amount of quartz which might lead to fibrotic lung disease, silicosis or cancer. 
Dust may cause eye and skin irritation. 
Dust inhalation may cause respiratory tract irritation. 
Ingestion may cause digestive tract irritation 
E, GIT, S 
Res Hy  20/07/09 
Silica gel 
Silica, 
amorphours, 
precipitated and 
gel (100%) 
0 1 0 
Limited evidence of a carcinogenic effect based on animal data. 
Dust may cause eye or skin irritation 
Dust is irritating to respiratory tract 
Ingestion may cause gastrointestinal irritation with nausea, vomiting and diarrhoea. 
E, GIT, S 
Res Hy 08/01/10 
Activated carbon Carbon (100%) 1 1 0 
Dust may cause eye and skin irritation. 
Dust inhalation may cause lung damage, chronic inhalation may lead to decreased 
pulmonary function. 
Res S 09/05/11 
Activated alumina Aluminum oxide (100%) 0 1 0 
Dust may cause mechanical eye and skin irritation. 
May cause repiratory tract irritation and lung damage. 
Chronic inhalation of fine dusts may cause lung damage 
Ingestion of large amounts may cause gastrointestinal irritation. 
Res S 20/07/09 
Drierite Calcium sulfate (95%) 1 1 1 
May cause eye and skin irritation., may produce an allergic reaction. 
Ingestion may cause gastrointestinal irritation. 
Inhalation may cause irritation and allergic respiratory reaction. 
Res, S Hy 12/10/09 
Ascarite 
Sodium 
hydroxide (90-
95%) 
0 3 1 
Causes burns if in contact with eyes or skins. 
Cause burns to respiratory tract if inhaled. 
Cause burns if ingested. 
E, GIT, S,  
Res,  Hy 06/05/10 
 Silica amorphous (5-
10%) 
      Cause burns if inhaled. Cause burns if ingested. E, GIT, R     
Calcium oxide  1 3 2W 
Causes burns if in contact with eyes or skins, and might be harmful if absorbed. 
Cause burns to respiratory tract if inhaled. 
Cause burns if ingested. 
Prolonged skin contact may cause dermatitis; chronic inhalation may cause nasal septum 
ulceration and perforation. 
E, GIT, S, 
Res,  !-1. 13/02/08 
Bentonite 
(Montmorillonite Clay) 
Aluminium 
phyllosilicates 0 2 0 
Causes eye, skin, and respiratory tract irritation. 
Animal studies indicate that this may cause cancer 
The toxicological properties of this material have not been fully investigated. 
Res, E, 
Sk Hy 13/06/08 
 
Key:  E: Eyes; F: flammability; GIT: Gastrointestinal tract; H: Health; Hy: Hydroscopic; I: Instability; Res: Respiratory system; S: stable; Sk: 
skin 
!-1: Air sensitive, reacts violently with water. Moisture sensitive 
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4.2.2. Desiccants and adsorbents for gas purification 
A range of desiccant and adsorbent material and their adsorption capacity are discussed in 
this section.  
Silica gel (SiO2.nH2O) is amorphous silica produced from the reaction of sodium silicate and 
sulfuric acid. The sodium sulphate is removed by dissolution and the resultant mixture is 
then coagulated to hydrogel to produce the commercial silica gel. Silica gel’s primary use is 
in drying gas, desulfurization and gas purification.  
Molecular sieve belongs to the zeolite class of minerals (hydrated alkali metal or alkaline 
earth aluminosilicates). The structural units have cavities at their centre creating a porous 
structure of molecular dimensions and thus causing the sieving action. Some molecular 
sieves have pores of uniform dimensions and compounds smaller than the pores diffuse into 
the structure and are retained. The fundamental building block is made of oxygen anions 
surrounding a smaller silicon or aluminium cation. The zeolite molecular structure can be A, 
X or Y form. Zeolite A pores are restricted by 8 membered oxygen rings which forms a cubic 
structure. The sodium ions or other cations make up the positive charge deficit in the 
alumina terahedra. Different types of cations form different diameter pores: K+ cations form 
3A, Na+ cations form 4A, Ca2+ cations form 5A. Zeolite X or Y has pores which are restricted 
by 12 member oxygen rings which form a tetrahedron structure (76). 
 
 
Figure 4.2.2. Zeolite structure of molecular sieve 4A (76) 
Molecular sieves are generally available as cylindrical pellets, beads or powder. Pellets and 
beads are commonly used for gas dehydration and purification. The bead is characterised by 
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a screen cut through which all the beads pass and a screen cut that retains all the beads, in 
that order, with two sizes separated by an “x”. The two most commonly used screen cuts are 
4×8 or 8×12. All molecular sieves are excellent desiccants for dehydrating gas.  
Calcium sulfate (CaSO4), better known commercially as Drierite, Calcium sulfate is created 
by the controlled dehydration of gypsum, acting as a general-purpose desiccant geared 
mainly toward laboratory use. It is chemically stable, non-disintegrating, nontoxic, non-
corrosive, and does not release its adsorbed water when exposed to higher ambient 
temperatures. The low cost of calcium sulfate must be weighed against its equally low 
adsorptive capacity: it adsorbs only up to 10% of its weight in water vapor (Figure 4.2.2.). 
Calcium sulfate also has regeneration characteristics that tend to limit its useful life. 
Activated alumina is manufactured from aluminium hydroxide by dehydroxylating it in a way 
that produces a highly porous material. The compound is used as a desiccant and as a filter 
of fluoride, arsenic and selenium in drinking water. It is made of aluminium oxide (alumina; 
Al2O3). It has a very high surface-area-to-weight ratio. 
Silica gel and molecular sieves have the lowest health risks compared to other desiccants. 
The advantage of molecular sieve compared to silica gel is its better capacity with low 
relative humidity and elevated temperature gases. They provide extremely low dew points. 
4.2.3. Gas dehydration design  
4.2.3.1. Overview of adsorption dynamics 
When a gas mixture containing water vapour pass through a bed of fresh adsorbent, the 
water is adsorbed immediately at the to the bed, dehydrated gas passes through rest of the 
bed with only a small amount of additional drying taking place. When the adsorbent at the 
inlet becomes equilibrated with the water in the challenge gas the zone of water adsorption 
progress through the rest of the adsorbent bed. When this adsorptive wave reaches the 
outlet, the water content of exhaust gas will increase signifying the breakthrough point. 
During the adsorption period, the adsorbent can be characterised into three zones. The 
equilibration zone, the adsorbent bed is equilibrium with wet air supply. The middle zone is 
called mass transfer zone (MTZ) where water is being rapidly absorbed from the gas supply. 
The last zone is the unused adsorbent known as the active zone. 
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Figure 4.2.3.1. Principle of desiccant water adsorption 
In order for desiccant not to reach the breakthrough point while sampling, it is important to 
estimate the mass of desiccant required, bed diameter and bed length to build a cylindrical 
desiccant bed.  
4.2.3.2. Gas dehydration desiccant selection 
4.2.3.2.1. Dew point comparison 
Dew point is the temperature which a gas must be cooled at a constant pressure in order for 
water vapour to condense. Although relative humidity also measures moisture in air, it is 
dependent on temperature, so “dew point” is a more absolute indicator of moisture in air.  
Different desiccants result in different dew points after dehydration. The lower the dew point 
the desiccant achieve, the drier the air it filtered will be. The chart below shows the dew 
points the desiccants can achieve. 
  
Air 
inlet 
Air 
outlet 
Equilibrated 
zone Mass transfer zone 
Active zone 
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Figure 4.2.3.2.1. Desiccant dehydration selection chart 
Molecular sieve generates the lowest dew point (< -73C) and so it was considered the best 
candidate for gas dehydration from dew point comparison. However water capacity of 
desiccants also needs to be compared. Note as well that although molecular sieve can 
achieve very low dew points, it requires higher regeneration temperatures: 218C. 
4.2.3.2.2. Water capacity comparison 
Water capacity is the ratio of mass of water retained to mass of desiccant. The more water 
the desiccant can hold the more efficient it is. The aim of this comparison is to determine the 
desiccant with the highest water capacity for the breath sampler. However the water capacity 
varies significantly dependent on temperature and humidity, so it is essential the desiccant 
has stable water capacity across a range of temperature and relative humidity. Indoor 
temperature is usually kept around 20°C to 25°C, and 30 to 50% relative humidity. But in 
some locations, this could vary even more, so the desiccant needs to be stable from 10°C to 
35°C, and 20% to 60% relative humidity. 
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Figure 4.2.3.2.2. (top) Desiccant water capacity versus relative humidity based on air 
at atmospheric pressure and 25°C. (bottom) Desiccant water capacity versus 
temperature (77). 
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Figure 4.2.3.2.2 shows silica gel has a higher water capacity than molecular sieve above 
40% relative humidity, however at lower humidity, its water capacity is much lower. Although 
calcium oxide also known as quick lime has a high and stable water capacity at around 30%, 
it causes burns with any form of contact, so it is not a suitable candidate. Molecular sieve 
has a very stable water capacity at just above 20% from 0 to 100% relative humidity, so it is 
the best candidate regarding relative humidity. 
By observing Figure 4.2.3.2.2., silica has highest water capacity at lower temperature around 
15°C, but its water capacity seems to reduce significantly as temperature increases above 
20°C. Molecular sieve has a very stable water capacity at above 20% up to 50°C, so it is the 
best candidate regarding temperature. 
From the comparisons done above, it seems molecular sieve has the most stable water 
capacity at above 20% from 10°C to 35°C, and 20% to 60% relative humidity (atmospheric 
pressure). 
4.2.3.2.3. Molecular sieve comparison 
There are several different types of molecular sieves dependent on their zeolite structures 
and they are all capable of drying gas, however each has specific properties based on their 
pore size which gives them specific applications. Molecular sieve with a specific pore size 
will only absorb compounds that are smaller than the pore. For the breath sampler, it is 
beneficial to use a molecular sieve which also absorb other impurities in air and CO2.  
Molecular sieve beads are characterized by a screen cut, which identifies the Tyler screen 
size through which all of the beads pass and the size that retains all of the beads. The two 
common screen cuts are 4×8 or 8×12. Mesh size of molecular sieve indicates the size of 
sieve beads and has significant impact on the performance of filter. By decreasing the size 
of sieve, the path length contaminants compounds have to travel is reduced, and the 
adsorption rate therefore increases, and hence the molecular sieve will be more efficient. 
4×8 mesh size indicates the particle will fall through an opening of 4.75 mm and remain on a 
screen opening of 2.36 mm. 8×12 mesh size indicates the particle will fall through an 
opening of 2.36 mm and remain on a screen opening of 1.4 mm.  
Table 4.2.3.2.3 is a comparison of molecular sieves, and molecular sieve 13X seems to be 
the most suitable candidate, it absorbs a large range of small hydrocarbon compounds (e.g. 
di-n-propyl-amine), as well as its main use for the adsorption of H2O, H2S and CO2. Apart 
from the wide range of molecules 13X absorbs, it also has the highest water capacity of 
28.5%. 
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Table 4.2.3.2.3. Common types of commercial molecular sieves 
Basic 
type 
 
/n
m 
𝝆 
/g.cm-
3 
Water 
capacity 
(% m/m) 
Molecules 
absorbed Molecules excluded Typical applicatiions 
3A 0.3 47 20 H2O, NH3 Ethane and larger 
Dehydration of unsaturated 
hydrocarbons 
4A 0.4 45 22 
H2S, CO2, SO2, 
C2H4, C2H6, 
C3H6 Propane and larger 
Static desiccant in refrigeration systems, 
etc. Drying saturated hydrocarbons 
5A 0.5 43 21.5 n-C4H9OH 
Iso compounds, 4 
carbon rings and 
larger 
Separates n-paraffins from branched 
and cyclic hydrocarbons 
13X 1.0 38 28.5 
Di-n-propyl-
amine (C4F9)3N and larger Coadsorption of H2O, H2S and CO2 
 
4.2.3.3. System design  
4.2.3.3.1. Bed diameter 
Determining bed diameter is important for desiccant bed, since too large a diameter will 
require a high regeneration gas rate to prevent channelling. Too small a diameter will cause 
too high pressure drop and damage the sieve. The design pressure drop through the bed 
should be about 34 kPa . A design pressure drop higher than 55 kPa is not recommended as 
desiccant is fragile and can be crushed by total bed weight and pressure drop force. 
First calculate 𝑉௠௔௫ which the maximum superficial velocity is based on pressure drop (∆𝑃, 
Pa), length of the packed bed stands (𝐿, m), constant 1 (𝐵), constant 2 (𝐶), viscosity (𝜇), 
density (𝜌, kg.m-3): 
𝑉௠௔௫ = {(∆𝑃/𝐿)௠௔௫/𝐶} + [(𝐵/𝐶)(𝜇/𝜌)]                                           Equation 4.2.3.3.1.1. 
 
(∆𝑃/𝐿)௠௔௫= maximum allowable is 7.46 kPa.m-1   
𝑉௠௔௫ = {(∆𝑃/𝐿)௠௔௫/𝐶} + [(𝐵/𝐶)(𝜇/𝜌)]                                           Equation 4.2.3.3.1.2. 
𝐶=0.000136, 𝐵=0.152, 𝜇=viscosity and 𝜌=gas density 
The equation below calculates minimum bed diameter (𝐷௠௜௡௜௠௨௠ , m) based on maximum 
superficial velocity (𝑉௠௔௫, m s-1):  
 
𝐷௠௜௡௜௠௨௠ =
ସ௤
గ௏೘ೌೣ
                                                                            Equation 4.2.3.3.1.3. 
 
𝑞 is the actual gas flow rate, m3 s-1, which can be calculated from mass flow rate (?̇?, kg s-1 ): 
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𝑞 = ௠̇
଺଴
                                                                                                         Equation 4.2.3.3.1.4.  
Superficial velocity and bed diameter can be adjusted after 𝐷௠௜௡௜௠௨௠ is calculated: 
𝑉௔ௗ௝௨௦௧ = 𝑉௠௔௫
஽೘೔೙೔೘ೠ೘
஽ೞ೐೗೐೎೟೐೏
                                                                    Equation 4.2.3.3.1.5. 
4.2.3.3.2. Desiccant mass 
First estimate the water content to be removed (𝑊௥) by the desiccant, then calculate 
desiccant mass 𝑆௦ (g) required: 
Equation 2 
𝑆௦ =
ௐೝ
଴.଴ଽ×஼ೞೞ×஼೅
                                                                                            Equation 4.2.3.3.2. 
𝐶௦௦ and 𝐶் are correction factors for molecular sieve when gas is not water saturated or 
temperature is above 24°C . 
This method replaces the saturation capacity of 13% with an effective desiccant capacity 
which includes MTZ (mass transfer zone) effect, temperature and relative humidity 
corrections. An effective capacity of 8-10% is typically assumed. 
4.2.3.3.3. Bed length 
The bed length of equilibration zone (𝐿௦) can be calculated: 
𝐿௦ =
ௌೞ×ସ
గ×஽మ×௕௨௟௞ ௗ௘௡௦௜௧௬
                                                                         Equation 4.2.3.3.3.1. 
The bed length of mass transfer zone can be estimated: 
𝑳𝑴𝑻𝒁 = (
𝑽𝒂𝒅𝒋𝒖𝒔𝒕𝒆𝒅
𝟑𝟓
)𝟎.𝟑(𝒁)                                                                             Equation 3.2.3.3.3.2. 
𝑍 is 0.26 m for 1/16” inch sieve. 
The final bed length is the summation of saturation zone and MTZ zone bed length, no less 
than diameter. 
4.2.3.3.4. Calculation result 
Assuming the flow rate required is 20 L min-1, pressure is 101.3 kPa, compressibility factor is 
1, air molecular weight is 28.751, relative humidity is 40% and temperature is 22.5°C. 
Desiccant type = molecular sieve 13A 1/16” inch bead (8 × 12 mesh) using Equation  
Bed diameter minimum = 4.48 cm (using Equation 4.2.3.3.1.3.) 
Dehydration period = 24 hr (Estimated) 
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Superficial velocity = 143 cm min-1 (using Equation 4.2.3.3.1.1.) 
Water removed for 24 duration = 23 g 
Weight of molecular sieve desiccant = 2724 g (using Equation 4.2.3.3.2.) 
Bed diameter = 15 cm (using Equation 4.2.3.3.1.3.) 
Bed length = 30.28 cm (using Equation 4.2.3.3.3.) 
Cylinder bed volume = 5350 cm3 
4.2.4. Gas purification design 
4.2.4.1. VOCs removal by active carbon 
Active carbon is a term for a range of carbon-based materials that possess adsorptive 
properties. This includes coal, peat, wood or nutshells. The carbon based materials are 
activated by high-pressure steam at high temperature, so VOCs present are distilled off, 
leaving a highly porous structure. The amount of adsorptive activity developed depends 
upon the raw material. Chemical additives introduced to the raw materials before heating 
may result in enhanced adsorbent properties. 
There are a few guidelines for carbon adsorption: 
Larger molecules adsorb more strongly than smaller molecules (compounds with higher 
boiling point adsorb better than lower boiling point VOCs). Generally, VOCs with molecular 
weight between roughly 50 and 200 m/z corresponding to boiling points between 67°C and 
350°C. 
Non-polar molecular adsorb better than polar molecules. 
Non-soluble or slightly soluble molecules adsorb better than highly soluble molecules.  
Based on the polarity or solubility of molecules, pH may have an influence on level of 
adsorption. 
Other conditions also might affect adsorption capacity: 
 The lower the temperature, the better the adsorption capacity 
 The lower the relative humidity, the better the adsorption capacity. 
 The higher the pressure, the better the adsorption capacity. 
The chemicals below are suitable for activated carbon adsorption: 
All aliphatic and aromatic hydrocarbons that fulfil above rules such i.e. carbon numbers 
between C4 and C14+. 
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Most common halogenated solvents including carbon tetrachloride, ethylene dichlororide, 
methylene chloride, perchloethylketone and trichloroethylene. 
Most common ketones such as acetone and esters such as butyl and ethyl acetate. 
Common alcohols such as ethanol, propanol and butanol. 
Although all chemicals above are adsorbed by activated carbon, the capacity for different 
VOCs can vary significantly with: molecular weight, polarity or solubility. Table 4.2.4.1. below 
shows activated carbon capacity for some common VOCs: 
Table 4.2.4.1. Activated carbon capacity for VOCs (76) 
Compound name Molecular weight Boiling point ℃ Carbon capacity % 
nitrobenzene 123 211 51 
tetrachloroethane 166 147 40 
tetrachloroethylene 165 121 35 
styrene 104 145 25 
xylene 106 138 21 
napathylene 128 217 20 
toluene 92 111 20 
benzene 78 80 12 
MTBE 88 55 12 
hexane 86 68 7 
ethyl acrylate 100 57 5 
dichloroethane 99 99 7 
methyl ethyl ketone 72 80 4 
methylene chloride 84 40 2 
acrylonitrile 53 74 2 
acetone 58 56 0.8 
vinyl chloride 62 -14 0.7 
chloroethane 64 12 0.5 
bromotrifluoromethane 149 -58 0.13 
methane 16 -161 0.0003 
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However there are some VOCs that need to be avoided for activated carbon adsorption: 
 Compounds that react with carbon or with steam for regeneration i.e. organic acids 
such as acetic acid, formaldehyde, cyclohexane and some easily hydrolysed esters 
 Compounds that polymerize on the carbon 
 High molecular weight compounds that are difficult to remove such as plasticizers, 
resins, heavy hydrocarbons, phenols, glycols and amines 
4.2.4.2. System design 
4.2.4.2.1. Amount of activated carbon required 
The Fruendlich isotherm equation is an adsorption isotherm which represents adsorption 
capacity to equilibrium partial pressure of VOC (78).  
௫
௠
= 𝑘𝑃௡                                                                                                    Equation 4.2.4.2.1.1. 
𝑥 is mass of adsorbate, 𝑚 is mass of carbon, 𝑃 is partial pressure of VOC in gas (psia), 𝑘 
and 𝑛 are empirical parameters. 
𝑘 and 𝑛 are specific for each VOCs, so each VOCs adsorption capacity needs to be 
calculated individually. 
After adsorption capacities are calculated, calculate the number of moles of air molecules 
using ideal gas law.  
𝑃𝑉 = 𝑛𝑅𝑇                                                                                       Equation 4.2.4.2.1.2. 
𝑃 is the absolute pressure of gas, 𝑉 is gas volume, 𝑛 is amount of gas present, 𝑅 is gas 
constant, 𝑇 is temperature. 
The amount of carbon required can now be calculated using adsorption capacity. 
4.2.4.2.2. Bed diameter and length 
The equation below calculates minimum bed diameter (𝐷௠௜௡௜௠௨௠ , m) based on maximum 
superficial velocity (𝑉௠௔௫, m s-1):  
𝐷௠௜௡௜௠௨௠ =
ସ௤
గ௏೘ೌೣ
                                                                                    Equation 4.2.4.2.2.1. 
The bed length of saturation zone (𝐿௦) can be calculated: 
𝐿௦ =
ௌೞ×ସ
గ×஽మ×௕௨௟௞ ௗ௘௡௦௜௧௬
                                                                               Equation 4.2.4.2.2.2. 
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4.2.4.2.3. Calculation results 
Assuming the flow rate required is 20 L min-1, pressure is 101.3 kPa, compressibility factor is 
1, air molecular weight is 28.751, relative humidity is 40% and temperature is 22.5°C. 
Based on research on indoor air contaminants, contaminant VOCs have of average 1-10 
ppmv, assuming VOCs are in 1 ppmv level, the list of contaminants used to estimate amount 
of carbon required are shown below. 
Table 4.2.4.2.3. Isotherm data for common indoor VOCs (76) 
Compounds 
molecular 
weight Conc in air  k m isotherm pressure 
Equilibrium 
capacity 
    ppmv     Pa   
Benzene 78 1 0.597 0.176 0.69 0.118025088 
Toluene 92 1 0.551 0.11 0.69 0.200056008 
acetone 58 1 0.412 0.389 0.69 0.011452419 
Trichloroethane 133 1 1.06 0.161 0.69 0.240605674 
Xylene 106 1 0.708 0.113 0.69 0.250053684 
Phenol 94 1 0.855 0.153 0.69 0.208913312 
Dichloroehtane 99 1 0.976 0.281 0.69 0.073358394 
chlorobezene 113 1 1.05 0.188 0.69 0.185861441 
cyclohexane 84 1 0.508 0.21 0.69 0.07342834 
 
These compounds are representative of the most prevalent VOCs contaminants in air, 
however there are many more VOCs present in air, so a calculation such as this is only an 
estimate for amount of carbon required. Assume there are around 200 types of VOCs 
present at 1 ppmv in indoor air, and a safety factor of 100% added for a conservative design.  
Weight of activated carbon = 695 g 
Gas purification period = 3 months 
Equilibrium pressure of VOC = 0.69 Pa 
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4.2.5. Gas hydration and purification combination design 
4.2.5.1. Mixed bed-designs 
Molecular sieve and activated carbon combined together increase the range of compounds 
that may be removed by adsorption. Molecular sieve adsorbs relatively small polar 
compounds such as water, carbon dioxide and C1 to C4 hydrocarbons. Activated carbon is 
suitable for relatively larger compounds such as benzene, and toluene. 
Since activated carbon is a stronger adsorbent than molecular sieve, the air inlet goes 
through the weaker molecular sieve adsorbent first to remove water and relatively small 
polar compounds, before the relatively larger compounds are absorbed by activated carbon. 
 
 
Figure 4.2.5.1. Combining molecular sieve and activated carbon 
4.2.5.2. Initial purification filter designs 
 
 
Figure 4.2.5.2.1. Filter design 1  
Molecular sieve 
Weak 
Small polar 
compounds 
Activated carbon 
Strong 
Larger non-polar 
compounds Air 
inlet 
Air 
outlet 
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Combine molecular sieve 13X (gas dehydration unit) and activated carbon (gas 
purification unit) together in same container, separating them by glass wool (or 
another type of separator), enabling both to be regenerated together. 
 
Figure 4.2.5.2.2. Filter design 2 
Since molecular sieve 13X and activated carbon have very different adsorption capacities 
they will have different service intervals. This design enables them to be regenerated 
separately. 
4.3. Instrumentation 
4.3.1. Portable breath sampler setup 
The portable adaptive breath sampler consists of two subunits: breath sampling unit and air 
supply unit. The main components of the breath sampling unit are: a sampling control box 
and breathing masks. The air supply unit consists of and air supply pump, a dehydration 
filter, a VOC purification filter and a dust particulate filter. The schematic diagram listing all 
main components of portable adaptive breath sampler is shown in Figure 4.3.1.1.  
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Figure 4.3.1.1. Schematic diagram of portable adaptive breath sampler illustrating the 
main components: breath mask (A), mask air supply assembly (B), adsorbent 
sampling assembly (C), micro-control valves (D), pressure transducer (E, F), 
electronic interface (G), precision air sampling pump (H), dust filter (I), activated 
charcoal filter (J), molecular sieve 13X filter (K), air supply pump (L), pressure 
regulator (M), laptop containing DAC card and labview software (N) and portable 
suitcase (O) 
All of the portable breath sampler components were housed inside a heavy-duty steel cart. 
The cart was fitted with lifting handles, a telescopic drag handle, and wheels. The prototype 
adaptive breath sampler built was assembled in three sections stacked one on top of the 
other. At the bottom was an air supply pump, in the middle was the air purification unit and at 
the top was the breath sampling unit, placed there for easy access. Gas connections 
between the sections were made with 6.4 mm bore silicone tubing. The connections 
between components in the air purification stage were ¼ inch stainless-steel tubing and 
connectors (Swagelok, USA); these can be disconnected easily for cleaning and servicing 
purposes. Figure 4.3.1.1. illustrates prototype portable adaptive breath sampler at each 
level.    
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Figure 4.3.1.2. The prototype portable breath sampler setup at each individual level. 
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4.3.2. Breath sampling unit 
The breath sampling unit consisted of a sampling control box and a breathing mask for the 
participant. The micro-control valves within the sampling control box, controlled by a Labview 
virtual instrument, switched the sampling pump between a sampling and vent mode 
depending on the phase of breathing cycle of the participant. As the participant inhaled, the 
micro-valve switched to vent mode to avoid sampling, inspired air and when the participant 
exhaled, the micro-valves switched to sampling mode at the point set in the breathing cycle. 
A pressure transducer tracked inspiration and exhalation and was connected to the mask 
with a silicone tube. The breathing profile and controls were displayed on Labview software 
program. The user was able to analyse and exhaled breath profile and set the system to 
sample a specific portion of the breath to collect. The targeting sampling of exhaled breath is 
essential feature for sampling variable breaths of participants with impaired lung function.  
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Figure 4.3.2. (Top) Screenshot of virtual instrument Labview used to collect a 
participant’s breath (Bottom) Photograph of collection of a breath sample from 
participant. 
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The medical breathing mask (ResMed, Mirage Full Mask Series 2) was carried with the 
sampling unit at top level of the carrier and was prepared for use at the sampling location. 
The mask was fitted with a custom made detachable PTFE valve which was connected to 
the air purification unit. The PTFE valve was fitted with a single use one-way valve with to 
exhaust exhaled breath and surplus air supply while preventing the accidently ingress of 
ambient air into the mask and sampling zone. The mask also had two Luer fittings: One 
fitting was connected to the pressure transducer inside the sampling control box, and the 
other was connected to the adsorbent sampling assembly. The adsorbent sampling 
assembly contained a custom made PTFE interface which connected a multi-adsorbent 
adsorbent sampling tube (Tenax® TA/ Carbograph 1 TD, Markes International, UK) for 
breath VOC collection. The exhaled breath was drawn from immediately beneath the nostrils 
into the adsorbent tube by a 5 cm × 0.53 mm MXT stainless steel capillary guard column 
(Thames Restek, UK) fitted inside the PTFE interface. The other end of the adsorbent tube 
was connected to the micro-valve switching ports on the breath sampling unit which in turn 
were connected to an Escort ELF air pump (MSA, USA) with silicon tubing.  
4.3.3. Air supply and purification  
A linear air pump (HP-200, HIBLOW, Techno Takatsuki ltd, Japan) was housed at the 
bottom of the portable carrier. Surrounding room air was drawn through its in-built coarse 
filtered inlet and up to 200 L min-1 was delivered to its outlet. 9 air holes around 1 cm in 
diameters were cut out at the bottom level to ensure sufficient air flow and cooling for the air 
pump. A custom made PTFE fitting connected the pump outlet to 6.4 mm bore silicon tubing. 
The room air was supplied into the three filters at the middle level of the portable carrier.  
A three-stage process dried, purified and filtered the air. The first-stage was a custom built 
stainless steel molecular sieve 13X 10A filter (L260 mm × O.D.100 mm, 100psig pressure 
rating, 5351 cc). It is made airtight using custom made soft silicon gasket and mesh screen 
fitted at both ends of the filter. The primary function of the molecular sieve 13X desiccant 
filter was to dry the air supply. It has a very stable water capacity from around 20% to 
maximum of 28.5% at relative humidity range of 10% to 100% and ambient temperature of 
10°C to 50°C (76). The dehydrated air was then passed through the custom built stainless 
steel activated carbon filter (L278mm × O.D.25.4mm) via ¼ inch stainless steel tubing. Since 
activated carbon is a stronger adsorbent than molecular sieve, the air inlet went through the 
weaker molecular sieve adsorbent first to remove water and relatively small polar 
compounds, before the relatively larger non-polar compounds were removed by activated 
carbon. The molecular sieve serves both a drying and low Carbon number purification 
adsorbent protecting the activated carbon filter from overloading. Additionally, the larger 
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molecular sieve filter also cools down pumped air from around 30°C to 20°C, increasing the 
capacity of the carbon filter to absorb and more comfortable for participants to breath.  
The last filter in the purification assembly was a stainless steel dust and particulate filter with 
¼ NPT in-line port (3.2 cm × 7.9 cm, 5000psig pressure rating, Model 97S6, Parker Baslton, 
USA). It contains a replaceable microfiber cartridge (Model 050-50-BQ, Parker Baslton, 
USA) which filters gas at 0.01 µm of more than 99.99% of its particulate (79).  
After drying and purification the room air, was supplied to the breathing mask at flow of 30 to 
40 L.min-1. The purified air met or exceeded the air quality requirement of ISO8573-1:2010 
Class 1 with a particulate count not exceeding 20,000 particles in the 0.1 - 0.5 micron size 
range4. All three filters contain re-generable adsorbent or replaceable cartridges which were 
regenerated at regular intervals.  
4.4. Experimental 
4.4.1. Exhaled breath sampling method work-flow 
4.4.1.1. Preparation and validation 
Figure 4.4.1.1 illustrates the detailed breath sampling work-flow using the portable adaptive 
breath sampler. The work-flow can be separated into three stages: preparation, validation 
and sampling. It is based on the method adopted using the original breath sampler with 
enhanced method stages and checklist for a more rigorous process (80).  
Preparation is an essential stage for portable adaptive breath sampling since the adsorbents 
filters require regeneration after use to create purified air. Additionally, thorough cleaning of 
all portable breath sampler parts in between samples minimise exogenous VOCs in breath 
samples.  
All three filters in the purification assembly can be readily disconnected and removed from 
portable breath sampler for regeneration. The molecular sieve 13X filter can be cleaned 
using the thermal desorption method. The filter regeneration process consists of heating and 
cooling stages. Heated took place inside a conditioning oven while being back-flushed with 
dry high-purity nitrogen gas at 20 L.min-1 for 5 hours at 288°C. It was then cooled to 22.5°C 
and left to stabilise for a further 2 hr. It was important to ensure that the filter was allowed to 
cool completely to room temperature before sampling to avoid variation in adsorption 
capacity. The regeneration temperature of 288°C was based on industrial desiccant tower 
regeneration temperature (78), and the regeneration conditions was calculated based on 
maximum sampling duration of 4 hours and stripping gas flow rate equation (81). The 
activated carbon trap can also be regenerated by the thermal desorption method (82). The 
filter was heated to 300°C while back-flushed with dry high-purity nitrogen at 10 L min-1 for 5 
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hours followed by cooling and thermal stabilisation for 1 hr at 22.5°C. The fine particulate 
filter cartridge was also checked periodically for dust accumulation and replaced accordingly. 
All stainless steel parts and silicon tubing were baked out in vacuum oven at 150°C 
overnight before use to eliminate any VOCs residuals 
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Figure 4.4.1.1. Work-flow chart detailing the exhaled breath analysis method using the 
portable adaptive breath sampler including preparation, validation and sampling 
stages 
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Table 4.4.1.1. TD-GC-MS system instrumental parameters 
Thermal desorption Gas chromatography Ion trap mass spectrometer 
Parameters Setting Parameters Setting Parameters Setting 
Pre-desorption purge 1 min Initial temperature 40°C Mass range  40 m/z to 445 m/z 
Tube desorption  5 min at 300°C Final temperature 300°C Scan mode EI auto 
Pre-trap purge  1 min Hold temperature/time 300°C for 8 min Emission current 10 µAmps 
Trap desorption 5 min at 300°C   Rate 5°C/min Target TIC 20000 counts 
Heating rate Maximum °C/min Initial pressure 27.3 psi Maximum ion time 25000 µseconds 
Flow path temperature 180°C Final pressure 56 psi Scan time 0.38 seconds/scan 
Trap low temperature -10 °C Hold pressure/time 56 psi for 7.83 min Data rate 2.63 Hz 
HV temperature  180°C Rate 0.55 psi/min Trap temperature  150°C 
Cold trap flow rate 50 cm3/min GC column DB-5 60m length × 0.25mm i.d. × 0.25 µm film thickness Manifold 50°C 
Cold trap packing General purpose hydrophobic Total analysis time  60 min Transferline temperature 300°C 
Split ratio Splitless Carrier gas Helium   
    Carrier gas flow rate 2 cm3/min     
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Finally all regenerated and cleaned filters, connectors and tubing were assembled together 
using 9/16” and ½” spanners to form air tight seals. The connected purification unit were 
checked for air leaks with a leak detector while pressurised with high purity nitrogen or 
helium gas supply at around 10 psig. Any leaking connections were tightened with spanners. 
After re-connecting the air purification unit to the air pump, the flow rate of the purified air 
supply was checked with a rotameter (50 L min-1 maximum flow). The minimum flow required 
for relaxed breathing at resting state was 30 L min-1.  
The purification efficiency of the filter assembly was checked at regular intervals. The drying 
efficiency was tested using a humidity detector (Environics, Finland), and the background 
exogenous VOCs level were also be checked by collecting an air sample (2 L) from the air 
outlet for GC-MS analysis. 
The coarse filter to the inlet of the air pump was periodically checked every 6 month 
according to manufacture specification. If the pump was used intensively, then frequency of 
inspection was increased to a check every 3 month. A dirty filter might introduce high levels 
of contaminants into the air supply, or reduce the flow-rate. The portable breath sampler 
should be cleaned with high purity water periodically to avoid dust accumulation. 
The medical breath mask was sterilised by soaking it in 0.55% aqueous ortho-phthaldehyde 
solution for one minute, followed by careful scrubbing with a soft brush for thorough clean. 
The sterilised masks were then rinsed with clean distilled water and air dried away in 
enclosed fume cupboard. Finally it is conditioned in a vacuum oven at 0.1 kPa at 50ºC for a 
minimum of 2 hours. 
4.4.1.2. Sampling 
All exhaled breath sampling experiments were conducted in accordance with the ethical 
principles of good lab practice and the Declaration of Helsinki. The research method 
followed non-invasive exhaled breath sampling protocol coded G09-P5 that was approved 
by the Ethics Advisory Committee at Loughborough University. Participants gave written 
consent and were screened by a health questionnaire.  
The portable breath sampler was moved to the sampling location where a 220 V AC supply 
was required. The air purification had been setup and tested during preparation while the 
face mask and its connections to the sampling control box were transported in an air-tight 
container within the cart to be assembled on-site to avoid contamination in transit. The 
sampling room was also checked for any sources of VOC contamination. The sampling 
location was specified to be well-ventilated by temperature controlled to about 20°C. The 
participant(s) was (were) asked to refrain from using make up or strongly scented personal 
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care products on the day of sampling. The flow rate from the air purification unit was 
checked after setup and then connected to the sampling face mask air inlet. The face mask 
was fitted to a seated participant with straps and tightened gently until the mask was air tight. 
The participant was then encouraged to relax and get used to wearing the face mask while 
breathing in a relaxed manner through their nose. During this acclimatization, which lasted 
up to 10 min, the participant’s breath profile was recorded and tracked on Labview software. 
The sampling parameters were adjusted to only collect exhaled breath from their distal 
airways. 2.5 L breath samples were then collected from the participant onto multi-adsorbent 
tubes and stored in 4°C fridge. Additionally, 2.5 L samples were taken of the purified medical 
air supply and the room air. The collected samples were transported back to the analytical 
laboratory at 4°C using cool packs in a well-insulated container. They were analysed within 
72 hours. For large scale studies where immediate sample analysis is not possible, the 
sample may also be stored at - 80°C for up to 6 week (See Chapter 3 for more details).  
4.4.2. Air supply drying test 
The aim of the drying test was to determine the capacity of the molecular sieve 13X 
desiccant. This was achieved by identifying the equilibration and break through points for the 
molecular sieve filter.  
The HiBlow HP200 air pump was connected to molecular sieve filter with a flow rate of 40 
L.min-1 recorded using a rotameter. The outlet from the molecular sieve 13X filter was 
connected to a gas-sensing array that included relative and absolute humidity (g m-3) 
sensors (VAMPPI Environics oy, Finland) using a ¼” inch stainless steel T-union. A portion 
of the outlet air flow was split into the VAMPPI sensor array at 1.3 L min-1. The monitoring 
continued until the molecular sieve trap appeared equilibrated with water. The RH% and 
absolute humidity data measured by VAMPPI was monitored and recorded on ChemPro-100 
software (Environics oy, Finland). The recorded data was exported into Excel format for data 
analysis.  
4.4.3. Air supply purification test 
The air supply purification test determined the effectiveness of the activated carbon filter unit 
in reducing the levels of air contaminants supplied to the face mask.   
Ten 2.5 L air samples were collected from purified air supply along with three 2.5 L 
background room air sample, to act as comparisons. The air supply to the portable breath 
sampler was pumped from surrounding room air and a comparison between these two types 
of air samples enabled the efficiency of the activated carbon filter to be estimated. Room air 
samples were collected using Elf Escort (flow rate range: 0.5 to 3 L min-1, MSA, USA) air 
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sampling pump at flow rate of 0.5 L min-1. Purified air supply samples were collected via a 
custom made sterile stainless steel needle valve at a flow rate of 0.5 L min-1.  All air samples 
were collected over 2 hr and analysed within 48 hr using two-stage thermal desorption Unity 
Series 1 (Markes international, USA) interfaced with Varian 3800 GC coupled to Varian 4000 
ion-trap mass spectrometer. Retention index mixture of 18 hydrocarbons compounds with 
known concentration was injected before and after sample analysis as quality control.  
4.4.4. Regeneration study 
The regeneration study sought to establish the regeneration efficiency of the air purification 
unit. This included testing the proposed thermal desorption regeneration methods to dry and 
clean the exhausted molecular sieve 13X and activated carbon filters.  
After approximately 4 hr with 20 samples collected the air supply and purification unit was 
nearly exhausted. The whole unit was disassembled and regenerated according to the 
protocol described in Section 4.4.1.1. After regeneration and re-assembly, the performance 
efficiency of the regenerated components was tested by collecting a 2.5 L air sample from 
the purified air supply and monitoring humidity with the VAMPPI device. The air sample was 
analysed immediately by TD-GC-MS method.  
4.4.5. Trial with human participants 
The portable breath sampler was tested extensively through a series of 10 purified air supply 
sampling and regeneration cycles, following the breath sampling work-flow. After the testing 
phase, the sampler was then trialled with 10 volunteer participants who completed consent 
forms and health questionnaires before sampling began. Some participants had mild 
asthma. Two 2.5 L breath samples were collected from each participant in under 30 min, and 
all 10 participants were sampled over one week period. They were closely monitored for any 
signs of discomfort during sampling along with the air-supply flow rate; measured at around 
40 L.min-1. One breath sample was collected using the portable breath sampler and the 
second sample was collected using the original adaptive breath sampler described in 
Chapter 2. This enabled comparison of breath samples collected using the two methods. 
Breath profiles were also recorded to assess if any changes in the breathing pattern with the 
two methods were discernible. The collected samples were stored at 4°C and analysed 
within 48 hr.  
The reproducibility of breath samples was also assessed by collecting 10 replicate breath 
samples from the same individual over a 2 hr interval. The collected samples were stored at 
4°C and analysed within 48 hr.  
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4.5. Results and discussion 
4.5.1. Air drying test 
The air inlet had an average relative humidity of 22.9% at 20°C calculated from 10 minutes 
of data. Once this initial measurement has been acquired experiment was set up and run,  
and Figure 4.5.1. illustrates the RH% plotted against time. %RH was less than 0.1 % (T= 
20°C) for 4.02 hours with breakthrough detected at that time after approximately 9.6 m3 of air 
had been processed. The %RH increased until at 40.7 hours whereit reached the %RH level 
of the inlet air.  
 
Figure 4.5.1. Line plot of RH% against dehydration duration using molecular sieve 13X 
desiccant filter. Both break through point and saturation point are labelled on the 
graph 
4.5.2. Air supply purification test 
4.5.2.1. Purification level comparison with background air 
The air supply unit not only dried the air supply, it also purified it by trapping entrained 
VOCs. The purification capacity of air supply unit was dependent on the adsorption capacity 
of activated carbon filter for VOCs in combination with the adsorption capacity of the 
molecular sieve 13X filter. The adsorption capacity of the air supply unit was demonstrated 
by comparing the levels of 12 common indoor airborne contaminants in purified air samples 
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and background room air samples (Table 4.5.2.1.). The average combined peak area of the 
12 room-air sample compounds was measured at 637 kcounts ± 223 kCounts. The average 
combined peak area of these compound in the samples of purified air was 216 kCounts ± 58 
kCounts. The adsorption efficiency varied significantly depending on the chemical and 
physical properties of any specific compound. The halogenated compounds were 
determined to have the highest adsorption rate among targeted compounds, chloroform was 
reduced most significantly by 97.8%, followed closely by trichlorofluoromethane (Freon 11) 
whose level in the air supply was reduced by 97.5%. In contrast, the air supply unit has 
shown significantly lower adsorption capacity for methylated benzene compounds, ethyl 
benzene level comparison shown no reduction between room air and purified air samples, 
xylene level was only reduced by 27.7% in the purified air samples.  
Table 4.5.2.1.  The adsorption capacity of 12 common indoor air contaminant 
compounds by portable breath sampler air purification unit. 
Compound name 
Purified air 
(kCounts) 
Background room air 
/Counts Reduction 
% Aver
age RSD% Average RSD% 
1,4-dichlorobenzene 7 62.9 15 80.3 56.5 
2-Butanone 62 49.1 269 46.9 77.0 
Acetone 507 29.9 1103 32.5 54.0 
Benzene 183 11.7 1149 17.3 84.1 
Chloroform 16 48.8 730 75.7 97.8 
Ethyl benzene 407 32.3 387 37.0 0.0 
Heptane 11 79.2 265 71.1 56.9 
Tetrachloroethylene (PERC) 8 41.1 22 64.3 64.4 
Toluene 688 19.2 2633 20.6 73.9 
Trichlorofluoromethane (Freon 11) 9 58.2 352 72.8 97.5 
Trimethylbenzene 39 24.8 55 52.5 29.8 
o-Xylene 656 29.9 907 45.0 27.7 
 
RSD% variation of compound peak area from 10 replicate purified air sample was measured 
at 40.6%. Similar to the variation in adsorption rates, the RSD% also ranges significantly 
from 11.7% to 79.2%. The variation appears to be largely dependent on the compounds 
peak intensity, generally compounds with greater peak intensity seem to have lower RSD% 
variation.  
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Figure 4.5.2.1. Comparison of common air contaminants levels found in room air and 
purified air from the portable breath sampler. P denotes purified air supply and R 
denotes background room air. 
4.5.2.2. Comparison with original adaptive breath sampler 
The original adaptive breath sampler used three stage filtration with Grade DX, Grade BX 
and Grade-000 high capacity purifiers (2000 Balston series, Parker Hannifin Corporation, 
USA). The air supply was generated from an air compressor and a wall mounted membrane 
drier. The purification efficiency of this air supply unit setup has been described in detail 
previously (41). The levels of volatile common room air contaminants were greatly reduced 
and less variable in the purified air. For example, average acetone concentration were 14 
times higher than 14 times more variable compared to room air sample. Volatiles generated 
from personal care and cleaning products were also significantly reduced (4 times reduction) 
in purified air. 
The average signal responses of the 12 compounds are listed in Table 4.5.2.1. For the 
original breath sampler was 272 kCounts ± 48 kCounts compared to 216 kCounts ± 58 
kCounts. The contamination levels in the air from portable breath sampler was lower 
although more variable. The RSD variation for 10 portable breath sampler generated air 
sample was measured at 40.6% compared to variation only 20.8% obtained from original 
adaptive sampler. This variation may be due to be the variability of the intake air to the 
portable sampler due compared to air in the plant room intake. Some variability may also be 
attributed to the packing of the adsorbents inside the portable breath sampler. An example 
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chromatogram comparing purified air supply from the two sources is illustrated in Figure 
4.5.2.2. 
 
Figure 4.5.2.2. TIC chromatogram of purified air supply from two sources on the same 
day: purification elements from original adaptive breath sampler (top) and custom 
built purification unit from portable breath sampler (bottom) 
The adsorption rate of 12 compounds by original breath sampler purification unit was 
determined by comparison with their respective background room air level, and it was 
measured with average at 42.7%. The portable breath sampler air purification unit measured 
purification efficiency at 59.5% against its own background air inlet. The inlet air to the two 
devices are from different sources, the portable breath sampler uses room air as inlet 
source, whereras original adaptive breath sampler uses generator air as its own air inlet 
source, the purification efficiency calculated is just to show the portable breath sampler is 
able to achieve comparable purification efficiency compared to the original adaptive breath 
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sampler. Also this is highly compound dependent and a significant adsorption capacity 
variation can be observed across the 12 compounds. Similar to portable breath sampler, the 
original adaptive sampler also has the highest adsorption capacity for chloroform 
compounds with 92.7%. The original adaptive also achieve similar adsorption capacity for 
other compounds such as heptane, acetone and benzene, however the adsorption capacity 
differ significantly for other compounds such as tetrachloroethylene which it shown poor 
adsorption capacity (0%) compared to significantly higher adsorption at 64.4% by portable 
breath sampler. For other compounds the original adaptive sampler seems to perform more 
efficiently, portable breath sampler demonstrated poor adsorption for ethyl benzene (0%), 
but the original adaptive sampler was able to remove around 53.7% of contaminant present 
in pumped air. The significant difference in adsorption capacity for these specific compounds 
is likely to be due to the specific adsorbent material used inside the filter. The high capacity 
Balston filter used in original adaptive breath sampler partly consists of Grade 000 CI type 
cartridge to remove trace quantities of oil vapour. The cartridge itself is made of activated 
carbon adsorbent sandwiched between two microfiber materials, but no details can be found 
on the specific type of activated carbon used (83) (84). Although the portable breath sampler 
also uses activated carbon as trace VOCs adsorbent, but there are various and complex 
types of activated carbon adsorbent available on the market, and their adsorption capacity 
differ significantly due to huge range of criteria such as surface characteristics, size and 
preparation methods. Hence it is important to test and establish the adsorption capacity of 
activated carbon adsorbent for target compounds or applications, and the purification test 
carried out on the 12 common indoor contaminant compounds has determined that the 
portable breath sampler three stage filtration process and multi-adsorbent combination of 
molecular sieve 13X and activated carbon can successfully remove the majority of trace 
contaminant VOCs present in the air supply to produce purified air for breath sampling, 
additionally its comparison with a commercial filter assembly has established it can achieve 
the same level of adsorption capacity with smaller and lighter setup, adding a new aspect of 
portability.      
4.5.3. Regeneration test 
The air purification unit was regenerated periodically depending on frequency of sampling, 
generally the maximum sampling time was 4 hours, based on sampling time of 10 minutes 
per breath sample, around 20 breath samples can be taken before it needs to be 
regenerated. The thermal desorption regeneration used was described in Section 4.4.1.1. 
The average VOCs adsorption capacity % of air purification unit just after regeneration was 
determined to be 95.1% compared to 59.5% before regeneration. The adsorption capacity 
was calculated from the adsorption rate of the 12 common airborne VOCs. The increase in 
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adsorption capacity demonstrates that the thermal desorption cleaning procedure for the 
purification filters adopted was successful in regenerating the desiccants. Additionally after 
the thermal desorption regeneration procedure, the dehydration capacity of the desiccants 
was too successfully recovered to full, the humidity level % after regeneration was measured 
at 0% compared 100% just before. The adsorption capacity of molecular sieve and active 
carbon is limited and decline as a function of the number of regeneration cycles. The life 
time of the purification unit depends very much on frequency of breath sampling, therefore it 
is essential to keep monitor and measure the adsorption capacity of the purification unit after 
sampling, and replace the adsorbent beds readily if a reduction in adsorption capacity is 
observed. 
4.5.4. Trial with human participants 
All 10 participants were asked about the experience with portable breath sampler and the 
original adaptive breath sampler after sampling, none reported any difficulties with breathing 
during sampling. None reported any major differences in experience between the portable 
breath sampler and original breath sampler. One participant reported purified air supply in 
portable breath sampler was very relaxing and was falling asleep during sampling. Although 
most (8 out of 10) participants reported that breathing the purified air supply felt very 
different to breathing room air and some reported that it took time to acclimatised, but all 
participants felt they were able to breathing comfortably and relaxingly during sampling. 
Table 4.5.4.1. Participant portable breath sampling trial summary. 
Participants number 10 participants 
Study duration 4 days 
Breath samples on portable breath sampler 10 samples 
Breath samples on original breath sampler 10 samples 
Background air samples for breat samples 8 ( 2 per day) 
 
The sample of these 10 participants were carried out in 4 separate days, 2 breath samples 
were collected per participant, additionally room air and air supply samples were collected 
after and before breath sampling (See Figure 4.5.4.1.). Sampling time for each sampling 
session is between 3 to 4 hrs. The desiccant air filters were regenerated by thermal 
desorption process in between the sampling days. Air humidity tests carried out after the 
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session have all shown 0% humidity indicating the filters have not reached breath through 
point.  
 
Figure 4.5.4.1. TIC chromatogram illustrating participant breath sample using the 
portable breath sampler (top), room air (middle) and purified air supply (bottom) 
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The breath profiles of the 10 participants recorded during breath sampling sessions were 
observed for breathing patterns. Each breath sample generated from the portable breath 
sampler took on average 5.39 ± 0.19 minutes (RSD = 3.49%) to collect while passing 2.52 ± 
0.02 L (RSD = 0.70%) into the adsorbent trap. Average breath amplitude was calculated at 
1.71 V ± 0.68 V (RSD = 39.8%). The average exhaled sample comprised of 89 ± 33 breaths 
(RSD = 37.2%) with a breathing rate of 17 ± 2 breath per minute (RSD = 38.8%) and 
frequency of 0.058 ± 0.006 minute per breath (RSD = 58.4%). Statistics summarising breath 
amplitude, breath rate and numbers of breaths are dependent on the physical status of the 
participant; hence significantly greater variation was observed for these factors compared to 
the sampling volume and duration.  
Breath samples were also collected from the same 10 participants using original breath 
sampler. The breath profiles were analysed and compared to those collected from the 
portable breath sampler. Table 4.5.4.2. illustrates comparison of breathing patterns of the 
same 10 participants collected from two different type of sampling devices. Using paired two-
tailed t-test demonstrated no significant changes in breathing profiles can be observed with 
calculated p value at 0.20 (P = 0.05). Thus showing high degree of similarity between the 
breathing patterns using two type of sampling devices. Figure 4.5.4.2. shows an example of 
breath profile observed from one of the healthy participants. 
The 12 common airborne VOCs compounds from the 12 participants were analysed. The 
signal responses for these 12 compounds were hugely varied between the participants. The 
RSD% ranged from 28.2% to 165.7%. Trimethylbenzene had the lowest RSD of 28.2% and 
while 1,4-dichlorobenzene had the highest RSD of 165.7%. Additionally many compounds 
were recovered from one participant but completely absent in the next sample. The 
significantly varying RSDs between the participants is to be expected due to individual 
absorption and elimination metabolic rate. These values are summarised in Table 4.5.2.1. 
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Table 4.5.4.2. Comparison of breath profiles of 12 participants generated from portable breath sampler and original adaptive breath 
sampler 
  Portable breath sampler Original adaptive breath sampler 
Breath profile statistics Average Standard deviation RSD% Average  Standard deviation  RSD% 
Total sampling time (sec) 323.2 11.3 3.5 321.6 14.5 4.5 
Total sampled vol. (L) 2.5 0.0 0.7 2.5 0.0 0.6 
Total number of breath  89.0 33.1 37.2 86.2 33.2 38.6 
Breathing rate (Breath per 
min) 13.9 5.4 38.8 13.8 5.6 40.5 
Single breath duration  (min) 0.09 0.05 58.4 0.09 0.04 50.5 
Average breath amplitude* 1.71 0.68 39.84 1.87 0.82 43.80 
*Average breath amplitude is the average height of exhaled breath measured from the baseline  
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A comparison between breath samples taken from portable breath sampler and original 
adaptive breath sampler shown that no significant difference between the two methods. 
Paired two-tailed t-test was performed based on the two set of signal responses of 12 VOCs 
compounds from the two samples, p value was calculated at 0.96 (P=0.05). 
Overall the analysis of breath profile and breath VOCs samples have shown great system 
stability and reproducibility (RSD of 3.49% for breath collection duration) , thus 
demonstrating that the augmented portable breath sampler could be deployed in large scale 
breath VOCs studies for extensive sampling period. Additionally when compared with the 
original adaptive breath sampler, the two datasets have shown no significant difference, 
since the original adaptive breath sampler has already been successfully deployed in 
numerous large scale clinical studies, the comparable datasets the portable breath sampler 
can generates indicates that it can successfully replace the current system with no impact on 
data quality. 
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Figure 4.5.4.2. An example of breath profile from a healthy participants collected from 
portable breath sampler (Top) and original adaptive breath sampler (Bottom) 
4.5.5. Breath reproducibility study  
The stability of portable breath sampler was determined by assessing the reproducibility of 
10 replicates breath sample collected from the same participant within a short time frame. 
The 10 replicates breath samples were collected in 1.5 hr and the participant reported no 
changes in the breathing experienced during this period. The air supply had a stable flow 
rate of 40 L min-1 throughout. Each sample took on average 5.47 ± 0.03 min (RSD 0.47%) to 
collect an average sample volume of 2.51 ± 0.01 L (RSD 0.27%). Breathing rate was stable 
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at 22.8 ± 1.4 (RSD 5.39%) breath per min with total number of breath per sample at 135.4 ± 
3.7 (RSD 2.72%). High level of reproducibility can be observed from breaths profile of the 10 
replicate breath samples, thus determines that the portable breath sampler can be used 
reliably to collect large amount of breath samples with high degree of stability. 
 
Figure 4.5.5. The variability of 11 common room air contaminants found in breath 
sample using the portable breath sampler. 
The 12 common airborne room air contaminants in the 10 replicates breath samples were 
analysed. The average RSD variation between the 12 compounds was determined to be 
34.6%, however there is a significant RSD variation between the 12 compounds ranging 
from 16.2% for tetrachloroethylene (PERC) to 111.8% for toluene. Trichlorofluoromethane 
(Freon 11) level was not detected in most breath samples. Compounds with the lowest 
variation were tetrachloroethylene (PERC) (16.2%), acetone (20.8%) and 1,4-
dichlorobenzene (23.6%). Compounds with the highest variation were chloroform (110.8%), 
toluene (111.8%) and ethyl benzene (85.5%). The RSD variation of signal responses for 
different compound species is potentially due to varying wash out rate for different 
compounds, certain exogenous VOCs would be absorbed, metabolised and eliminated out 
of system slower than others leading to those compounds level during sampling to vary more 
significantly. 
4.6. Summary 
A portable breath sampling system was designed and developed from the original adaptive 
breath sampler. Its concept originated from the limitation where breath VOCs studies could 
only be carried out in specific locations. This significantly hindered participant recruitment, 
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especially in clinical facilities where participants may have difficulties reaching designated 
facilities. The earlier design of the adaptive breath sampler required space and time for initial 
set up, and most importantly it required a medical air supply. These requirements have been 
found difficult to meet in many facilities, so this work investigated and explored the different 
aspects required to provide a portable breath sampling system to achieve reproducible and 
standardized breath samples.  
In order to replace a static air generator with a wall mounted drying and purification 
assembly, a smaller bespoke air supply unit was developed built and tested. It was portable 
and delivered up to 40 L min-1 and required regular regeneration. A thermal desorption 
regeneration procedure for the purification media was developed and successfully tested.  
The capability of the portable breath sampler to dehydrate and purify air supply was also 
investigated. The VOCs adsorption rate of its air purification unit based on signal responses 
from 12 common airborne room air contaminants was measured to be approximately 59.5%. 
While its air supply dehydration rate was measured to be 0% which is complete dryness for 
up to 4 hours. Maximum sampling period of around 4 hours was measured based on 
maximum air dehydration capacity of molecular sieve 13X desiccant filter.  
After rigorous testing of portable breath sampler, it was then trialled with human participants. 
In participant experience feedback, no participants reported any discomfort or difficulties 
during breath sampling session. The stability of portable breath sampler was tested when 10 
replicate breath samples were taken from the same individual continuously for extended 
sampling period, reproducible breath profile and signal responses from targeted VOCs were 
achieved. The results from 13 participant’s trial study had shown more variation for both 
breath profiles and targeted compounds responses. This variation between participants can 
be down a number of factors. Such as individual metabolic adsorption and elimination rate 
for VOCs, their lung capacity or breathing actions. However when compared with their 
counterpart results collected using original adaptive breath sampling system, the two 
datasets were highly comparable (p = 0.96), this indicates the enhanced portable breath 
sampler can achieve the same level of breath sampling capability and reproducibility.  
The portable breath sampler described was subsequently used in breath VOCs studies at 
various locations (chemistry laboratory, swimming pool side and sports centre laboratory) 
with participants with asthma, see Chapter 5. It is important to note that the portable breath 
sampling system described here is only the first prototype, and it can be improved further. 
One aspect is the limit of an air supply flow rate of 40 L min-1. Although this flow rate is 
enough for relaxed breathing at rest, a higher flow rate is required for breath sampling during 
exercise when the breathing rate is much higher; elite athletes will breath at up to             
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300 L min-1. Another aspect that could be developed further is the size of the current system. 
The current system can be wheeled to a remote location for sampling or transport to further 
afield. It is much too big to be incorporated with a handheld sampler. Further redesigns to 
the next generation prototype should be focused on reducing its size and weight further to 
make it even more portable. The goal is a clinically compatible user friendly adaptive breath 
sampler for diagnostic purposes that can be used anywhere enabling research in breath 
analysis in a much wider range of locations. 
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CHAPTER 5: VOCS PROFILING OF EXERCISED INDUCED 
BRONCHOCONSTRICTION (EIB) IN YOUNG ATHLETES USING 
PORTABLE BREATH SAMPLER 
5.1. Introduction 
5.1.1. Brief description of exercise-induced bronchoconstriction (EIB)  
Exercise-induced bronchoconstriction (EIB) is a common pulmonary disorder characterized 
by airflow obstruction occurring after several minutes of physical activity. Typically short 
period (4 – 10 minutes) of intense exercise can trigger constriction of bronchial smooth 
muscles typically 5 to 15 minutes following the completion of the exercise. It may also occur 
after 30 minutes of continuous exercise. EIB is recognized as an indirect measure of non-
specific bronchial responsiveness and severity of asthma. It has been used as an 
epidemiological tool for diagnosing asthma. Common symptoms of EIB may include 
coughing, wheezing, chest pain and shortness of breath.  
EIB is a common form of asthma and occurs in 70% to 80% of untreated asthmatics and 
35% to 40% of those with allergic rhinitis/hay fever symptoms if challenged under 
appropriate exercise conditions. This can represents approximately 12% to 15% of 
populations. Exercise is the most common trigger of bronchospasm in asthmatics with 50%-
90% of all individuals with asthma have airways that are hyper-reactive to exercise.  
EIB can also occur in up to 10% of the population who are not known to be asthmatic, and 
up to 40% of children with documented EIB have no symptoms of asthma. The health 
consequence of unrecognized or inadequately treated EIB are significant. In a review of over 
30 years of Isreali military recruit data, it was found that asthma was the main risk factor for 
unexplained death (85). Another research has identified 61 deaths was caused by asthma 
occurring in close association with sporting event or physical activity (86). Out the 61 deaths, 
81% occurred in subjects who were younger than 21 years of age and 57% occurred in 
subjects who were considered to be elite young athletes. It was also found that 10% of these 
deaths occurred in subjects who were not known to be asthmatics. These research suggest 
that all individuals participating in organized sports should be made adware the risk of EIB. 
5.1.2. EIB in athletes 
The prevalence of exercise related bronchospasm in athletes range from 11% to 50% (87), 
and up to 90% of subjects with asthma with have EIB (88). Recent research has 
demonstrated EIB is also commonly found in elite sports athletes. Athletes who compete in 
high ventilation or endurance sports are more likely to experience symptoms of EIB 
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compared to low ventilation sports. Athletes in endurance sports such as cross country 
skiing, swimming and long distance running with long period of elevated ventilation are 
especially prone to EIB (89). EIB is also prevalent in winter sports which is thought to be due 
to cooling of airway at high ventilation rate for extended period of time (90). One study found 
that 18% to 26% of Olympic winter sport athletes and 50% of cross-country skiers were 
shown to have EIB (90). Another study has shown out of a group of both asthmatic and non-
asthmatic 50 elite summer athletes studied, 50% were found to have EIB. The US Olympic 
Committee reports an 11.2% occurrence of EIB in all athletes who competed in the 1984 
summer Olympics (91).  
Correctly diagnosing and treating EIB in elite athletes is essential as it can have significant 
impact on their performance and health. Inappropriate treatment of EIB can lead to tremor, 
tachycardia, increase in EIB, poor response to inhaler and even death. From a performance 
point of view, EIB can significantly reduce their exercise capacity and speed. However, 
accurate diagnosis of EIB in athletes has proven to be difficult in the past, mainly because 
spirometry is poor indicator of EIB in athletes and physicians therefore rely heavily on 
athletes’ own symptoms description to form diagnosis. But the relationship between 
symptoms and objective evidence of EIB was found to be poor in athletes leading to many 
misdiagnosis. Eucapnic voluntary hyperpnoea (EVH) using dry air was proven to be the 
most sensitive and accurate bronchial provocation test to identify EIB in elite athletes. One 
study has found that out of 65 football players with physician diagnosis of asthma/EIB, only 
51% of these subjects tested had a positive bronchial provocation test result, thus 
demonstrating the difficulty of accurately diagnosing EIB in athletes.  
5.1.3. Origin of EIB 
The first theory regarding EIB was proposed in the 1970, it suggest that respiratory 
evaporative water loss induced airway cooling trigger bronchoconstriction (92). Later theory 
suggests EIB is the result of rapid warming of airway at end of exercise (93). However other 
studies have demonstrated the dehydration of airways is the main contributing factor to EIB 
(94) (95).  
The physiological response to asthma exacerbation which includes a cascade of mediator 
events leading to smooth muscle hyperresponsiveness, mucus hypersecretion, and changes 
in mucociliary function. Antigen introduction into the pulmonary system stimulates the 
releases of mast cells, eosinophils, leukotrienes, prostaglandins, T lymphocytes, and other 
cellular mediators, leading to the physiological stress of bronchoconstriction. EIB may be 
unique in its pathophysiological response to exercise. During exercise, catecholamine 
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release initiates a bronchodilatory response in both healthy subjects and asthmatic patients. 
The results include progressive bronchoconstriction (96). 
5.1.4. Pathology of EIB 
The pathogenesis of EIB is associated with following factors: minute ventilation (VE) (tidal 
volume times the respiratory rate per minute), the temperature and humidity of the inhaled 
air, and the baseline airway reactivity of the patient. Airway obstruction is more pronounced 
when the inhaling air is dry and cold, and less pronounced when the air is warm and humid. 
High levels of VE is required for more vigorous exercise and is associated with a greater 
degree of airway obstruction. Therefore the degree of VE and climate conditions associated 
with specific sport is considered the difference in asthmogencity. Sports such as golf, 
baseball and boxing is considered of low asthmogenicity. High asthmogenicity sports include 
downhill skiing, basketball, cycling and football. EIB sufferers are recommended to carry out 
activity of low asthmogencity associated with a warm and humid climate condition. Patients 
carrying out higher asthmogencity activity associated with colder and drier climate conditions 
would be more prone to EIB requiring medical intervention. 
5.1.5. Cardiopulmonary exercise testing (CPET) and assessment of EIB 
Cardiopulmonary exercise testing (CPET) is non-invasive and sensitive stress test that is 
widely used to assess the limits and mechanisms of exercise tolerance of human body. The 
test participant participating a CPET test will be required to perform exercise challenge in a 
controlled manner to measure oxygen uptake (VO2), carbon dioxide output (VCO2), ventilation, 
breathing pattern as well as other pulmonary and cardiovascular functions. CPET assesses 
profile and performance of the responses of the heart, lungs and muscles individually as well 
as in union. Pulmonary and cardiovascular conditions can cause symptoms such as 
shortness of breath and exercise intolerance, thus can lead to reduction in lung, heart and 
muscles responses during CPET testing. It can be used for the diagnose conditions such as 
exercise induced bronchoconstriction/asthma (EIB/EIA) and cardiac ischeamia. CPET can 
be used to provide information on dysfunction, monitoring and prognostic value in a wide 
range of other conditions such as chronic lung diseases and cardiac diseases. In recent 
years, CPET has become a popular testing method in pulmonary medicinal field due to its 
non-invasive nature, wide range of clinical applications and additional information it provides 
compared to lung function testing at resting state (97).   
The aim of CPET is to induce exercise stress to organs involved in the exercise. The 
exercise chose for CPET must therefore involve exercising large muscle group. The exercise 
usually used for CPET is running on a treadmill or by cycling on an ergometer. However, 
cycle ergometer is generally the preferred method for CPET due to a few reasons; It is 
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easier for attach a breathing valve to participant’s mouth or nose during exercise. Cycling on 
ergometer introduces less movements and noise making measurements easier. Also the 
work rate is largely dependent on body weight. The key requirement for exercise used for 
CPET is that the exercise stimulus must be quantifiable and is directly proportional to 
participant responses measured. For ergometer cycle, the workload can be added on 
incrementally as a stimulus to increase pulmonary and cardiovascular responses such as 
heart rate and breathing rate.  
There are two types of standard clinical exercise protocols that is widely used for CPET; One 
is incremental test and other one is constant work rate exercise testing. In incremental 
exercise testing, the exercise stimulus is increased continuously or uniform amount each 
time for a set duration. The aim is to provide a smooth gradational stress to participants so 
the entire exercise can be carried out in a short period of time. For constant work rate 
exercise testing, the exercise stimulus is increase continuously before constant steady state 
exercise for a set duration. Constant work rate exercise testing is useful for measuring 
steady state responses at a moderate intensity work rate. At a high intensity work rate, it can 
be used to assess whether the exercise testing is sustainable by the participant. For the 
assessment of EIB, constant work rate testing is preferred to achieve a high level of 
ventilation to trigger bronchoconstriction. 
5.2. EIB study design 
Exhaled breath collected from alveolar region contains endogenous VOCs contains 
aerosolized airway lining fluid and volatile compounds that provide non-invasive indications 
of biochemical and inflammatory information. Volatile exhaled breath compounds had been 
used as biomarkers of lung inflammation. Potential correlation between biomarkers of EIB 
between systemic circulation and those found in exhaled breath had been indicated in recent 
research. A panel of healthy athletes and EIB prone athletes participate in an intense 
exercise challenge to investigate cellular & molecular mechanisms of EIB. In order to 
achieve comprehensive CPET, an array of additional testing including blood, nitric oxide, 
and spirometer will be used to combine different aspect of interest together to explore 
biochemical and inflammatory information of EIB. The hypotheses is that CPET will trigger 
bronchoconstriction in EIB positive participants which will lead to a change in VOC profile 
compared to healthy participants post exercise.  
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Table 5.2. List of testing for EIB challenge 
Number Name Run time 
/minute 
Description 
1 Breath VOC 
collection 
5 Exhaled breath VOCs collection from alveolar 
region 
2 EBC collection 5 Exhaled breath condensate collection at -10℃ 
3 Breath 
temperature 
measurement 
3 Measurement of exhaled breath temperature 
4 Nitric oxide 
measurement 
10 Exhaled breath nitric oxide measurement 
5 Blood sample 
collection 
3 Collection of blood to be analysed for airway 
inflammation, remodelling and gene information 
6 Respiratory 
muscle pressure 
test 
5 Testing for muscle stress 
7 Breath by breath 
analyser 
measurement 
8 Measurement of participant CO2, O2, and lung 
function during exercise challenge 
8 Spirometry 10 Lung function test 
 
The exercise testing used for the assessment of EIB is high intensity ergometer cycling at a 
constant work rate in order to achieve a high ventilation rate. The constant work rate 
exercise protocol adopted in this study is a slightly modified version of the recommended 
procedure (97). The procedure consists of a rapid increase in work rate within 3 to 5 minutes 
to 85% to 95% of the participant’s maximal heart rate, and sustaining the work rate and 85% 
to 95% maximal heart rate at the same work load for 6 minutes. The recommended 
procedure suggests 4 minutes of high intensity constant work rate exercise, this has been 
extended in our protocol to 6 minutes to increase the probability of triggering EIB. The 
workload (W) of ergometer is used as the exercise stimulus to increase work rate. At the 
first, second and third minutes of cycling the work rate was set at 60%, 75% and 90% of 
target value. In EIB positive participants, the FEV1 (forced expiratory volume in 1 second) 
generally falls to minimum level within 10 minutes after exercise, with substantial recovery to 
the baseline level by 30 minutes. To assess the participant response to exercise, forced 
spirometry measurements are to be performed before and then at 2, 5, 7, 10 and 20 minutes 
after exercise. The post exercise FEV1 is subtracted to baseline FEV1 pre-exercise and 
132 
 
expressed as percentage of pre-exercise FEV1. A greater than 10% fall in FEV1 post 
exercise is regarded as abnormal and greater than 15% fall is regarded as diagnostic of EIB. 
The work flow chart for constant work rate exercise testing and forced spirometry 
measurements is shown in Figure 5.2.1. 
    
Figure 5.2.1. Constant work rate exercise testing and diagnostic spirometry using an 
electric cycle ergometer 
A key aspect of the CPET is the interpretation of gas exchange measurement. The 
conventional technique of measuring gas exchange involves directing the expired air into a 
collection bag. VO2 and VCO2 values are then measured and calculated from the oxygen and 
carbon dioxide mixed gases in the bag. In recent years, on-line digital computer analysis of 
physiological transducer signals has become widely used, it has become practical to 
measure VO2 and VCO2 values breath by breath. The breath is broken down into a number 
parts and VO2 and VCO2 values were computed for each interval. Individual intervals are 
added together over the expiration to compute total volume. The main advantage of digital 
breath by breath analyser is high resolution compared to bag collection where gas exchange 
can only be measured every couple of minutes. Although bag collection is still a much 
cheaper way of measuring gas exchanges. 
Breath by breath analyser is only capable of detecting oxygen and carbon dioxides species 
in the expired breath. Separate analysers can be added on for measuring other gas species. 
Nitric oxide (NO) is widely reported as marker of exercise stress which can be monitored by 
breath analyser. During exercise stress, endothelial cells produces vasodilator and 
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vasoconstrictor compounds such as NO for the regulation of vascular tone. Other exercise 
and asthmatic species needs to be monitored by more complex means of measurements. A 
wide range of exhaled breath VOCs relevant to exercise such as isoprene can be monitored 
using TD-GC-MS method. Other metabolic fluids such saliva and blood collected pre and 
post exercise are used to monitor other large non-volatile species.  
Other non-compound specific breath measurements were also carried out, respiratory 
muscle strength can be assessed by measuring maximal inspiratory pressure, it determines 
the strength of diaphragm and other inspiratory muscles. It can be used to establish any 
respiratory muscle weakness caused by EIB. Participant breath temperature before, during 
and after exercise challenge can also be measured. The hypotheses is that participant 
suffering from EIB can cause elevation in breath temperature. Core temperature is 
measured before and after exercise challenge.  
A total of 8 analysis are to be carried out on the participant before, during or after exercise. 
Due to the high number of analysis, it is essential to have comprehensive planning and time 
management to keep total experimental time to a minimum to avoid excessive strain on the 
participant. A complete EIB time schedule is shown in Figure 5.2.2. The estimated total 
experimental time for one participant is around 1 hour 30 minutes. However, actual testing 
time can actually go up to 2 hours per participant. The testing setup time prior to start of the 
experimental is estimated to be around 3 hours. This study will focus mainly on participants 
exhaled breath VOCs profiles from before and after exercise challenge.  
 
 
 
Figure 5.2.2. Participant schedule for EIB ergometer exercise challenge with estimated 
total duration of 1 hour 30 minutes  
5.3. Experimental 
5.3.1. Ethics 
The study was conducted in accordance with ethical principles of good clinical practise and 
Declaration of Helsinki. All research protocols used in this study was reviewed and approved 
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by the Loughborough University ethics advisory committee; Exhaled breath VOCs sampling 
protocol G09-P5, Exercise challenge protocol G09-P8, Spirometry protocol G99-P5 and 
Ventilated gas volume measurements protocol G04-P2. 
5.3.2. Participant preparation 
All participants were given information sheets explaining the study when they were first 
recruited. Before the start of study, the participants were given healthy screen questionnaire, 
exhaled breath collection questionnaire and consent form to fill in. For participants with 
history of asthma, an additional asthmatic questionnaire was also filled in to assess the 
severity of their asthma. The participant information sheet and questionnaires used in this 
study are attached in the Appendix section.  
Twelve male and twelve female participants aged between 19 and 23 years participated in 
the study. Nine participants have reported to be suffering from asthma. All participants were 
hockey or rugby athletes who trained regularly on a daily or weekly basis. Some of the 
participants which including healthy and asthmatic participants have reported to have 
experienced EIB during outdoor training sessions. 
All participants were also asked to avoid any medications, alcohol, caffeine and abstain from 
strenuous exercise for 24 hours prior to the start of the procedure. Asthmatic participants 
were asked to bring rapid acting inhaled bronchodilators to reverse a severe bronchospasm 
episode.  
Participants were also asked to wear sportswear or loose cloth for the exercise challenge. 
Just before the procedure, participants were asked to have a short warm up session.  
Prior to the start of the procedure, all participants had their weight, height and body 
temperature measured. A heart rate monitor with wet electrodes were fitted around 
participant’s chest.  
Room air temperature, humidity and pressure were also measured and recorded.  
5.3.3. Clinical exercise challenge and ventilation measurement protocol 
A sport cycle ergometer (Lode Excalibur, Netherlands) was used to conduct the exercise 
challenge. It uses an electromagnetic eddy current braking system and is intended to be 
used as a stress test device in a medical environment. It can measure workload (W), 
Revolutions per minute (rpm), time (min and sec) and distance (km). The testing capacities 
of the Ergometer include a workload range between 8 to 2500 W, minimum load increments 
of 1W, maximum continuous load of 1500 W and pedal speed range between 25 to 180 rpm. 
The seat height and handle bars were adjusted to the correct level for individual participant.  
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Breath by breath analyser (Ultima CPX™ metabolic stress testing system, MGC Diagnostics, 
USA) was used in this study for cardiopulmonary exercise (CPX) testing. CPX measures the 
body's ability to perform gas exchange during an stress test by measuring the performance 
of the respiratory, cardiovascular, and circulatory systems all in one test. This testing detects 
the causes of symptoms such as shortness of breath, chest pain, and fatigue. The key 
component of a CPX test is the measurement of instantaneous gas exchange-oxygen 
uptake and carbon dioxide output of each breath. The concentration of these gases is 
measured by in-built oxygen and carbon dioxide analyzers. The volume of air moving in or 
out of a person's lungs per minute (minute ventilation or VE) is measured by a flow sensor or 
volume-measuring device. These signals are then phase-aligned by the computer to 
produce breath-by-breath measurements of gas exchange.  
The breath by breath analyser and its pneumotach was calibrated prior to start of the 
procedure to ensure stable signal value and breath measurements. A clean pneumotach 
was connected to the breath by breath analyser via an umbilical line (Figure 5.3.3.). The 
pneumotach was fitted into participant’s mouth and its head straps were fitted on 
participant’s head. The participant was asked to wear a nose clip during the procedure to 
ensure mouth breathing.  
After the participant is ready to start, he was asked to first to gently pedal for one minute with 
low work load specific for that individual. A timer with 10 minutes count down was started, 
workload was increased by 1kg every 30 seconds according to participant’s heart rate. The 
target was gradually increase the participant’s heart rate to 85% to 95% of maximum heart 
rate (MHR) at around 4 minute. The participant’s VE and VCO2 values were constantly 
monitored via breath by breath analyser throughout also used to assess workload increase. 
After participant’s heart rate has reached 85% to 95% of MHR, the workload was then kept 
constant for 6 minute. Throughout the exercise challenge, the participants were encouraged 
to keep their work rate (rpm) constant at around 60 to 70 rpm, participants were asked to 
give an exercise stress score from 0 to 10 every minute to assess their condition, if the 
participant feels too strained during the continuous exercise stage to maintain the same work 
rate, workload can be reduced to continue the exercise challenge.    
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Figure 5.3.3. (Left) Photo of participant during EIB ergometer exercise challenge 
(Right) Photo of breath by breath analyser pneumotach used by participant during 
exercise challenge 
5.3.4. Spirometry measurements 
Micro Loop spirometer (CareFusion, USA) consisting of hand-held instrument, battery 
charger and turbine transducer was used to carry out spirometry during this study. The 
spirometer was calibrated on the day of measurement as per American Thoracic Society 
(ATS) guidelines for spirometry testing (98). A series of baseline lung function 
measurements was carried out prior to start of exercise challenge; Forced expiratory volume 
(FEV1, L), forced vital capacity (FVC, L), percentage forced expiratory volume to forced vital 
capacity (FEV1/FVC, %), peak expiratory flow (PEF, L min-1), forced expiratory flow related 
to 25% to 75% of FVC curve (FEF23-75, L s-1), maximal voluntary ventilation (MVV, L min-1). 
Participants were asked to wear nose clip and coached on the correct technique of forced 
spirometry manoeuvre. At least 3 repeat forced spirometry blows meeting ATS/ERS criteria 
were measured and recorded. The highest FVC and FEV1 value from the 3 or more repeats 
was used as the baseline spirometric value. 
After exercise challenge, participant was asked to repeat forced spirometry measurement at 
a series of time intervals; 2, 5, 7, 10 and 20 minutes. Same sets of pulmonary function 
measurements were taken as baseline measurement with 3 acceptable repeats blows. The 
highest FEV1 and FVC was used at each time point.  
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Figure 5.3.4. Photo of participant undertaking spirometry after exercise challenge 
5.3.5. Exhaled breath VOCs collection using the portable breath sampler 
The portable breath sampling system was used to collect 2 L of participant exhaled breath 
onto multi-sorbent tube (Markes international, UK). The samples were collected from 
participants around 15 minutes before the start of exercise challenge and around 20 minutes 
after exercise challenge, and the sampling takes around 5 to 10 minutes. 2 L of air supply 
and background room air samples were also collected prior to the start of exercise 
challenge. The collected samples were stored at stored at 4°C fridge prior to sample 
analysis on TD-GC-MS. After sample analysis, thermal desorption tubes are conditioned at 
300°C for re-use. The activated carbon and molecular sieve filters are conditioned at 200°C 
under high purity nitrogen. Breathing mask and other connections are cleaned and dried 
under vacuum before re-use. A detailed sampling work flow and procedure for exhaled 
breath VOCs collection using the portable adaptive breath sampler can be found in Chapter 
4. 
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Figure 5.3.5.1. Photo of exhaled breath VOCs sample collection using portable breath 
sampler 
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Figure 5.3.5.2. The 3 stages of EIB study design plotted by PERT chart 
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5.4. Results and discussion 
5.4.1. Direct exhaled breath measurements 
5.4.1.1. Spirometry   
Each participant is assessed by their percentage fall in FEV1 post exercise (ΔFEV1). ΔFEV1 
is calculated by taking the each participant’s highest FEV1 result from post exercise 
spirometry subtracted from the pre exercise baseline FEV1 value. The difference is then 
calculated as percentage of the pre exercise FEV1. At least 3 repeats forced spirometry 
blows meeting ATS/ERS criteria needs to be recorded at each time point. A greater than 
10% fall in FEV1 after exercise is regarded as abnormal, and a greater than 15% fall is 
diagnostic of EIB. 
 
 
 
Figure 5.4.1.1. FEV1 percentage change pre and post exercise challenge between EIB 
positive participant (red line with triangle symbol) and EIB negative participant (green 
line with square symbol) 
Out of all 24 participants, 4 participants had shown a greater than 15% drop in post exercise 
FEV1 and can be diagnosed as EIB positive. Out of these 4 participants, only 2 were 
reported to be asthmatic. One of the other 2 participants didn’t report to be asthmatic, but 
had previous experiences of EIB symptoms during outdoor exercise. The last participant was 
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not reported to be asthmatic and has no previous experience of EIB symptoms, but did 
suffer from flu the previous week and had variable spirometry results, so this participant’s 
result could be a false positive.  
2 participants had shown a greater than 10% drop in FEV1 post exercise and is regarded as 
potentially EIB positive. One of these participant is reported to be asthmatic and had often 
experienced EIB symptoms during outdoor exercise. The other participant wasn’t asthmatic 
and had no previous EIB experience.  
It to be noted that there are 6 asthmatic participants who had shown no significant FEV1 
drop post exercise. Some of them had reported to have had previous experience of EIB 
symptoms while exercising outdoor, thus could mean there are some false negative in the 
spirometry results.  
When compared to EVH testing results that was carried out separately on a different day, 
there are 4 participants who had positive EVH results (greater than 15% drop in FEV1 during 
EVH testing), but had negative spirometry results post exercise challenge. 3 out of the 4 
participants who were diagnosed to be EIB positive from the exercise challenge were also 
EVH testing positive. The other EIB positive participant didn’t take the EVH test, but was 
asthmatic and regularly takes bronchodilator inhaler before training to avoid EIB symptoms. 
This does seem to shown that it is possible the exercise challenge couldn’t trigger EIB in 
some potentially EIB positive participants.   
5.4.1.2. Breath by breath analyser 
The breath by breath analyser accurately measures the responses of VO2, VCO2 and VE from 
participant during exercise in every inspired breath, thus generates real-time comprehensive 
data for ventilation and gas exchange during exercise. Figure 5.4.1.2. demonstrates the 
ventilation rate, VO2 work load and heart rate during the 10 minutes constant work rate 
exercise challenge. Participant carbon dioxide/oxygen output, ventilation rate is directly 
proportional to heart rate and work load during exercise.  
Lung diseases usually causes an increase in ventilation rate and heart rate, therefore y 
comparing participants FEV1 drop against heart rate and ventilation rate for any correlation. 
Participants who shown greater than 5% drop FEV1 post exercise have an average 
ventilation rate of 127.3 L min-1 and heart rate of 177.8 beats min-1. Participant who shown 
no significant change in FEV1 post exercise have an average ventilation rate of 126.6 L min-1 
and heart rate of 125.7 beats min-1. It does seem to shown an elevated ventilation rate and 
heart rate in participants with significant drop in FEV1 post exercise. 
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Figure 5.4.1.2. Standard clinical ergometer exercise challenge to induce 
bronchoconstriction by maximising participant exercise workload (red line) to 95% of 
maximum heart rate (black line).  
5.4.2. Exhaled breath VOCs multivariate analysis (MVA) 
5.4.2.1. Multivariate analysis  
Exhaled breath GCMS data collected from the EIB study was first deconvoluted and 
retention indexed using AnalyzerPro (Spectralworks, UK) into breath components identified, 
all the found breath components from all participants pre and post exercise challenge were 
then pooled into a single breath components matrix separated by participants against 
identified breath components. Each breath component was referenced using unique breath 
library ID code consisting of its RI value and de-convolved mass spectrum, the breath library 
ID code was written in the format of BRI-XXX-YY-YY-YY-YY-YY, where XXX is the 
calculated retention index valve and YY is the 5 most abundant fragmentation ions found in 
its mass spectrum. Also, individual integrated peak area was generated for each breath 
component in the breath matrix. The breath matrix was then manually checked through 
against raw GCMS data to eliminate any replicates and noise data using Varian MS 
workstation software (Varian, UK). A more detailed description of data processing method 
used for exhaled breath analysis can be found in Chapter 2.  
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Figure 5.4.2.1.1. Exhaled breath VOCs sampling work-flow using the portable breath 
sampler for EIB study 
The breath matrix constructed contained identified and peak integrated 692 breath 
components based on the 24 participants data pre and post exercise. Background air and air 
supply samples data were analysed using the same method as participant breath samples, 
the resultant background air matrix was compared against breath matrix to determine the 
origin of each individual breath component (See Figure 5.4.2.1.2.). If the breath component 
was to be found in the background air or air supply matrix to a comparable level, that specific 
compound was said to be an exogenous component that originated from a source outside 
human body. These compounds will be excluded from subsequent MVA. The breath matrix 
was separated into 226 endogenous and 466 exogenous breath components.  
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Figure 5.4.2.1.2. TIC chromatogram of participant breath sample (bold line), purified 
air supply (dash line) and background room air (dash dot line) illustrating the 
comparison between endogenous and exogenous VOCs 
Multivariate analysis (MVA) was applied to the resultant endogenous breath matrix using 
data analysis software SIMCA-P+ (Version 12.0.1.0, Umetrics, UK). Each individual breath 
samples pre and post exercise challenge were assigned as observations and each breath 
components were assigned as X variables. Subsequently, all variables were assigned to 
single block weight of 1(1/SQRT) and Pareto base scaling (Par). Depending on the 
classification required, all breath samples were assigned individual classes prior to 
modelling, eg, to observe effect of exercise, pre and post exercises classes were assigned 
to each sample. Initial unsupervised principal components analysis (PCA) was then 
performed on the scaled breath matrix to determine the correlation between pre and post 
exercise challenge. 
Exercised induced bronchoconstriction (EIB) is unique type of asthma in which the 
symptoms of bronchoconstriction is only onset by vigorous exercise. Many mild EIB sufferers 
aren’t aware of the disease since there is no symptoms occurring in their daily lives. Unlike 
pure exercise or asthmatic studies where the MVA modelling is purely based on two distinct 
classes (ie pre or post exercise, healthy or asthmatic participants), the modelling for EIB 
study is dependent upon both exertion of exercise and participant health status. Therefore 
prospection for markers of EIB was focused on biomarkers that were onset after vigorous 
exercise challenge and in participants where the symptoms of EIB occurs. Two types of 
modelling were used to achieve this, initially unsupervised and supervised MVA modelling 
classed by pre and post exercise was used to determine correlation and upregulated 
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markers of exercise. Subsequent MVA modelling was applied to the small group of 
upregulated exercise markers to prospect for markers with high correlation between exercise 
and asthmatic symptoms hence potential markers of EIB. Upregulated biomarkers here 
refers to potential biomarkers that were produced in the human body as result of exercise. 
The concept of determination of EIB biomarkers is illustrated in Figure 5.4.2.1.3. 
 
Figure 5.4.2.1.3. The concept of determination of EIB biomarkers based on both 
exercise and asthmatic modelling  
5.4.2.2. The effect of exercise 
Initial unsupervised PCA model classified by exertion of exercise challenge on participants 
using endogenous breath components had shown separation between the pre (blue dot) and 
post (green dot) exercise datasets (Figure 5.4.2.2.1.). In order to determine breath 
components which shown high correlation to exercise, supervised MVA modelling 
orthogonal partial least square – discriminant analysis (OPLS-DA) was applied to the breath 
matrix. In both the unsupervised PCA model and supervised OPLS-DA model, the pre and 
post exercise participants were separated through the first principal component. The 
unsupervised PCA consists of three principal components with combined R2X value (fraction 
of variability of the X variables explained by the PCA model) of 56.7% which explained 
majority of the data variability. The supervised OPLS-DA model due to discriminatory focus 
on exercise, has a reduced R2X value of 27.01% for the two principal components, with first 
the principal component (t1) which the exercise classification separates on showing a value 
of 9.81%. As shown from the supervised OPLS-DA model, pre-exercise participant dataset 
was dispersed on the right side of the scatter plot (blue dots) and post-exercise participants 
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dataset dispersed on the left side of the scatter plot (green dots) shown clear separation 
between the groups. One participant was out of the 95% confidence defined by the 
Hostelling region.  
 
Figure 5.4.2.2.1. (Top) Unsupervised PCA model (Bottom) supervised OPLS-DA mode 
are classified by exertion of exercise challenge on participants using endogenous 
breath components had shown separation between the pre (blue dot) and post (green 
dot) exercise datasets.  
After plotting the S-plot and loading plot for the supervised OPLS-DA model, a list of 
discriminating VOCs between pre and post exercise challenge can be determined (Figure 
5.4.2.2.2.). The variables located on the right hand side of the S-plot with positive p1 (weight 
combining the original X variables to form t1) value correlates to pre-exercise challenge 
observations and the ones located on the left hand side of S-plot with negative p1 value 
correlates to post-exercise challenge observations. Variables located in the center of the plot 
with p1 value close to 0 has low correlations to both observations groups and doesn’t 
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contribute to the first principal component. As observed from the S-plot, most of the 
discriminating VOCs that contribute to OPLS-DA model are compounds with high p1 value 
that correlate with pre-exercise observations, these compounds are potential downregulated 
biomarkers which has shown reduced levels after participant undergo vigorous exercise 
challenge. Most of these downregulated breath components are cyclosiloxane derivative as 
result of water content from participant breath, this shows participant exhaled breaths were 
much drier after exercise challenge. Although there are potential downregulated markers 
correlating to post-exercise observations, they are located much closer to the centre of the 
S-plot which means they shown lower correlations to observations compared to 
downregulated markers, hence they aren’t as discriminatory. A list of top discriminating 
VOCs was created from the S-plot. The same unsupervised and supervised approach was 
repeated to determine the best discriminator of exercise. 
 
Figure 5.4.2.2.2. S-plot and loading plot for the supervised OPLS-DA model, a list of 
discriminating VOCs between pre and post exercise challenge. 
A new PCA model with 4 variables (Figure 5.4.2.2.3.) was created, the unsupervised model 
shows a much clearer separation between pre and post exercise observations than the initial 
model through the first principal component. The first two principal components explained 
76.6% of the data variability. All 4 variables used in the model are upregulated breath 
components that correlate strongly with post-exercise observations. This is demonstrated by 
the closely clustered pre-exercise observations and much more dispersed post-exercise 
observations demonstrating the much greater level of variability post participant undergoing 
exercise challenge.  
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Figure 5.4.2.2.3. Unsupervised PCA model with 4 most discriminating variables 
between pre and post exercise observations 
The list of potential markers of exercise is summarised in Table 5.4.2.2. All four breath 
compounds had shown high correlation to post-exercise observations and its spectra has 
been compared in NIST library for identification. However only compounds with forward and 
reverse library match score higher than 750 were identified in the summary table, 
compounds with low NIST library match score were only given proposed functional groups 
description based on the list of matches and its mass spectra. Out of the four compounds, 
butylated hydroxytoluene (BHT) and indole have been successfully identified with forward 
and reverse match of 835/835 and 893/893. The other two compounds were identified as 
terpene or ketone or benzoic acid derivatives. 
Table 5.4.2.2. Summary of upregulated markers of exercise 
Name Library entry MS F/R RI O/E CAS No. 
BRI-1568-205-57-220-206-
145 Butylated Hydroxytoluene 835/835 1568 128-37-0 
BRI-1331-117-90-89-116 Indole 893/893 1331 120-72-9 
BRI-1537-161-203-175-218-
189 Terpene or benzoic acid derivative N/A 1537 N/A 
BRI-1449-147-119-91 
Methylated aryl ketone or benzoic acid 
derivative N/A 1449 N/A 
 
Box whiskers plots summarising the difference between pre and post exercise dataset were 
shown in Figure 5.4.2.2.4. Although all four compounds are upregulated in the post-exercise 
participant gourp, out of the four compounds butylated hydroxytoluene (BHT) has shown to 
have highest weight value (p1 = 0.63)) due to the significantly increased level after exercise 
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challenge. The unknown terpene or benzoic acid derivative (BRI-1537-161-203-175-218-
189) has the second highest weight score (p1 = 0.52), the compound was undetected in all 
but two participants pre-exercise data. The other upregulated breath component indole (p1 = 
0.48) is present in majority of pre-exercise participant dataset, but a significant increase after 
exercise challenge can be observed for all participants. For the unknown methylated aryl 
ketone or benzoic acid derivative (BRI-1449-147-119-91), the increase in the post-exercise 
participant dataset is much less apparent compared to the other three compounds due to 
huge variation in the pre-exercise data. Example selected ion chromatograms of each 
upregulated discriminating VOCs that differentiate participants pre and post exercise 
challenge are shown in Figure 5.4.2.2.5. 
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Figure 5.4.2.2.4. Box whiskers plots summarising the difference in before and after 
exercise challenge datasets The top figure is the zoomed in version.  
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Figure 5.4.2.2.5. The 4 highest discriminating VOCs for separating pre and post 
exercise participants. 
5.4.2.3. Markers of exercise induced asthma (EIB) 
After establishing the discriminating VOCs determining the effect of exercise on participants, 
the 4 variables are then re-classed using forced expiratory volume in 1 second (FEV1) 
measurements. As discussed in previous sections, FEV1 values were measured using 
spirometer pre and post exercise challenge at fixed time intervals, percentage variation at 
FEV1 value before and after exercise challenge was calculated. The lowest FEV1 response 
recorded after exercise was subtracted from pre-exercise value and the differenced was 
expressed as a percentage of pre-exercise FEV1 value. A drop in FEV1 value of more than 
10% is seems as abnormal and >15% drop can be diagnosed as EIB positive. Participants 
with a significant post-exercise >5% drop in FEV1 value were separated into one class (red 
dot), participants with no significant FEV1 drop (<5%) after exercise were separated into a 
second class (green dot).   
A new unsupervised PCA model with new percentage FEV1 drop classifications was created 
for both pre and post exercise (Figure 5.4.2.3.1.). As observed from the pre-exercise 
dataset, there is no clear separation between the EIB positive and healthy participants 
before exercise based on the 4 upregulated exercise-dependent breath compounds. For the 
post-exercise dataset, clustering of mostly healthy participant’s data was observed onto the 
left side of the plot. The participants’ data with significant FEV1 drops and some healthy 
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participants data were dispersed onto right side of the plot. This difference shows there is 
correlation between the upregulated discriminating VOCs for exercise and EIB positive 
participant data. The specificity and sensitivity of the post exercise dataset only model was 
calculated at 68.8% and 50%. High rate of false negatives is common for EIB exercise 
testing in a laboratory, thus could be influenced by many factors during the exercise 
challenge, such as the duration and intensity of exercise challenge, the temperature and 
humidity of inspired air, and the time since last exercise induced airway narrowing all affect 
the percentage FEV1 drop post exercise (24). It been reported that high intensity exercise 
with extended duration can also trigger the release of catecholamine and may induce 
bronchodilation resulting in false negative diagnosis (25). Previous journal has reported 
some participants who was involved in repeated exercise challenge on different days, but 
was diagnosed negative for one test and positive for the second one, which indicates the 
level of variability participant is responding to duplicate exercise challenge (99). 
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Figure 5.4.2.3.1. PCA of 4 markers of exercise listed in previous section re-classified 
using spirometry result and meta data from participants, (Top) pre-exercise (Bottom) 
post-exercise 
It is observed that 6 participant datasets with no significant difference after exercise were 
mixed with the participants with high FEV1 drop on the scatter plot, as well as two 
participants with significant FEV1 drop clustering with healthy participants. A closer look at 
the participants’ metadata show some of the participants with no post exercise FEV1 drop 
were diagnosed to be asthmatic or were shown to have significant FEV1 drop during EVH 
testing, this indicate that some of the participants who had shown no significant FEV1 drop 
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could have shown signs of bronchoconstriction post exercise at physiological and 
biochemical level, but it was not detected by spirometry measurements.  
By combining different types of breath diagnostic measurements performed on participants 
and their metadata from participants healthy questionnaires. The dataset was re-modelled 
on 4 classes (Figure 5.4.2.3.2.): participants who were shown >5% drop in FEV1 post 
exercise (red dots), participants who shown significant FEV1 drop (>10%) during EVH testing 
(blue dots), participants who have indicated they been diagnosed with asthma in the past 
(yellow dots) and participants who were negative of three previous classes (green dots). The 
combination of different diagnostic data were used to reveal if there is any possible mild lung 
inflammation which was not significant enough to be detected by spirometry, but were 
detected in other forms of testing. EVH testing is widely regarded as gold standard for 
diagnosing EIB, the participant breathes in cold and dry air at very high ventilation rates 
which simulates outdoor sports conditions better than indoor exercise challenge, hence more 
likely to detect EIB positive participants.  
 
Figure 5.4.2.3.2. Unsupervised PCA model with combined diagnostics; participants 
who were shown >5% drop in FEV1 post exercise (red dots), participants who shown 
significant FEV1 drop (>10%) during EVH testing (blue dots), participants who have 
indicated they been diagnosed with asthma in the past (yellow dots) and participants 
who were negative of three previous classes (green dots). 
For the new PCA model with combined diagnostics, the specificity and sensitivity of the 
model was calculated to be 50% and 87.5% respectively. Compared to the spirometry only 
model, the sensitivity of the model has increased by 37.5% after EVH and past medical 
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asthma diagnoses were added, but specificity has reduced by 18.8%, this indicating there is 
indeed possible mild asthmatic symptoms after exercise challenge that was not detected by 
spirometry. This could be due to a number of reason; The exercise challenge although was 
vigorous enough to increase participant heart rate to 95%, but the indoor condition was too 
warm and humid to trigger significant bronchoconstriction, the average room temperature 
and humidity was measured at 21.5 ± 0.92 °C and 33.5 ± 14.3% for all participants, although 
the variation to temperature was not significant, significant variability to room humidity can 
be observed with minimum humidity measured at 22% and maximum humidity at 65%, the 
temperature and humidity directly affects the stress level in the airway, hence the prevalence 
of EIB is higher among winter athletes compared to summer athletes. The indoor air where 
exercise challenge took place was air conditioned, but humidity of the room couldn’t not 
have been controlled. Research has demonstrated that the temperature of inhaled air was 
less important, and no difference in response between cold and dry air challenges, but EVH 
testing which has been the gold standard analysis does specify the use of dry air that 
contained eucapnic carbon dioxide content for inducing asthma, therefore it is possible the 
variable humidity in the testing room could have made triggering significant asthma difficult 
after exercise challenge, but during EVH testing, the condition of the inhaled air was much 
more controlled was able to trigger an asthmatic reaction for the same participant. 
As shown by the loading plot for combined diagnostics PCA model (Figure 5.4.2.3.3.), the 
unknown methylated aryl ketone or benzoic acid derivative was found to have the highest 
weight value (p1 = 0.99) for the principal component (t1), its location toward lower right hand 
side corner shows it is strongly correlated to EIB positive participants. Both indole and BHT 
also show positive correlation towards EIB positive participant’s datasets post exercise, but 
they also show significantly reduced level of correction compared to the unknown ketone or 
benzoic acid. The other unknown terpene or benzoic acid derivative which had been the 
highest discriminating VOC for the exercise model, is now shown to have a negative weight 
value, this indicates it had no correlation towards EIB positive datasets.   
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Figure 5.4.2.3.3. Loading plot for combined diagnostics PCA model 
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Figure 5.4.2.3.4. Box whisker plots of the four variables for separating healthy and 
participants with significant drop in FEV1 post exercise.  
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5.4.2.4. Biomarkers origin 
All four compounds were found to have high p1 value in the MVA for separating pre and post 
exercise participants, but only indole, butylated hydroxytoluene and unknown ketone or 
benzoic acid derivative have shown positive p1 value when used in the PCA for separating 
healthy and EIB positive participants.  
Indole is an aromatic heterocyclic organic compound. It has a bicyclic structure, consisting of 
a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring. It is 
a naturally occurring compounds that can be found in many types of organisms including 
bacteria, plants and animals, and its signalling activity is quite dynamic in various organisms. 
It is an intercellular signal molecule found in many types of Gram-negative and Gram-
positive bacteria regulating a variety of bacterial physiological activity including extracellular 
signal, drug resistance, virulence control and biofilm formation. Indole is precursor for 
formation of amino acid tryptophan in bacteria which is essential protein for many organisms 
including humans and the precursor of neurotransmitter serotonin (100). In the human body, 
it is believed that indole are produced by the enteric intestinal bacteria, and these bacteria 
are essential for human nutrient assimilation and immune system. Compounds that contain 
an indole ring are called indoles or indole derivatives. Research have suggested the indole 
derivatives such as indoxyl sulfate and indole-3-propionic acid were also produced in the 
human body by enteric bacteria. Derivatives of indole are widely distributed in human body, 
and research have suggested these derivatives may have diverse biological function in the 
human body. Due to its diverse biological function, indole and its derivatives have been 
studied closely in recent years, pharmaceutical drugs using indole derivatives treating a wide 
range of diseases have been developed, these applications include anti-cancer drug, anti-
depressant drug, anti-viral drug, anti-emetic drug etc, and most notably application relating 
to this study, one of its application is anti-asthmatic drug (101).  
Several of indole derivatives have known to have anti-asthmatic activities due to their effect 
on the leukotriene formation pathway. One of the common asthma treatment drug Zafirlukast 
is an indole-containing structure with lipid-like tail, acidic head region and indole-backbone. 
Zafirlukast is leukotriene receptor antagonist (LTRA) which blocks the action of cysteinyl 
leukotrienes (LTC4, LTD4 and LTE4), thus reducing bronchoconstriction and lung 
inflammation (102) (103). Zafirlukast has been widely used for treating EIB and have shown 
to inhibit maximal bronchoconstriction response after exercise by 50% to 80%. When the 
drug is taken before exercise, it also promote faster normal lung function recovery and 
reverse EIB (104).  
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As well as being LTRAs, other indole derivatives also have been shown to be 5-
lipoxygenase inhibitors. By inhibiting the catalytic action of 5-lipoxygenase on arachidonic 
acid, the biosynthesis of leukotrienes is prevented, thus preventing any asthmatic symptoms. 
Competitive inhibitors of 5-lipoxygenase which are based on thiopyranoindole and thiazole 
structures are more selective than other inhibitors (102).  
In recent years, indole has been reported to be a marker of chronic obstructive pulmonary 
disease (COPD) (44) (105). It has been found to be in elevated level in subjects suffering 
from COPD compared to healthy controls. Other study has shown indole to be a product of 
non-physical stimuli, indole has been found to be at elevated level in participants who took 
stress intervention tests (75).   
Indole has also been reported to be produced after exercise. Early study examining muscles 
tissue after exercise, a wide range of compounds have been found to be produced during 
exercise which include indole as well as lactic acid, oxybutyric acid, carbon dioxide, 
hydrochloride, sulfuric acid, phenol and skatole etc. Indole, phenol and skatole were 
products of protein disintegration in the muscle and are capable of producing exercise 
fatigue symptoms (106). 
With its extremely dynamic biological activities in organisms, indole has links to both 
exercise and asthmatic activity. The initial theory derived from its other reported activities in 
anti-asthma and exercise would be indole was produced after exercise challenge but 
potentially at an elevated level in asthmatic participants due to increased ventilation level 
and airway stress.     
Butylated hydroxytoluene (BHT) is lipophilic organic compound, a chemical derivative of 
phenol. It is widely used as food additive due to its anti-oxidant properties. It also been used 
in health food supplement capsules as it was reported to have anti-viral effects. Most of the 
BHT found in human body is likely to come from food intake, human body is not known to 
produce BHT intrinsically, BHT is metabolized by liver to BHT-acid with minor amount BHT-
alcohol via oxidation. BHT is mostly excreted in urine or feces in animal models, but it is 
believed to accumulate to a greater extent in human due to the lack of enterohepatic 
circulation in human (107). BHT has been reported to have biological activities in human. 
When administered orally, it Is said to have hepatic and gastro-intestinal tract toxicity in rats, 
it is found to enhance the development of spontaneously occurring liver tumours in rats (108) 
(109). It is also said to exacerbates chronic urticaria via Type 1 allergy (110). The link 
between BHT and lung inflammatory has been extensively studied over the years. In mice 
models, the injection of BHT causes increased DNA, RNA and lung weight due to cell injury 
and necrosis occurring at alveolar epithelium and interstitium with production of fibrosis 
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(111). Although BHT is widely used as anti-oxidant, but at a higher dose it can result in 
oxidative stress. Studies have shown that the oxidative stress caused by higher doses of 
BHT can enhance high affinity IgE receptor mediated degranulation through P13K enzyme 
activation and increasing intracellular Ca2+ concentration in mast cells, thus action can 
enhance passive cutaneous reaction in rats, although these studies have mostly conducted 
on rats models or in vitro, it does suggest BHT can have the ability to affect allergic rhinitis 
and asthma in human as well (112).  
The other discriminating variables weren’t able to be determined in this study, so only 
speculative determination of its function groups were able to be described here based on its 
NIST library matches. One of the unknown BRI-1449-147-119-91 is likely a methylated aryl 
ketone or benzoic acid derivative, it was found to be a discriminating variable found in 
elevated level in both post exercise and asthmatic participants. Both ketone and benzoic 
acid derivatives have been reported to have biological activity in lung tissue (113) (114). 
Benzoic acid is found naturally in plants and acts as intermediate metabolite during 
biosynthesis of other secondary metabolites. It is metabolized by human body and excreted 
as hippuric acid in urine. Benzoic acid was also reported to be asthmatic biomarker in 
children (67). Domestic exposure to airborne ketone compounds were also reported to be 
asthma and allergy triggers (115).  
The last unknown variable BRI-1537-161-203-175-218-189 is likely to be a terpene or 
benzoic acid derivative, this variable was a strong discriminator for exercise MVA analysis 
model, but it had negative p1 value for discriminating asthmatic participants. Terpene 
derivative has been previously reported to be a stress marker (75). 
5.5. Summary 
Constant work rate CPET was used to induce bronchoconstriction indicative of EIB in 
participants. The initial hypothesis was that EIB participant will show a difference in their 
VOC profile post exercise compared to healthy participants. Our study has found preliminary 
findings that are consistent with our initial hypothesis of possible existence of EIB specific 
response shown in human VOC profiles. Three upregulated EIB discriminating VOCs have 
been determined through unsupervised PCA using post exercise spirometry results with a 
sensitivity of 68.5% and specificity of 50%. The reduced sensitivity is due to high number of 
false negatives in the model. High rate of false negatives is common for EIB exercise testing 
in a laboratory, thus could be influenced by many factors during the exercise challenge, such 
as the duration and intensity of exercise challenge, the temperature and humidity of inspired 
air, and the time since last exercise induced airway narrowing all affect the percentage FEV1 
drop post exercise (99). It been reported that high intensity exercise with extended duration 
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can also trigger the release of catecholamine and may induce bronchodilation resulting in 
false negative diagnosis (116). Breath by breath analyser results does show an elevated 
level of both ventilation rate and heart rate during exercise in participants who shown a 
significant drop in FEV1 post exercise. It is reasonable to assume that high intensity CPET 
will cause a significant physiological and biochemical change in participants who are EIB 
positive, thus will lead to a change VOC profile.   
Two out of three VOCs were identified through NIST library matches to be indole and 
butylated hydroxytoluene. Both VOCs have been linked to biological activities in lung 
diseases. Especially indole which have been shown to increase in exercise and stress. 
However due to small size of this study, this result need to be established in larger scale 
before these VOCs can be confirmed to be indicative of metabolic or biochemical response 
to bronchoconstriction triggered by high intensity CPET. The quantification of these 
compounds was not possible at the time of the experiment, targeted studies with labelled 
standards with large group of participants should be the appropriate follow up study. 
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CHAPTER 6. CONCLUSIONS AND FUTURE WORK 
6.1. Chapter 1 and 2 summary 
Chapter 1 explores physiology, composition and origin of exhaled breath VOCs. Then, the 
application of exhaled breath VOCs as diagnostic tool for lung diseases in recent years is 
discussed in details. Finally, it investigates the current exhaled breath VOCs collection, 
sampling and analysis methods used. Chapter 2 describes the current exhaled breath 
analysis work-flow employed in this thesis in detail. The exhaled breath analysis work-flow 
consists of 3 sections: exhaled breath sampling, sample analysis by TD-GC-MS and data 
analysis using MVA. Each section both cover the methodology adopted and the theoretical 
principles of the method or technique.  
6.2. Chapter 2 summary  
Thermal desorption has been used extensively in exhaled breath volatile organic compound 
(VOC) analysis, and in large scale studies it is often necessary to store the adsorbent tube 
samples before analysis. The possible introduction of storage artefacts is an important 
potential confounding factor in the development of standard methodologies for breath 
sampling and analysis.  
The stability of VOCs trapped from breath samples onto a mixed bed Tenax® 
TA:Carbograph 1TD adsorbent tube and stored for up to 12 months at - 80C was studied. 
25 samples were collected from a participant over a 3 hr interval and then stored at - 80C. 
Tubes were selected at random for subsequent analysed by thermal desorption-gas 
chromatography-mass spectrometry at 5 times points throughout a 12.5 month storage 
period. 3 deuterated internal standards were used to validate the instrument variability 
throughout the year. A breath-matrix consisting of 161 endogenous and 423 exogenous 
VOC was created using retention index and data deconvolution methods. Iterative OPLS-DA 
and Principal components analysis indicated that 1.5 months was the maximum storage 
duration with sensitivity and specificity of 100% and 94%. Individual analysis of endogenous 
and exogenous datasets shown endogenous compounds are more sensitive to storage. 
Paired two-tailed t-test on endogenous compounds has concluded optimum storage duration 
is at 1.5 month with 94% compounds stable and decrease to 73% at 6 month time point.     
6.3. Chapter 3 summary 
The original adaptive breath sampler for exhaled breath VOCs collection was created in 
2006. It utilises pressure sensor sampling control unit to selectively collect alveolar portions 
of human exhaled breath onto adsorbent tube where it is analysed using TD-GC-MS system. 
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A portable adaptive breath sampling system was developed based on this original concept of 
adaptive breath sampling. It enables breath sampling to be carried out outside the 
designated laboratory with no location restriction. It can be setup quickly in clinical settings, 
sports venue or even private residents at participant’s convenience. Additionally, custom 
build filtration system and comprehensive regeneration procedure was used to enhance and 
standardise background VOCs purification.  
6.4. Chapter 4 summary 
Exercise-induced bronchoconstriction (EIB) is a common pulmonary disorder characterized 
by airflow obstruction occurring after several minutes of physical activity. This study sought 
to determine if there is detectable changes in participant exhaled breath VOCs profile after 
high intensity cardiopulmonary exercise testing (CPET). Breath samples were collected from 
24 participants (12 female and 12 male) before and after 10 minutes’ constant work rate 
exercise testing using portable adaptive breath sampling system. 9 participants from the 
group were reported to be asthmatic. Heart rate, ventilation rate, oxygen output and carbon 
dioxide output were monitored throughout the exercise challenge. Forced spirometry was 
used to assess the participant response after exercise with measurements taken before and 
after exercise at 2, 5, 7, 10 and 20 minutes. A greater than 15% fall in post exercise FEV1 
measured compared to baseline value is regarded as diagnostic of EIB. Breath samples 
were collected onto Tenax/Carbograph 1 thermal desorption tubes using portable adaptive 
breath sampler and analysed using thermal desorption gas chromatography – mass 
spectrometry. Multivariate analysis was performed on participant exhaled breath VOCs 
profiles to generate supervised orthogonal partial least squares discriminant analysis (OPLS-
DA) model, thus generated three compounds which had shown to discriminating for 
participants with significant post exercise FEV1 drop. Indole and butylated hydroxytoluene 
were successfully identified from mass spectral NIST library, the other compound couldn’t 
not be determined due to low library match score, but its mass spectral is indicative of 
methylated aryl ketone or benzoic acid derivative.   
6.5. Thesis summary 
Around 400 to 600 VOCs were identified in a single human exhaled breath sample by 
studies discusses in this thesis. On average 100 to 200 VOCs were identified to be 
endogenous breath components and only a handful were identified to be potential 
biomarkers. For exhaled breath studies involving a group of participants, thousands of 
breath VOCs can be discovered. This demonstrates the complexity of breathomics, as well 
as its sensitivity to a variety of factors. The changes in metabolic profiles of participants with 
respiratory diseases can be trace pptv to ppbv level, thus requires a reproducible and 
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standardised approach to breath sampling methodology. A lack of reproducibility in the 
exhaled breath data can impact on multivariate modelling since small changes in participant 
VOCs profiles can be difficult to determine.  
Many clinical studies experience difficulty in participant recruitment especially if the 
participant is suffering from serious illness. This means the breath samples collected from 
participants for one study can be spread out over several month if not years. This can 
introduce inter-instrumental variability to the data that can cause significant difficulties during 
data processing. A long term storage study was carried out assessed the stability of exhaled 
breath collected on multi-sorbent tubes at - 80°C, the result has determined a maximum 
storage duration of 6 months for endogenous breath components. Therefore study has 
established a storage protocol that can be used when planning and conducting other 
exhaled breath clinical studies.  
Exposure to air borne contamination can also significantly influence the composition of 
exhaled breath. Air borne contaminants can also enter the body through inhalation and skin 
absorption, and can be released at different rates through breath or other excretion. Clinical 
or laboratory environments can introduce a wide range of VOCs from solvents, equipment or 
disinfecting solutions. A strictly controlled clean room is an ideal solution to avoid air borne 
background contamination. However, it is not always possible to bring participants to the 
designated breath collection facility, especially if the participant is suffering from respiratory 
diseases. Therefore, a portable breath sampling system has been developed to collect 
breath samples from participants at remote locations. The use of custom made filtration 
assembly and standardised breath sampling setup enables all participants to be sampled 
under the standardised conditions.  
The standardised breath sampling and storage approach was then applied to a clinical study 
to determining detectable changes of breath VOCs profiles in participants suffering from 
excised induced bronchoconstriction (EIB). Breath samples were collected from 24 
participants before and after 10 minutes’ constant work rate exercise testing using ergometer 
cycles. In order to capture breath VOCs profile changes during possible bronchospasm, it is 
essential to be able to collect breath samples right after exercise. This means samples need 
to be collected at remote sports facility away from laboratory conditions, and sports facility 
can introduce extra air borne contaminants from human sweats and odour. The use of 
portable breath sampling system enabled remote breath sampling right next to the 
participant as well as the elimination of background room air contaminants in breath 
samples. The study had generated three compounds which had shown to discriminating for 
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participants with significant post exercise FEV1 drop. Out of three compounds, Indole and 
butylated hydroxytoluene were successfully identified from NIST library matching.  
6.2. Future works 
6.2.1. Further improvement to the portable breath sampling system 
The portable breath sampling system described in this thesis is only the first prototype 
developed. One aspect is the limit of an air supply flow rate of 40 L min-1. Although this flow 
rate is enough for relaxed breathing at rest, a higher flow rate is required for breath sampling 
during exercise when the breathing rate is much higher; elite athletes will breath at up to 300 
L min-1. Another aspect that could be developed further is the size of the current system. The 
current system can be wheeled to a remote location for sampling or transport to further 
afield. It is much too big to be incorporated with a handheld sampler. Further redesigns to 
the next generation prototype should be focused on reducing its size and weight further to 
make it even more portable. The goal is a clinically compatible user friendly adaptive breath 
sampler for diagnostic purposes that can be used anywhere enabling research in breath 
analysis in a much wider range of locations. 
6.2.2. Further development of data processing method 
Currently the data processing method employed for analysing exhaled breath GCMS data 
involves the use of multiple data processing and analysis softwares, as well as extensive 
manual checking against raw data files. This is extremely time consuming and significantly 
limits the sample turnaround time. One of the most important future works will be to develop 
an alternative simplified standardised approach to data processing for breathomics data that 
can still preserve the integrity of comprehensive data analysis approach used now.  
6.2.3. Development of exhaled breath condensate (EBC) method to 
compliment exhaled breath VOCs 
The metabolic pathways of many VOCs identified as biomarkers for various diseases are 
poorly understood. The endogenous VOCs identified are usually by-products of biochemical 
mechanisms occurring in the human body. Exhaled breath condensate (EBC) collected from 
exhaled breath contain aerosols particles that reflect the composition of bronchoalveolar 
extracellular lining fluid. Larger non-volatiles compounds that cannot be collected using 
VOCs sampling method can be analysed using EBC method. Important biochemical 
mediators such as cytokines that have been identified in EBC can be used to reveal 
important information regarding the origins of potential biomarkers and developing a 
comprehensive breathomics approach.   
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Appendix 1. EIB study information sheet 
 
 
 
Exercise challenge testing 
 
Principal Investigator:      Study co-ordinators: 
Dr Martin R Lindley    Ms Nilam A Khan   Shuo Kang 
M.R.Lindley@lboro.ac.uk   N.A.Khan@lboro.ac.uk 
S.Kang@lboro.ac.uk                                          
Contact tel: 01509 226349   01509 226352   01509 564100 
 
Address of correspondence: 
School of Sport, Exercise and Health Sciences (SSEHS) 
Inflammation, Exercise and Metabolism Research Group 
Loughborough University 
Epinal Way 
Loughborough 
LE11 3RT 
 
 
PURPOSE OF STUDY 
 
As part of my PhD studies, I am looking into Exercise Induced Bronchoconstriction (EIB) 
which is the term used for airway narrowing that occurs after physical exertion in some 
individuals. As EIB is very frequent among young athletes and little is known of the reasons 
about the condition, we wish to conduct a research study to analyse the presence of EIB in 
athletes at Loughborough University. 
 
INFORMATION FOR PARTICIPANTS
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In this study we will look closely at symptoms occurring after an exercise challenge in 
athletes with EIB (as confirmed by a previous eucapnic voluntary hyperventilation test). 
 
 
WHO IS DOING THIS RESEARCH AND WHY? 
 
This study is part of a Student research project supported by Loughborough University. 
 
 
EXCLUSION CRITERIA 
 
- Male and female participants with no history of exercising 
- Participants under 18 and above 25 years of age 
- Participants taking caffeine-related products (beverages, chocolate etc.) 24 hours 
before testing 
- Smokers 
 
RIGHT TO WITHDRAW 
 
After you have read this information and asked any questions you may have we will ask you 
to complete an Informed Consent Form, however if at any time, before, during or after the 
sessions you wish to withdraw from the study please just contact Nilam Khan. You can 
withdraw at any time, for any reason and you will not be asked to explain your reasons for 
withdrawing. 
 
 
STUDY DEMANDS 
 
You will be asked to visit the Exercise & Physiology laboratory at Loughborough University 
once.  
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In short, this will involve questionnaire filling, an exercise challenge test eliciting a heart rate 
response of 85-90% of maximal heart rate, blood sample collections before and after the 
exercise, collection of a cheek swab, exhaled breath condensate and performing spirometry. 
The following diagram highlights the sequence of events on the day of testing: 
 
 
 
 
DETAILS  
 
At the start, we will ask You to fill in three questionnaires: 
1. A Health Screen questionnaire – to determine Your level of physical activity 
2. A Juniper Asthma Control questionnaire – to determine whether 
you have a previous diagnosis of asthma or not (so we can 
bear this in mind when interpreting the test result) 
3. A symptom score sheet – to find out what symptoms, if any, 
you experienced before and after the test 
4. For exhaled breath collection; a questionnaire asking for details 
of diet, lifestyle and exposure to chemicals (make-up) in the last 
week.  
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You will then perform a lung function test, or forced spirometry, 
before the EVH test. This will also be performed at several time 
points after the test, as this helps us to find out if the results are 
positive or negative for exercise-induced bronchoconstriction. 
 
 
 
 
 
 
 
Fig 1: Spirometry test 
 
 
We will also perform a Fractional exhaled nitric oxide assessment which a non-invasive test 
involving slow breathing into a valve to detect airway inflammation. This will also be done 
before and after the EVH test. It will be followed by an exhaled breath condensate (EBC) 
collection, before and after the exercise session. During the EBC collection, you will be 
asked to breathe at normal pace into a tube and then put on a mask and breathe at normal 
pace for 5 minutes.  
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Fig 2: Nitric oxide (NO) test           Fig 3: Exhaled breath collection 
 
 
Blood will be drawn from your arm and collected into two tubes, 
immediately prior to the exercise session. When you complete the 
exercise session, blood will be drawn again into two tubes.  
 
Whilst exercising, we need tp collect the air that you exhale, so that 
we can measure your ventilation and your use of oxygen. To do this, we will ask you to: 
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- breathe through a mouthpiece which is        connected to  some valves and tubing. 
This is light, but you will notice it in your mouth. However, it will not cause you any 
difficulty with breathing (you may notice a slight dryness at the back of the throat).  
- wear a heart rate monitor which continuously records your   heart rate data. 
- wear a nose clip, so that we do not loose air this way.  
 
 
 
 
 
 
 
 
       
 
HOW MUCH TIME WILL IT TAKE? 
 
Questionnaires:  10 minutes in total 
Exercise challenge:  10 minutes 
Lung function:   10 minutes before, and 20 minutes after exercise 
FENO assessment:   10 min before and 10 min after exercise 
EBC collection:  10 min before and 10 min after exercise 
Blood collection:   5 min before and 5 min after exercise 
 
This amounts to 1hour and 40 min in total, BUT could go up to 2 hours.  
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PREPARATION FOR THE TESTS 
 
- Exercise: No vigorous exercise should be undertaken 4 hours prior to testing.  
- Medication: We ask you to refrain from medication 12 hours prior to testing. However, 
if you need to use your medication you should and then inform us so that we can 
reschedule your testing. You must bring your medication with you when you arrive for 
testing.  
NB: Antihistamines should be withheld for 48 hours. 
- Food intake: Alcohol should not be consumed 12 hour prior to testing. Caffeine 
products (coffee, tea, cola, chocolate) should not be consumed on the morning of 
testing. These points are very important in order to prevent external variables 
influencing the study findings and we will discuss this with you in depth prior to the 
main trials. 
 
 
TESTS AND TRIALS INVOLVED 
 
Exercise challenge: 10min ergometer exercise including a 4 min ‘climbing’ period where we 
try to increase heart rate to 85-90% of maximum by increasing work load and 6 min exercise 
maintaining the 90% maximum heart rate. 
 
Spirometry: Full lung function test that will measure how well your lungs are working by 
asking you to blow at different times into a machine. You will be asked to take a maximum 
breath in and a maximum forced breath out into a machine. You will be asked to do this at 
least three times before the EVH test, and immediately, at 5, 10, 15 and 20 minutes after the 
EVH test has been completed. Three blows will be required at each of the time points.  
 
Exhaled nitric oxide: A blowing test to measure the amount of a gas that you naturally 
produce in your air passages, called nitric oxide,that you release when you breathe out. This 
provides us with some information of how active your asthma is. You will be asked to take a 
normal breath in and then breathe out slowly into a nitric oxide analyser, connected to a 
computer. You will do this three times to get an average. You will do this before and after the 
EVH test. 
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Exhaled breath collection:  
 
1. Exhaled breath volatile organic compounds (VOCs) collection: Human breath contain 
trace amount of VOCs which reveal important information on status of human health. 
An adaptive breath sampler will be used to collect specifically for breath VOCs. You 
will asked to breath normally for 5 to 10 minutes while wearing an air tight breathing 
mask with purified air supply before and after intense exercise. Collected breath 
VOCs will be analysed in laboratory later. 
  
2. Exhaled breath condensate collection (EBC): EBC collects both volatile and non-
volatile part of exhaled breath. You will be asked to breath into a mouth piece for 
around 5 minutes before and after intense exercise. Exhaled breath breathed into the 
mouth piece is quickly condensed into liquid by freezing it at -10C. Collected EBC will 
be analysed in laboratory later. 
 
NB: Please note that the tests will be carried out by trained individuals, and in 
accordance with international/European guidelines and by strictly adhering to 
Loughborough University’s policies.  
 
 
POSSIBLE RISKS 
 
There are risks of worsening asthma symptoms in relation to refraining from medication 12 
hours prior to testing or during testing. This is why you must bring your asthma medication 
with you. If you wish, your GP can be informed in case symptoms worsen or cause 
exacerbation.  
 
Risk with spirometry includes lightheadedness. The researchers performing spirometry are 
fully familiar with the procedures and have carried them out before.  
  
Please note that all tests will be carried out under standard operating procedures and 
include careful monitoring of participants. There will always be more than one person in the 
laboratory whilst tests are taking place. 
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BENEFITS OF THE STUDY  
 
The study should lead to greater understanding of the respiratory problems occurring after 
exercise in young athletes. The respiratory problems arising from exercise-induced 
bronchoconstriction can have quite marked effects on the general health, quality of life, 
mental health and social interactions of young people.  
 
We will give you feedback on your results and direct you to support services relating to 
respiratory symptoms. Our researchers have years of experience and expertise in Exercise 
Physiology & Health and will be able to provide information on exercise training for you.  
 
 
CONFIDENTIALITY 
 
Although information will be stored on computer each participant will be entered as a number 
rather than a name. Data will be used for research purposes only and confidentiality will be 
maintained in any publications arising from the study. Participant data will be kept for a 
maximum of 3 years from the time of collection and deleted upon completion of thesis writing 
and publication of the findings. The official closure date of this study is September 2014.  
 
 
MISCONDUCT 
 
Any issues of research misconduct should be reported to Ms Zoe Stockdale at the following 
e-mail address: z.c.stockdale@lboro.ac.uk 
 
In addition, Loughborough University has a policy relating to Research Misconduct and 
Whistle Blowing which is available online at 
http://www.lboro.ac.uk/admin/committees/ethical/Whistleblowing(2).htm.   
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Appendix 2. Participant health questionnaire for EIB study 
Name/Number   ...............…….  
 
Health Screen Questionnaire for Study Volunteers 
 
As a volunteer participating in a research study, it is important that you are currently in good 
health and have had no significant medical problems in the past.  This is (i) to ensure your 
own continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
If you have a blood-borne virus, or think that you may have one, please do not take part in 
this research  
 
Please complete this brief questionnaire to confirm your fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ............ Yes  No  
(b) attending your general practitioner ................... Yes  No  
(c) on a hospital waiting list ................................... Yes  No  
 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP ................................................ Yes  No  
(b) attend a hospital outpatient department ........... Yes  No  
(c) be admitted to hospital  .................................... Yes  No  
 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy  .......................................  Yes  No  
(b) Asthma  ............................................................  Yes  No  
(c) Eczema  ...........................................................  Yes  No  
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(d) Diabetes  ..........................................................  Yes  No  
(e) A blood disorder  ..............................................  Yes  No  
(f) Head injury  ......................................................  Yes  No  
(g) Digestive problems  ..........................................  Yes  No  
(h) Heart problems  ................................................  Yes  No  
(i) Problems with bones or joints     .......................  Yes  No  
(j) Disturbance of balance/coordination  ...............  Yes  No  
(k) Numbness in hands or feet  ..............................  Yes  No  
(l) Disturbance of vision  .......................................  Yes  No  
(m) Ear / hearing problems  ....................................  Yes  No  
(n) Thyroid problems  ............................................  Yes  No  
(o) Kidney or liver problems  ..................................  Yes  No  
(p) Allergy to nuts  .................................................  Yes  No  
 
4. Has any, otherwise healthy, member of your family under the 
age of 35 died suddenly during or soon after 
exercise?  ................................................................. 
Yes  No  
 
If YES to any question, please describe briefly if you wish (eg to confirm problem 
was/is short-lived, insignificant or well controlled.) 
...................................................................................................................................................
...................................................................................................................................................
................ 
 
5. Allergy Information 
(a) are you allergic to any food products? Yes  No  
(b) are you allergic to any medicines? Yes  No  
(c) are you allergic to plasters? Yes  No  
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If YES to any of the above, please provide additional information on the allergy 
……………………………………………………………………………………………………………
………………….. 
 
5. How many times per week do you currently engage in physical activity (e.g. gym, 
running)?  
(a) Once a week .....................................................  Yes  No  
(b) Twice a week  ...................................................  Yes  No  
(c) Three times a week or more    ...........................  Yes  No  
(d) I don’t engange in regular physical activity Yes  No  
 
6. Additional questions for female participants 
(a) Could you be pregnant?    .................................  Yes  No  
(b) Are your periods normal/regular?....................... Yes  No  
(c) Have you ever skipped your period for more than 
3 months? 
Yes  No  
(d) Do you use birth control pills? Yes  No  
 If yes, what kind?.................................................................................... 
 If yes, for how long?............................................................................... 
(e) How old were you when your menstrual periods started?  Age:………... 
(f) When was your last menstrual period?                              Date:............ 
(g) How many days are there between your menstrual periods? Days:…… 
(h) How many periods did you have in the last 12 months?     Periods:…...  
 
Please provide contact details of a suitable person for us to contact in the event of any 
incident or emergency. 
 
Name:………………………………………………………………………………………………
……… 
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Telephone Number:……………………………………………………Work  Home  
Mobile  
 
Relationship to 
Participant:……………………………………………………………………………… 
 
Are you currently involved in any other research studies at the University or elsewhere? 
 Yes  No  
 
If yes, please provide details of the study 
………………………………………………………………………………………………………
…….. 
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Circle the number of the response that best describes how you have been during the past week 
1. On average, during the past week, how often were you woken by your asthma 
during the night? 
0 Never 
1 Hardly ever 
2 A few minutes 
3 Several times 
4 Many times 
5 A great many times 
6 Unable to sleep because of asthma 
2. On average, during the past week, how bad were your asthma symptoms 
when you woke up in the morning? 
0 No symptoms 
1 Very mild symptoms 
2 Mild symptoms 
3 Moderate symptoms 
4 Quite severe symptoms 
5 Severe symptoms 
6 Very severe symptoms 
3. In general, during the past week, how limited were you in your activities 
because of your asthma? 
0 Not limited at all 
1 Very slightly limited 
2 Slightly limited 
3 Moderately limited 
4 Very limited 
5 Extremely limited 
6 Totally limited 
4. In general, during the past week, how much shortness of breath did you 
experience because of you asthma? 
0 None 
1 A very little 
2 A little 
3 A moderate amount 
4 Quite a lot 
5 A great deal 
6 A very great deal 
 
5. In general, during the past week, how much of the time did you wheeze?  
 
0 Not at all 
1 Hardly any of the time 
2 A little of the time 
3 A moderate amount of the time 
4 A lot of the time 
5 Most of the time 
6 All the time 
 
6. On average, during the past week, how many puffs of short-acting 
bronchodilator (eg. Ventolin) have you used each day? 
0 None 
1 1±2 puffs most days 
2 3±4 puffs most days 
3 5±8 puffs most days 
4 9±12 puffs most days 
5 13±16 puffs most days 
6 More than 16 puffs most days 
 
To be completed by a member of the clinic staff 
7. FEV1 pre-bronchodilator: ................................   0 >95% predicted 
1 95±90% 
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FEV1 predicted ................................................   2 89±80% 
3 79±70% 
FEV1 % predicted ...........................................  4 69±60% 
5 59±50% 
6 <50% predicted 
(Record actual values on the dotted lines and score the FEV1 % predicted in the next column) 
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Appendix 3. Publications 
Kang S, Paul Thomas CL, How long may a breath sample be stored for at - 80 °C? A study 
of the stability of volatile organic compounds trapped onto a mixed Tenax: Carbograph trap 
adsorbent bed from exhaled breath. J Breath Res. 2016 7;10(2):026011. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
References 
1. Volatile metabolites in the exhaled breath of healthy volunteers: their levels and 
distributions. Smith D, Turner C , Spaněl P. s.l. : Journal of Breath Research, 2007, Vol. 
1(1):014004. 
2. Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-
MS study over 30 days. Ann M Diskin, Patrik Španěl and David Smith. s.l. : Physiological 
Measurement, 2003, Vols. Volume 24, Number 1. 
3. A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 
subjects using selected ion flow tube mass spectrometry. Turner, C., Španěl, P. and Smith, 
D. s.l. : Physiol. Meas., 2006, Vols. 27, 321–337. 
4. A selected ion flow tube mass spectrometry study of ammonia in mouth- and nose-
exhaled breath and in the oral cavity. Smith D, Wang T, Pysanenko A, Spanel P. s.l. : 
Rapid Commun. Mass Spectrom., 2008, Vols. 22, 783–789. 
5. Endogenous Production of Methanol after the Consumption of Fruit. Lindinger W, 
Taucher J, Jordan A, Hansel A, Vogel W. s.l. : Alcohol Clin Exp Res. , 1997, Vols. 
21(5):939-43. 
6. On the mammalian acetone metabolism: From chemistry to clinical implications. MP, 
Kalapos. s.l. : Biochim Biophys Acta., 2003, Vols. 1621(2):122-39. 
7. The McGraw-Hill Companies. Respriration. [Online] [Cited: ] 
http://www.rci.rutgers.edu/~Uzwiak/AnatPhys/Respiratory_System.html. 
8. Elimination of inert gas by the lung. Farhi, L.E. s.l. : Respiration Physiology, 1967, Vols. 3, 
1–11. 
9. A mathematical model for breath gas analysis of volatile organic compounds with special 
emphasis on acetone. Julian King, Karl Unterkofler, Gerald Teschl, Susanne Teschl, 
Helin Koc, Hartmann Hinterhuber, Anton Amann. 959-999 (2011), s.l. : J. Math. Biol., 
2010, Vol. 63. 
10. Variation in volatile organic compounds in the breath of normal humans. Phillips M, 
Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. s.l. : J Chromatogr B Biomed 
Sci Appl., 1999, Vols. 729(1-2):75-88. 
183 
 
11. Detection of isoprene in expired air from human subjects using proton-transfer-reaction 
mass spectrometry. Taucher J, Hansel A, Jordan A, Fall R, Futrell JH, Lindinger W. s.l. : 
Rapid Commun Mass Spectrom., 1997, Vols. 11(11):1230-4. 
12. Gender and age specific differences in exhaled isoprene levels. Lechner M, Moser B, 
Niederseer D, Karlseder A, Holzknecht B, Fuchs M, Colvin S, Tilg H, Rieder J. s.l. : 
Respir Physiol Neurobiol., 2006, Vols. 154(3):478-83. 
13. Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 
4-83 years. Spaněl P, Dryahina K, Smith D. s.l. : J Breath Res., 2007, Vol. 1(1):011001. 
14. An exploratory comparative study of volatile compounds in exhaled breath and emitted 
by skin using selected ion flow tube mass spectrometry (SIFT-MS). Turner C, Parekh B, 
Walton C, Spanel P, Smith D, Evans M. s.l. : Rapid Commun Mass Spectrom., 2008, Vols. 
22(4):526-32. 
15. On-line, simultaneous quantification of ethanol, some metabolites and water vapour in 
breath following the ingestion of alcohol. David Smith, Tianshu Wang and Patrik Spanel. 
s.l. : Physiol Meas., 2002, Vols. 23(3):477-89. 
16. Real-time metabolic monitoring with proton transfer reaction mass spectrometry. Winkler 
K, Herbig J, Kohl I. s.l. : J Breath Res., 2013, Vol. 7(3):036006. 
17. Analysis of Compounds in Human Breath after Ingestion of Garlic Using Proton-Transfer-
Reaction Mass Spectrometry. Johann Taucher, Armin Hansel , Alfons Jordan , and 
Werner Lindinger. s.l. : J. Agric. Food Chem., 1996, Vols. 44 (12), 3778–3782. 
18. Analysis of exhaled breath from smokers, passive smokers and non-smokers by solid-
phase microextraction gas chromatography/mass spectrometry. Buszewski B, Ulanowska 
A, Ligor T, Denderz N, Amann A. s.l. : Biomed Chromatogr., 2009, Vols. 23(5):551-6. 
19. Compounds enhanced in a mass spectrometric profile of smokers’ exhaled breath vs. 
non-smokers as determined in a pilot study using PTR-MS. Kushch I, Schwarz K, 
Schwentner L, Baumann B, Dzien A, Schmid A, Unterkofler K, Gastl G, Spaněl P, 
Smith D, Amann A. s.l. : J Breath Res., 2008, Vol. 2(2):026002. 
20. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition 
Chromatography. Linus Pauling, Arthur B. Robinson, Roy Teranishi, and Paul Cary. 
s.l. : Proc Natl Acad Sci U S A. , 1971, Vols. 68(10): 2374–2376. 
21. Classification of Asthma. WebMD. [Online] [Cited: 01 11 2017.] 
https://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview. 
184 
 
22. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and 
humans. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. s.l. : 
Biochem Biophys Res Commun. , 1991, Vols. 181(2):852-7. 
23. Increased nitric oxide in exhaled air of asthmatic patients. Kharitonov SA, Yates D, 
Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. s.l. : Lancet., 1994, Vols. 
343(8890):133-5. 
24. Volatile organic compounds in exhaled air from patients with lung cancer. Gordon 
SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. s.l. : Clin Chem. , 1985, Vols. 
31(8):1278-82. 
25. A computerized classification technique for screening for the presence of breath 
biomarkers in lung cancer. O'Neill HJ, Gordon SM, O'Neill MH, Gibbons RD, Szidon 
JP. s.l. : Clin Chem. , 1988, Vols. 34(8):1613-8. 
26. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional 
study. Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay 
WP. s.l. : Lancet., 1999, Vols. 353(9168):1930-3. 
27. Detection of lung cancer with volatile markers in the breath. Phillips M, Cataneo 
RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN. s.l. : 
Chest, 2003, Vols. 123(6):2115-23. 
28. Allergic asthma exhaled breath metabolome: A challenge for comprehensive two-
dimensional gas chromatography. Caldeira M, Perestrelo R, Barros AS, Bilelo MJ, 
Morête A, Câmara JS, Rocha SM. s.l. : J Chromatogr A., 2012, Vols. 7;1254:87-97. 
29. Identification of volatile lung cancer markers by gas chromatography–mass 
spectrometry: comparison with discrimination by canines. Bogusław Buszewski, 
Tomasz LigorTadeusz JezierskiAnna Wenda-PiesikMarta WalczakJoanna Rudnicka. 
s.l. : Analytical and Bioanalytical Chemistry, 2012, Vols. 404(1): 141–146. 
30. Exhaled volatile organic compounds for phenotyping chronic obstructive 
pulmonary disease: a cross-sectional study. Maria Basanta, Baharudin Ibrahim, 
Rachel Dockry, David Douce, Mike Morris, Dave Singh, Ashley Woodcock and 
Stephen J Fowler. s.l. : Respir Res., 2012, Vol. 13(1): 72. 
31. Machine learning methods on exhaled volatile organic compounds for 
distinguishing COPD patients from healthy controls. Phillips CO, Syed Y, Parthaláin 
NM, Zwiggelaar R, Claypole TC, Lewis KE. s.l. : J Breath Res., 2012, Vol. 6(3):036003. 
185 
 
32. Metabolomics pilot study to identify volatile organic compound markers of 
childhood asthma in exhaled breath. Gahleitner F, Guallar-Hoyas C, Beardsmore CS, 
Pandya HC, Thomas CP. s.l. : Bioanalysis., 2013, Vols. 5(18):2239-47. 
33. Exhaled volatile organic compounds predict exacerbations of childhood asthma in 
a 1-year prospective study. Robroeks CM, van Berkel JJ, Jöbsis Q, van Schooten FJ, 
Dallinga JW, Wouters EF, Dompeling E. s.l. : Eur Respir J. , 2013, Vols. 42(1):98-106. 
34. Breath Analysis in Real Time by Mass Spectrometry in Chronic Obstructive 
Pulmonary Disease. Martinez-Lozano Sinues P, Meier L, Berchtold C, Ivanov M, Sievi 
N, Camen G, Kohler M, Zenobi R. s.l. : Respiration., 2014, Vols. 87(4):301-10. 
35. Profiling of Volatile Organic Compounds in Exhaled Breath As a Strategy to Find 
Early Predictive Signatures of Asthma in Children. Agnieszka Smolinska, Ester M. M. 
Klaassen, Jan W. Dallinga, Kim D. G. van de Kant, Quirijn Jobsis, Edwin J. C. Moonen, 
Onno C. P. van Schayck, Edward Dompeling, Frederik J. van Schooten. s.l. : PLoS 
One. , 2014, Vol. 9(4):e95668. 
36. Noninvasive detection of lung cancer using exhaled breath. Xiao-An Fu, Mingxiao 
Li, Ralph J Knipp, Michael H Nantz, and Michael Bousamra. s.l. : Cancer Med., 2014, 
Vols. 3(1): 174–181. 
37. Exhaled Breath Analysis for Lung Cancer Detection Using Ion Mobility 
Spectrometry. Hiroshi Handa, Ayano Usuba, Sasidhar Maddula, Jörg Ingo Baumbach, 
Masamichi Mineshita, and Teruomi Miyazawa. s.l. : PLoS One. , 2014, Vol. 9(12): 
e114555. 
38. Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. 
Mario Cazzola, Andrea Segreti, Rosamaria Capuano, Alberto Bergamini, Eugenio 
Martinelli, Luigino Calzetta, Paola Rogliani, Chiara Ciaprini, Josuel Ora, Roberto 
Paolesse, Corrado Di Natale and Arnaldo D’Amico. s.l. : COPD Research and Practice, 
2015, Vol. 1:7. 
39. Application of an artificial neural network model for selection of potential lung 
cancer biomarkers. Ligor T, Pater Ł, Buszewski B. s.l. : J Breath Res. , 2015, Vol. 
9(2):027106. . 
40. A dual center study to compare breath volatile organic compounds from smokers 
and non-smokers with and without COPD. Gaida A, Holz O, Nell C, Schuchardt S, 
Lavae-Mokhtari B, Kruse L, Boas U, Langejuergen J, Allers M, Zimmermann S, 
Vogelmeier C, Koczulla AR, Hohlfeld JM. s.l. : J Breath Res., 2016, Vol. 10(2):026006. 
186 
 
41. An adaptive breath sampler for use with human subjects with an impaired 
respiratory function. Basanta M, Koimtzis T, Singh D, Wilson I, Thomas CL. s.l. : 
Analyst., 2006, Vols. 132(2):153-63. 
42. Point-of-care breath test for biomarkers of active pulmonary tuberculosis . Phillips 
M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, Pandya M, Natividad 
MP, Patel U, Ramraje NN, Schmitt P, Udwadia ZF. s.l. : Tuberculosis (Edinb). , 2012, 
Vols. 92(4):314-20. 
43. Profiling of Volatile Organic Compounds in Exhaled Breath As a Strategy to Find 
Early Predictive Signatures of Asthma in Children. Agnieszka Smolinska, Ester M. M. 
Klaassen, Jan W. Dallinga, Kim D. G. van de Kant, Quirijn Jobsis, Edwin J. C. Moonen, 
Onno C. P. van Schayck, Edward Dompeling, Frederik J. van Schooten. 2014. 
44. A dual center study to compare breath volatile organic compounds from smokers 
and non-smokers with and without COPD. Gaida A, Holz O, Nell C, Schuchardt S, 
Lavae-Mokhtari B, Kruse L, Boas U, Langejuergen J, Allers M, Zimmermann S, 
Vogelmeier C, Koczulla AR, Hohlfeld JM. s.l. : J Breath Res., 2016, Vol. 10(2):026006. 
45. Determination of individual hydrocarbons in automobile exhaust from gasoline-, 
methanol- and variable-fueled vehicles. F, Lipari. s.l. : Journal of Chromatography A, 
1990, Vol. 503. 51-68. 
46. On the use of Tedlar® bags for breath-gas sampling and analysis. Beauchamp J, 
Herbig J, Gutmann R, Hansel A. s.l. : J Breath Res. , 2008, Vol. 2(4):046001. 
47. The Effects of Adsorption on the Reusability of Tedlar® Air Sampling Bags. 
McGarvey LJ, Shorten CV. s.l. : AIHAJ. , 2000, Vols. 61(3):375-°. 
48. CO2-controlled sampling of alveolar gas in mechanically ventilated patients. 
Schubert JK, Spittler KH, Braun G, Geiger K, Guttmann J. s.l. : J Appl Physiol., 2001, 
Vols. 90: 486–492. 
49. Method for the Collection and Assay of Volatile Organic Compounds in Breath. M, 
Phillips. s.l. : Anal Biochem. , 1997, Vols. 247(2):272-8. 
50. Human breath isoprene and its relation to blood cholesterol levels: new 
measurements and modeling. Karl T, Prazeller P, Mayr D, Jordan A, Rieder J, Fall R, 
Lindinger W. s.l. : J Appl Physiol., 2001, Vols. 91(2):762-70. 
51. Lung cancer identification by the analysis of breath by means of an array of non-
selective gas sensors. Di Natale C, Macagnano A, Martinelli E, Paolesse R, 
187 
 
D'Arcangelo G, Roscioni C, Finazzi-Agrò A, D'Amico A. s.l. : Biosens Bioelectron. , 
2003, Vols. 18(10):1209-18. 
52. Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations 
by an electronic nose: a pilot study. van Geffen WH, Bruins M, Kerstjens HA. s.l. : J 
Breath Res., 2016, Vol. 10(3):036001. 
53. Sorbent-based sampling methods for volatile and semi-volatile organic 
compounds in air. Part 2. Sorbent selection and other aspects of optimizing air 
monitoring methods. E, Woolfenden. s.l. : J Chromatogr A. , 2010, Vols. 1217(16):2685-
94. 
54. Sorbent-based sampling methods for volatile and semi-volatile organic 
compounds in air Part 1: Sorbent-based air monitoring options. E, Woolfenden. s.l. : J 
Chromatogr A., 2009, Vols. 1217(16):2674-84. 
55. Harold M. McNair, James M. Miller. Basic Gas Chromatography. s.l. : John Wiley & 
Sons, 2011. 1118211200. 
56. Scott, Raymond P.W. Introduction to analytical gas chromatography, Second 
Edition, . s.l. : CRC Press, 1997. 
57. Ion Trap Mass Spectrometry. Philip S.H. Wong, R. Graham Cooks. s.l. : Bioanal 
chem., 1997, Vols. 47906-1382. 
58. Raymond E. March, John F. Todd. Quadrupole Ion Trap Mass Spectrometer, 
Second edition. s.l. : J. Wiley , 2005. ISBN: 0471488887. 
59. Ltd, Markes International. Thermal Desorption Technical Support Note 5: Advice 
on sorbent selection, tube conditioning, tube storage and air sampling. [Online] 
https://www.markes.com/. 
60. Ltd., Parker Hannifin. Introduction to ISO air quality standards. [Online] 
http://www.ito.gr/wp-content/uploads/2015/04/Introducing-Iso-8573.pdf. 
61. Centering, scaling, and transformations: improving the biological information 
content of metabolomics data. Robert A van den Berg, Huub CJ Hoefsloot, Johan A 
Westerhuis, Age K Smilde and Mariët J van der Werf. s.l. : BMC Genomics. , 2006, Vol. 
7: 142. 
62. James N. Miller, Jane Charlotte Miller. Statistics and Chemometrics for Analytical 
Chemistry, 5th edition. s.l. : Prentice Hall/Pearson, 2005. ISBN 9780273730422. 
188 
 
63. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA 
classificationy. Max Bylesjö, Mattias Rantalainen, Olivier Cloarec, Jeremy K. 
Nicholson, Elaine Holmes, Johan Trygg. s.l. : Journal of Chemometrics, 2006, Vols. 20 
(8-10):341-351. 
64. Multivariate analysis for Omics. Wiklund, S. s.l. : Umetrics, 2008. 
65. Detection of lung cancer using weighted digital analysis of breath biomarkers. 
Michael Phillips, Nasser Altorki, John H.M. Austin, Robert B. Cameron, Renee N. 
Cataneo, Robert Kloss, Roger A. Maxfield, Muhammad I. Munawar, 1, Harvey I. Pass, 
Asif Rashid. s.l. : Clinica Chimica Acta, 2008, Vols. 393(2): 76–84. 
66. A profile of volatile organic compounds in breath discriminates COPD patients 
from controls . Van Berkel JJ, Dallinga JW, Möller GM, Godschalk RW, Moonen EJ, 
Wouters EF, Van Schooten FJ. s.l. : Respir Med. , 2010, Vols. 104(4):557-63. . 
67. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in 
children. Dallinga JW, Robroeks CM, van Berkel JJ, Moonen EJ, Godschalk RW, 
Jöbsis Q, Dompeling E, Wouters EF, van Schooten FJ. s.l. : Clin Exp Allergy, 2010, 
Vols. 40(1):68-76. 
68. Volatile biomarkers in the breath of women with breast cancer . Phillips M, 
Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. s.l. : J Breath Res., 2010, Vol. 
4(2):026003. 
69. The certification of benzene, toluene and mxylene sorbed on tenax in tubes. CRM 
112. Vandendriessche S, Griepink B. s.l. : Community Bureau of Reference, 
Commission of the European Communities,, 1989, Vol. EUR12308 EN. 
70. Certification of the content of chlorinated hydrocarbons sorbed on TENAX GR®. 
T.L. Hafkenscheid, B.M. Gawlik, A. Lamberty, S. Vandendriessche. s.l. : European 
Commission BCR information REFERENCE MATERIALS, 2003. 
71. Storage stability study of TO-14 compounds on single and multi-bed thermal 
desorption tubes. Measurement of Toxic and Related Air Pollutants. Wright, M D, 
Plant N T, Brown R H, DeGraaf I. s.l. : A&WMA Conference Proceedings,, 1998, Vols. 1: 
550-566. 
72. Effect of transportation and storage using sorbent tubes of exhaled breath 
samples on diagnostic accuracy of electronic nose analysis. van der Schee MP, Fens 
N, Brinkman P, Bos LD, Angelo MD, Nijsen TM, Raabe R, Knobel HH, Vink TJ, Sterk 
PJ. s.l. : J Breath Res., 2013, Vol. 7(1):016002. 
189 
 
73. Thermal Desorption Technical Support Note 19: Minimising artifacts – 
Considerations for storage and transportation of sorbent tubes. Markes International. 
[Online] May 2009.  
74. Comparison of sampling efficiency and storage stability on different sorbents for 
determination of solvents in occupational air. Gjølstad M, Bergemalm-Rynell K, 
Ljungkvist G, Thorud S, Molander P. s.l. : J Sep Sci. , 2004, Vols. 27(17-18):1531-9. 
75. The effect of a paced auditory serial addition test (PASAT) intervention on the 
profile of volatile organic compounds in human breath: a pilot study. M A Turner, S 
Bandelow, L Edwards, P Patel, H J Martin1, I D Wilson and C L P Thomas. s.l. : Journal 
of Breath Research, 2013, Vols. Volume 7, Number 1. 
76. Kohl, A.L. and Riesenfeld, F.C. Gas Purification (5th Edition), . s.l. : Gulf Publishing 
Co.,Houston, TX, 1997. 
77. Desiccant Chart Comparisons. Sorbent Systems. [Online] [Cited: 09 11 2017.] 
https://www.sorbentsystems.com/desiccants_charts.html. 
78. Gas Processors Suppliers Association, . Engineering Data Book FPS Version 
Volumes I & II Sections 1-26 (12th edition),. s.l. : Gas Processors Suppliers 
Association, 2004. ISBN: B00006KFVO. 
79. Parker Hannifin Corp. Compressed Air Filters Sample Filters. [Online] [Cited: ] 
http://www.balstonfilters.com. 
80. A workflow for the metabolomic/metabonomic investigation of exhaled breath 
using thermal desorption GC-MS. Guallar-Hoyas C, Turner MA, Blackburn GJ, Wilson 
ID, Thomas CL. s.l. : Bioanalysis. , 2012, Vols. 4(18):2227-37. 
81. Study of thermal regeneration of spent activated carbons: Thermogravimetric 
measurement of various single component organics loaded on activated carbons . 
Motoyuki Suzuki, Dragoslav M. Misic, Osamu Koyama, Kunitaro Kawazoe. s.l. : 
Chemical Engineering Science, 1978, Vols. 33(3):271-279. 
82. Study of thermal regeneration of spent activated carbons: thermogravimetric 
measurement of various single component organics loaded on activated carbons. 
Suzuki M, Misic DM, Koyama O, Kawazoe K. s.l. : Chemical Engineering Science, 1978, 
Vols. 33 (3), 271-279. 
83. Parker Hannifin Corporation, Filtration & Separation Division. Coalescing 
compressed air filter application note. [Online] www.balstonfilters.com. 
190 
 
84. Parker Hannifin Corporation, Filtration & Separation Division,. Sample filters 
application note. [Online] www.balstonfilters.com. 
85. Clinical characteristics of unexpected death among young enlisted military 
personnel: results of a three-decade retrospective surveillance. Amital H, Glikson M, 
Burstein M, Afek A, Sinnreich R, Weiss Y, Israeli V. s.l. : Chest, 2004, Vols. 126(2):528-
33. 
86. Asthma deaths during sports: report of a 7-year experience. Becker JM, Rogers J, 
Rossini G, Mirchandani H, D'Alonzo GE Jr. s.l. : J Allergy Clin Immunol, 2004, Vols. 
113(2):264-7. 
87. Exercise-Induced Bronchospasm in the Elite Athlete. Rundell, K.W. & 
JenkinsonRundell, K.W. & Jenkinson, D.M. s.l. : Sports Medicine, 2002, Vol. 32: 583. 
88. Exercise-Induced Asthma. E.R. McFadden, Jr., and Ileen A. Gilbert. s.l. : New 
England Journal of Medicine, 1994, Vols. 330:1362-1367. 
89. Screening of athletes for exercise-induced bronchoconstriction. Holzer K, Brukner 
P. s.l. : Clin J Sport Med., 2004, Vols. 14(3):134-8. 
90. Incidence of exercise-induced bronchospasm in Olympic winter sport athletes. 
WILBER, RANDALL L. and RUNDELL, KENNETH W. s.l. : Medicine & Science in Sports 
& Exercise, 2000, Vols. 32(4):732-737. 
91. The US Olympic Committee experience with exercise-induced bronchospasm. RO, 
Voy. s.l. : Medicine and Science in Sports and Exercise, 1986, Vols. 18(3):328-330. 
92. Influence of heat and humidity on the airway obstruction induced by exercise in 
asthma. R H Strauss, E R McFadden, Jr, R H Ingram, Jr, E C Deal, Jr, and J J Jaeger. 
s.l. : J Clin Invest., 1978, Vols. 61(2): 433–440. 
93. Postexertional airway rewarming and thermally induced asthma. New insights into 
pathophysiology and possible pathogenesis. E R McFadden, Jr, K A Lenner, and K P 
Strohl. s.l. : J Clin Invest., 1986, Vols. 78(1): 18–25. 
94. Sensitivity to heat and water loss at rest and during exercise in asthmatic patients. 
Anderson SD, Schoeffel RE , Follet R , Perry CP , Daviskas E , Kendall M. s.l. : 
European Journal of Respiratory Diseases , 1982, Vols. 63(5):459-471. 
95. The airway microvasculature and exercise induced asthma. S D Anderson, E 
Daviskas. s.l. : Thorax, 1992, Vols. 47:748–752. 
191 
 
96. The mechanism of exercise-induced asthma is . . . Sandra D. Anderson, PhD, DSc, 
and Evangelia Daviskas, PhD, M Biomed E. s.l. : J Allergy Clin Immunol., 2000, Vols. 
106(3):453-9. 
97. Clinical exercise testing with reference to lung diseases: indications, 
standardization and interpretation strategies. J. Roca and B.J. Whipp (co-chairmen), 
A.G.N. Agustí, S.D. Anderson, R. Casaburi, J.E. Cotes, C.F. Donner, M. Estenne, H. 
Folgering, T.W. Higenbottam, K.J. Killian, P. Palange, A. Patessio, C. Prefaut, R. 
Sergysels, P.D. Wagner and I. Weisman. s.l. : European Respiratory Journal , 1997, 
Vols. 10: 2662-2689. 
98. Standardisation of spirometry. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, 
R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P.M. van der Grinten, P. Gustafsson, R. 
Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. 
Pellegrino, G. Viegi and J. Wanger. s.l. : Eur Respir J., 2005, Vols. 26(2):319-38. 
99. Reproducibility of the airway response to an exercise protocol standardized for 
intensity, duration, and inspired air conditions, in subjects with symptoms suggestive 
of asthma. Sandra D Anderson, David S Pearlman, Kenneth W Rundell, Claire P Perry, 
Homer Boushey, Christine A Sorkness, Sara Nichols and John M Weiler. s.l. : 
Respiratory Research, 2010, Vol. 11:120. 
100. Indole as an intercellular signal in microbial communities. Jin-Hyung Lee, Jintae 
Lee. s.l. : FEMS microbiology reviews, 2010, Vols. 34(4):426-44. 
101. Indole: the molecule of diverse biological activities. S.BISWAL, U.SAHOO, 
S.SETHY, H.K.S KUMAR, M.BANERJEE. 2012, Asian Journal of Pharmaceutical and 
Clinical Research, pp. Vol 5, Issue 1, 2012. 
102. Asthma and leukotrienes: antileukotrienes as novel antiasthmatic. DAHLÉN, H.-E. 
CLAESSON & S.-E. s.l. : Journal of Internal Medicine, 1999, Vols. 245: 205–227. 
103. Leukotrienes, Antileukotrienes and Asthma. Montuschi, Paolo. s.l. : Mini-Reviews 
in Medicinal Chemistry, 2008, Vols. 8, 000-000. 
104. Treatment of asthma with drugs modifying the leukotriene pathway. Jeffrey M. 
Drazen, M.D., Elliot Israel, M.D., and Paul M. O'Byrne, M.B. s.l. : N Engl J Med, 1999, 
Vols. 340:197-206. 
105. Breath analysis in real time by mass spectrometry in chronic obstructive 
pulmonary disease. Martinez-Lozano Sinues P, Meier L, Berchtold C, Ivanov M, Sievi 
N, Camen G, Kohler M, Zenobi R. s.l. : Respiration. , 2014, Vols. 87(4):301-10. 
192 
 
106. Chemical factors in fatigue i. The effect of muscular exercise upon certain 
common blood constituents. Rakestraw, NW. s.l. : Journal of Biological Chemistry, 
1921, Vols. 47: 565-591. 
107. Toxicology and biochemistry of butylated hydroxyanisole and butylated 
hydroxytoluene. Branen, A. L. s.l. : Journal of the American Oil Chemists’ Society, 
1975, Vol. 52:59. 
108. On the mechanism of butylated hydroxytoluene-induced hepatic toxicity in rats. 
Y Nakagawa, K Tayama, T Nakao, K Hiraga. s.l. : Biochemical pharmacology, 1984, 
Vols. Volume 33, Issue 16. 
109. Enhanced tumour development by butylated hydroxytoluene (BHT) in the liver, 
lung and gastro-intestinal tract. Witschi, H.P. s.l. : Food and Chemical Toxicology, 
1986, Vols. Volume 24, Issues 10–11. 
110. Chronic urticaria exacerbated by the antioxidant food preservatives, butylated 
hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Goodman, D.L., 
McDonnell, J.T., Nelson, H.S., Vaughan, T.R., Weber, R.W. s.l. : Journal of Allergy and 
Clinical Immunology, 1990, Vols. Volume 86, Issue 4, Part 1. 
111. Lung injury induced by butylated hydroxytoluene: cytodynamic and biochemical 
studies in mice. Adamson IY, Bowden DH , Cote MG , Witschi H. s.l. : Laboratory 
Investigation; a Journal of Technical Methods and Pathology, 1977, Vols. 36(1):26-32. 
112. Enhancement of allergic responses in vivo and in vitro by butylated 
hydroxytoluene. Kouya Yamaki, Shinji Taneda, Rie Yanagisawa, Ken-ichiro Inoue, 
Hirohisa Takano, Shin Yoshino. s.l. : Toxicology and Applied Pharmacology, 2007, 
Vols. Volume 223, Issue 2. 
113. Occupational asthma and rhinitis caused by 1, 2-benzisothiazolin-3-one in a 
chemical worker. Scibilia, G. Moscato P. Omodeo A. Dellabianca M. C. Colli F. 
Pugliese C. Locatelli J. s.l. : Occupational Health and Industrial Medicine, 1997, Vols. 
47 (4): 249-251. 
114. Protective effect of ketotifen and disodium cromoglycate against 
bronchoconstriction induced by aspirin, benzoic acid or tartrazine in intolerant 
asthmatics. B., Wüthrich. s.l. : Respiration, 1979, Vols. 37:224–231. 
115. Volatile organic compounds and risk of asthma and allergy: a systematic review. 
Ulugbek B. Nurmatov, Nara Tagiyeva, Sean Semple, Graham Devereux, Aziz Sheikh. 
s.l. : European Respiratory Review, 2015, Vols. 24: 92-101. 
193 
 
116. Exercise-induced asthma screening of elite athletes: field versus laboratory 
exercise challenge. Rundell KW, Wilber RL, Szmedra L, Jenkinson DM, Mayers LB, Im 
J. s.l. : Med Sci Sports Exerc., 2000, Vols. 32(2):309-16. 
117. Determination of isoprene in human expired breath using solid-phase 
microextraction and gas chromatography-mass spectrometry. Hyspler R, Crhová S, 
Gasparic J, Zadák Z, Cízková M, Balasová V. s.l. : J Chromatogr B Biomed Sci Appl., 
2000, Vols. 28;739(1):183-90. 
118. Determination of ethane, pentane and isoprene in exhaled air--effects of breath-
holding, flow rate and purified air. Lärstad MA, Torén K, Bake B, Olin AC. s.l. : Acta 
Physiol (Oxf). , 2007, Vols. 189(1):87-98. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
